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Colorectal cancer (CRC) remains the third most prevalent cancer and the fourth 
most common cause of cancer-related mortality (Mármol et al., 2017). In recent 
years, the incidence and mortality rate of CRC has been rampant in several 
developing countries (Benarba et al., 2018). Although it is feasible to combat some 
cancers, this does not hold true for CRC due to its asymptomatic nature in the early 
stages, hence it is often diagnosed after symptoms become noticeable (Mishra et 
al., 2013). There are several therapeutic methods available for CRC management, 
such as surgical excision, chemotherapy and radiotherapy (Hodgkinson et al., 
2017). However, these therapeutic modalities have rarely yielded good prognosis 
in patients and have detrimental side effects (Mishra et al., 2013). Moreover, 
evolving resistance of cancer cells towards chemotherapeutic and biological drugs, 
as well as non-specific toxicity of these drugs on healthy tissues creates the need 
to explore other methods of CRC therapy (Hodgkinson et al., 2017).   
In recent years, researchers have been engaged in the quest for non-invasive 
therapies with high tumour affinity in order to improve the survival rate and quality 
of life of cancer-burdened patients, and photodynamic therapy (PDT) has provided 
a breakthrough in this arduous mission (Kruger and Abrahamse, 2018). PDT is a 
novel non-invasive therapy for premalignant and neoplastic lesions, which is based 
on three essentials, namely visible light, oxygen and photosensitizer (PS) (Kruger 
and Abrahamse, 2018). The activation of PSs using a specific wavelength of light, 
results in an energy transfer cascade that ultimately yields cytotoxic reactive 
oxygen species (ROS) and singlet oxygen, which in turn induce tumour cell death 
(Abrahamse and Hamblin 2016). PSs can accumulate either passively or actively 
within  tumorous tissue depending on the drug delivery mechanism (Kruger and 
Abrahamse, 2018). The merit of PDT is that it can selectively annihilate cancer 
cells and so exert negligible damage on healthy tissues (Kruger and Abrahamse, 
2019). This is attributed to the enhanced permeability retention (EPR) effect, a 
phenomenon whereby PSs preferentially localize in malignant tissues (Kruger and 
Abrahamse, 2018). However, current studies are devoted towards the 
improvement of the target-selectivity of PSs so that photosensitivity, localized 
healthy tissue damage and other additional undesirable side effects can possibly 
be eliminated (Kruger and Abrahamse, 2018). Thus, the integration of monoclonal 
antibody (mAb) specific biomarkers with either nanoparticles (NPs) and / or PSs, 
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further enhances NP-PS passive drug delivery, as well as enhances active PSs 
delivery, by ensuring that the PS drug is specifically and directly delivered to cancer 
cells that express antigenic determinate matching sites (Kruger and Abrahamse, 
2018). Studies by Calavia et al., (2018) showed improved PDT treatment of CRC 
in in vitro cell cultures when zinc sulpho-pthalocyanine (ZnPcS) PS drug was 
conjugated to gold nanoparticles (AuNPs), as the NPs improved the PSs passive 
uptake and so higher triplet lifetimes of ROS were generated in CRC cells, 
improving the overall PDT treatment effectivity. Additionally, studies by Danaee et 
al., (2017) noted that CRC tumour receptors tend to specifically over-express the 
GUCY2C protein gene and stated that Anti-GCC mAbs could be bound to NP-PS 
molecules, in order to enhance selective active targeting of CRC cells for enhanced 
PDT treatment. 
Generally, CRC is a very aggressive form of cancer and so metastasis of this 
disease is often eminent (Lin et al., 2015). Several lines of evidence stated that 
CRC cells have normal stem cell like (CSCs) properties which drive tumour 
progression, therapy resistance and metastasis (Hodgkinson et al., 2017). 
Moreover, recent studies by Wei et al. (2014) have noted that CRC stem-like cells 
(CSCs) exhibit a high resistance to current therapeutic methods, including 
photodynamic therapy (PDT), leading to its possible recurrence after treatment. 
Thus, an effective therapy for advanced types of CRC necessitates treatment of 
both primary tumours and systemic disease that may not be apparent at initial 
diagnosis (Bostad et al. 2015). In addition, studies by Shams et al., (2015) have 
shown that stimulation of the host immune system can trigger anti-tumour immune 
responses capable of controlling metastatic tumour growth. Thus, great efforts 
have been made to develop combination therapies that control both primary 
tumour growth such as PDT, as well as stimulate anti-tumour immunity for the 
control of metastatic disease and hinder subsequent tumour growth and spread. 
Studies by Aviello et al., (2012) indicated the chemo preventive in vitro effect of 
cannabidiol (CBD) (anticancer compound derived from Cannabis sativa plant) in a 
mouse CRC induced model and noted that it reduced cell proliferation through 
apoptotic cell death pathways while generating anti-tumour immune responses 
after treatment, and so aided within the control of CRC metastatic tumour 
proliferation and secondary spread. 
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The aim of this study was to combine an efficient singlet oxygen generating 
hydrophilic sulphonated metal PS called Zinc Phthalocyanine Tetrasulfonic Acid 
(ZnPcS4), with CRC specific targeting antibodies – Anti-Guanylate Cyclase mAb 
(Anti-GCC) on the surface of heterobifunctional PEG amine stabilized AuNPs to 
enhance PS passive / active delivery and specificity within in vitro CRC cultured 
cells so primary CRC can be effectively treated, without affecting normal human 
cells. However, to possibly enhance this CRC targeted PDT treatment outcome 
and try and hinder its secondary reoccurrence, this final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) was 
administered to in vitro cultured CRC in combination with Cannabidiol (CBD). 
To determine the optimal concentration of CBD and ZnPcS4-mediated PDT, a dose 
response study was performed for each drug. Different concentrations of ZnPcS4 
PS (0.0312, 0.0625, 0.125 and 0.25 µM) and CBD (0.5, 1, 1.5, and 2 µM) were 
administered to various experimental and control groups and incubated for 24 h. 
Some groups were irradiated at 673.2 nm with a fluency of 10 J/cm2 and incubated 
for another 24 h. Cellular biological responses were analysed 24 h post PDT 
treatment to determine the lowest possible concentration of ZnPcS4 PS or CBD 
which could be administered to in vitro cultured CaCo-2 to yield 50% cell viability, 
as well as induce a significant amount of cytotoxicity. This was performed in order 
to establish cell death induction potential (ICD50), but still allow cellular biological 
responses post PDT treatment to be determined. The optimal ICD50 dose response 
concentrations of ZnPcS4 and CBD post PDT treatment that induced approximately 
50 % cytotoxicity was found to be 0.125 µM ZnPcS4 and 1 µM CBD, after observing 
the morphological changes, cellular viability, cellular proliferation and cellular 
membrane damage.  
Following the construction of the final actively targeted PS nanoconjugate (ZnPcS4 
– AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) at the recommended 0.125 µM ZnPcS4
PS PDT (IC50), which was then utilised throughout the study, it underwent a number 
of elementary characterization and stability analyses to confirm the efficient binding 
of the Ab and PS to the functionalized AuNPs’ surface. The molecular 
characterization results indicated that the final molecular PS conjugate (ZnPcS4 – 
AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) was successfully synthesized. 
Furthermore, these assays revealed the final molecular conjugate’s structure, size, 
ROS generation and photostability. The final molecular conjugate displayed a UV-
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spectra with three major Q bands of emission (583, 634, 674 nm) within the far-red 
spectral range for maximum tissue depth penetration and PS excitation. Moreover, 
this final NP PS delivery system demonstrated a mean Z-average diameter of 
57.18 ± 3.04 nm, signifying that it was ideally small enough to embody an active 
nanodrug carrying system, with the definitive possibility of cellular uptake and 
absorption. 
In vitro cultured human CRC cells (CaCo-2) and normal human fibroblasts (WS1) 
were treated with the final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 - Anti-GCC Ab) in order to determine if the conjugated PS was 
able to actively localize more specifically in CRC tumour cells versus normal 
human cells. Immunofluorescent microscopy results validated that the final actively 
targeted PS nanoconjugate was able to actively and specifically localize in target 
CRC cells only and had no affinity for normal human cells (such as fibroblasts). 
These findings demonstrated that this final actively targeted PS nanoconjugate 
exhibited an appreciable safety profile and posed no phototoxic effects or any 
unwanted side effects on normal human tissues pre and post laser irradiation.  
The effect of the final actively targeted PS nanoconjugate (0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) when combined with CBD on human 
CRC cells (CaCo-2) and normal human cells (WS1) was assessed following laser 
irradiation. Post-irradiation, various biological and cellular response assays were 
used to evaluate cellular morphology, cell death induction and DNA damage in 
order to assess the potency of the combined therapy of the final actively targeted 
PS nanoconjugateand CBD on in vitro cultured CRC cells, as well as the safety 
and tolerability profile in normal human cells. The cells were divided into PDT 
experimental groups, which received 0.125 µM ZnPcS4 alone or when conjugated 
to AuNP-PEG5000-SH-NH2 or AuNP-PEG5000-SH-NH2 – Anti-GCC Ab and CBD 
only and were irradiated at 673.2 nm at a fluence of 10 J/cm2. The other PDT 
experimental groups received the combined therapy of 1 µM CBD and 0.125 µM 
ZnPcS4 alone or when conjugated to AuNP-PEG5000-SH-NH2 or AuNP-PEG5000-
SH-NH2 – Anti-GCC and laser irradiation. Post-irradiation, the experimental groups 
were compared to various control groups, such as untreated cells and cells which 
received CBD alone, 0.125 µM ZnPcS4 PS drug or when conjugated to AuNP-
PEG5000-SH-NH2 or AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, as well as the 
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aforementioned when combined with CBD, in order to establish a reference 
baseline of PDT induced cellular cytotoxicity or cell damage.  
All irradiated experimental groups of cells demonstrated significant changes in 
morphology, viability, cell death and DNA damage, however the most prominent 
results were exerted by the final actively targeted PS nanoconjugate (0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti GCC Ab) combinative treatment with 1 
µM CBD, where the cells changed from their initial morphological appearance, 
became distorted and round, some detached from the culture plate and emerged 
as free-floating cells. Furthermore, the final actively targeted PS nanoconjugate 
combined with CBD resulted in the most significant changes in the modes of cell 
death, when compared to any other experimental group post PDT.  Only 6% of the 
cell population was viable, 16% of the cells were undergoing early apoptosis, 52% 
were late apoptotic cells and a staggering 26% of the cells were undergoing a 
necrotic mode of cell death. These findings indicated that the cells that received 
the combined therapy of the final actively targeted PS nanoconjugate and CBD are 
unlikely to recover post PDT treatment, since most of CRC cells were in late 
apoptotic and necrotic mode of cell death, respectively. Moreover, following 
Hoechst 33258 immuno fluorescent staining, the cells that received the combined 
therapy of the final actively targeted PS nanoconjugate and CBD noted nuclei 
shrinkage with loss of cohesion between the cells and DNA chromatin 
fragmentation.  
In addition, when the combined therapy of the final actively targeted PS 
nanoconjugate and CBD was administered to normal human WS1 cells, no 
significant changes in the morphology nor in the modes of cell death were noted, 
suggesting that neither the PDT nor CBD combinative treatments exerted 
phototoxic or cytotoxic side effects on normal human cells.  
In conclusion, the final actively targeted PS nanoconjugate actively and specifically 
enhanced PS drug uptake and retention in in vitro CRC cells and augmented a 
significant PDT cytotoxic effect, due to its high triplet singlet oxygen and ROS yield 
with a long triplet lifetime and noble metal photothermal energy. Furthermore, when 
this treatment was combined with CBD even greater cell death was noted, 
suggesting that this combinative treatment would effectively allow PDT to 
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annihilate primary tumours, with CBD secondary tumour inhibition, and beneficially 
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1.1 Foreword  
Colorectal cancer (CRC) is the third most diagnosed malignancy worldwide and 
the sixth most fatal. Presumably 25% of patients will progress to metastatic disease 
at the time of primary CRC diagnosis, affecting a patient’s overall prognosis (Brand 
et al., 2018). Even though various therapeutic methods are available for managing 
CRC, such as surgical excision, chemotherapy, radiation therapy and 
immunotherapy, most yield a relatively poor outcome and tend to induce adverse 
side effects (Nkune et al., 2020). Therefore, novel therapeutic strategies, such as 
photodynamic therapy (PDT) have been under intense investigation, since this 
type of therapy has improved selectivity towards cancer tissues and so can 
enhance a patient’s overall quality of life and prognosis (Hong et al., 2016). 
Photodynamic therapy (PDT) is a well-coordinated laser irradiation mediated 
technology, which involves either the topical or intravenous administration of a 
photosensitizer (PS) to a patient (Hodgkinson et al., 2017). Upon entering the 
blood stream, the PS then accumulates either passively or actively within a tumour 
site, which is dependent on the type of PS delivery mechanism utilized (Kruger and 
Abrahamse, 2019). Activation of the PS is achieved through exposure to a specific 
wavelength of laser irradiation (Hodgkinson et al., 2017). Once the PS absorbs a 
photon of suitable energy, it converts from a ground state to an excited energy 
form, known as a singlet state (Abrahamse and Hamblin, 2016). A singlet state PS 
then converts to a triple excited state via a process called intercrossing, which 
triggers a change in the spin of an electron (Hodgkinson et al., 2017). In this triplet 
state, the PS interacts with the tumours surrounding molecular oxygen or other 
substrates in adjacent areas, generating cytotoxic reactive oxygen species (ROS) 
and singlet oxygen (1O2), which can induce tumour destruction via apoptotic and 
necrotic cell death pathways (Hong et al., 2016). 
Despite several main advantages of PDT cancer therapy, this modality is still not 
fully adapted in a clinical arena, due to some fundamental properties which PS lack 
(Hong et al., 2016). Most first and second-generation PS drugs are hydrophobic 
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and tend to aggregate under physiological conditions, drastically hindering 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018). In addition, another important drawback which hinders the wide 
application of PDT, is that conventional administrations of PS alone, without any 
further functionalization for active targeting, only rely upon passive accumulation 
in tumour cells and so inadequate PS absorption is often found, limiting the overall 
treatments outcomes (Hong et al., 2016). Furthermore, within clinical applications 
it has been reported that PS cannot overcome immune system biological barriers 
and so their concentrated uptake in tumours is low (Kruger and Abrahamse, 2018). 
Thus, initiatives have been undertaken to circumvent these PS challenges in 
relation to the solubility, stability and target / concentrated absorption uptake 
(Kruger and Abrahamse, 2018). 
In recent years, the integration of nanoparticles (NPs) with PS has gained a great 
deal of attention, since they can overcome the drawbacks conventional PS 
administration often faces (Hong et al., 2016). NPs can significantly enhance the 
solubility of PSs, improve either passive or active uptake in tumours, as well as 
make them more biocompatible to overcome immune system biological barriers 
(Kruger and Abrahamse, 2018). When PSs are combined with NPs, their passive 
uptake in tumour cells is improved via the enhanced permeability and retention 
effect (EPR), which is mediated by the leaky tumour vasculature and poor 
lymphatic drainage of tumour tissues (Hong et al., 2016; Mokwena et al., 2018; 
Kruger and Abrahamse, 2018). Furthermore, the active uptake of bound NP PS in 
tumour cells can be considerably improved, when the surfaces of NPs are modified 
with specific moieties, such as aptamers, monoclonal antibodies (mAb) and 
peptides, which are only overexpressed on tumour cells and so the specific and 
selective uptake of the PS is enhanced within targeted tumour cells only (Kruger 
and Abrahamse, 2019). Thus, NP PS active targeting allows for localized PDT 
treatments, since it increases the bioavailability of PSs to concentrate in tumour 
cells only and so reduces the possibility of any unwanted side effects on 
neighboring healthy tissues (Hong et al., 2016). In relation to PDT various studies 
have been conducted, which support this treatment modality in CRC, however, 
drawbacks such as bioavailability and biocompatibility of PSs, as reported above 
have been found and so in order to improve CRC PDT treatment outcomes PS 
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actively targeted nanoconjugates require investigation (Sekhejane et al., 2014; 
Kruger and Abrahamse, 2018).  
Furthermore, studies by Bostad et al., (2015) noted that CRC cells possess normal 
stem like cell properties named CRC stem cells (CSCs) or tumour initiating cells 
(TICs), which are associated with accelerating tumour progression, therapy 
resistance and tumour spread. In addition, Wei et al., (2014) noted that CSCs 
demonstrate a high resistance to PDT, which can trigger secondary recurrence of 
CRC and systemic disease post treatment. Thus, advanced types of CRC 
necessitate the treatment of both primary tumours and secondary systemic 
disease. Studies by Shams et al. (2015) have revealed that the stimulation of a 
patient’s immune system can yield anti-tumour immune responses capable of 
controlling metastatic tumour growth. Studies by Jeong et al. (2019) investigated 
the chemo preventive in vitro effect of cannabidiol (CBD) in CRC mouse induced 
models and noted that it decreased cell proliferation through apoptotic cell death 
pathways, while generating anti-tumour immune responses post treatment, and so 
aided within the control of CRC metastatic tumour proliferation and secondary 
spread. 
Thus, the effectiveness of primary CRC PDT treatment could possibly be achieved 
by exploring multicomponent synergistic combinations of active PS targeting 
strategies, combined with NP carriers, which can simultaneously evade the body’s 
immunological barriers, as well as allow PSs to be specifically absorbed by CRC 
tumour sites only. Furthermore, should this PDT treatment be combined with CBD, 
it could possibly allow for overall enhanced CRC treatment outcomes, since it 
should inhibit its secondary spread.  
1.2 Problem Statement  
CRC remains an arduous disease to control, as it is often misdiagnosed and 
usually detected at an advanced stage, due to its asymptomatic nature and so 
tumour cell dissemination of this disease is often eminent (Lin et al., 2015). 
Photodynamic therapy (PDT) is an emerging phototoxic treatment, primarily used 
in antitumor approaches, which relies on the retention of a PS in tumour sites and 
their activation upon light exposure (Taquet et al., 2007). The efficacy of PDT in 
cancer treatment is highly dependent on the quality of the PS used, and therefore, 
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it remains essential to investigate the development of novel PSs with enhanced 
delivery and uptake efficacy (Schmidt et al., 2018). 
Phthalocyanines (Pcs) belong to second-generation PSs and are structurally 
similar to porphyrins (Schmidt et al., 2018). In particular, metallophthalocyanines 
containing zinc as a central atom exhibit desirable photostability and high quantum 
yields of ROS production upon irradiation (Schmidt et al., 2018). Despite these 
inherent advantages, zinc phthalocyanine (ZnPc) suffers from poor solubility and 
strong aggregation tendencies in aqueous conditions, which in hinder its overall 
bioavailability (Li et al., 2012). Thus, sulfonation of PSs can alleviate these 
shortcomings, as it enhances their lipophilicity, as well as their bioavailability and 
tumour uptake (Hodgkinson et al., 2017). 
Zinc sulfothiolphthalocynine mixture (ZnPcSmix) is a hydrophilic second 
generation metallophthalocyanine bearing a zinc diamagnetic central atom, 
which generates high quantum yields of ROS, within the 680 nm wavelength 
range and possess negligible dark toxicity (Nombona et al., 2012). This 
compound also incorporates various sulfonated thiol groups which improve its 
solubility, as well as its biological tissue distribution and volume of distribution 
(Nombona et al., 2012). Studies by Manoto et al., (2012) and Sekhejane et al., 
(2014) reported a significant 60% decrease in cell viability with cytotoxic damage 
within in vitro cultured CRC cells (5 x 104 cells/ml), which received 20 µM ZnPcSmix 
PS and 680 nm PDT treatment at fluence of 5 J/cm2. Even though these findings 
were promising, these studies went on to note that in order to render this form of 
CRC PDT treatment more effective, further research was required to refine this 
treatment, as to ensure higher concentrations of the PS actively accumulated 
directly within the tumour cells, as passive diffusion was not enough. Moreover, 
they noted that the localized cellular uptake of the PS is an essential factor, which 
determines PDT potency and a PSs direct intracellular localization within a tumour 
site allows for enhanced cell death outcomes. Overall, these findings suggested 
that ZnPcSmix is an ideal PS to treat in vitro CRC within PDT applications, however 
it required additional tetra sulphonation for improved solubilization, as well as 
further functionalization and chemical modification with drug carriers in order to 
enhance it uptake in CRC tumours.  
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Additionally, studies by Kruger and Abrahamse (2019) reported that human 
immunological barriers often recognize PSs as foreign agents and so are attacked 
upon entering the body, resulting in a poor final uptake in tumour cells. Thus, in a 
clinical setting ZnPcSmix would have a short half-life in the bloodstream, due to its 
degradation by the body’s immunological barriers before reaching CRC tumour 
tissues. However, the development of nanomaterials and nanotechnology has had 
a tremendous impact on PDT, since NPs can effectively resolve the major 
challenges PSs face (Abrahamse and Hamblin, 2016). Their inherent hydrophilic 
properties significantly enhance the overall solubility of bound PSs and so improve 
their passive cellular uptake via the EPR effect (Kruger and Abrahamse, 2018). 
Additionally, NPs can camouflage bound PSs since they emulate biological 
molecules and so remain unnoticed by the immune system blockades, serving 
an excellent delivery platform for anticancer drugs (Kruger and Abrahamse, 
2019). Furthermore, nanotechnology-based drug delivery systems pose ideal 
therapeutic advantages, as they are easy to fabricate, have the capacity to 
encapsulate high volumes of therapeutic agents (due to their high surface area-
to-volume ratio), have small sizes (so can easily penetrate cancer cells) and their 
surfaces can be easily modified for possible functionalization (Aftab et al., 2018; 
Kruger and Abrahamse, 2019). Therefore, nanotechnology has enhanced 
pharmacokinetic parameters of PDT, since the integration of NPs and PSs can 
offer significant clearance values, large volumes of distribution and greater 
bioavailability to cancer cells via the EPR effect (Aftab et al., 2018).   
Inorganic NPs and in particular gold nanoparticles (AuNPs) have drawn 
considerable attention from researchers, since their surfaces allow for modification 
and so they can be further functionalized with various therapeutic drugs and targets 
to improve their binding and uptake in specific tumour cells (Aftab et al., 2018). 
Furthermore, they are not cytotoxic, they exhibit a high surface plasmon 
resonance, they have unique optical flexibility within PDT applications and they 
offer a greater stability to therapeutic drugs loaded onto their surfaces (Aftab et al., 
2018; Li et al., 2019). In addition, AuNPs exhibit remarkable physiochemical 
properties, which allows for conversion of irradiation energy into heat and so aid in 
photothermal ablation of solid tumours within PDT applications (Li et al., 2019). 
According to studies by Calavia et al. (2018) the conjugation of ZnPc PSs to AuNPs 
noted enhanced passive uptake within in vitro cultured breast cancer tumour cells 
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and showed an improved PDT efficiency, with higher triplet lifetimes than unbound 
ZnPc PS PDT treatment alone. Moreover, studies by Colombeau et al. (2016), 
reported that when PSs are bound to AuNPs, they are preserved and protected 
from biological barriers, as well as enzymatic degradation and so their in vivo 
circulatory half-life is improved, promoting increased passive tumour cell uptake 
via the EPR effect. 
However, studies by Sukumar et al. (2013) and Wakaskar (2017) have reported 
that a major drawback of NPs passive drug delivery systems is that they are not 
able to distinguish normal tissues from the tumorous ones, and so as a result, 
therapeutic drugs may accumulate to some extent in healthy tissues, disrupting 
their normal bodily functions. Thus, in an effort to enhance host PS accumulation 
specificity, and improve PDT PS safety and tolerability profile, great efforts have 
been devoted towards the synthesis of PS-nanoparticle bio-conjugates, to further 
enhance PSs active delivery, by specifically ensuring that PSs are only absorbed 
by tumour cells which overexpress the matching bio-conjugate antigenic 
determinate site (Kruger and Abrahamse, 2019). Studies by Danaee at al., (2017) 
noted that CRC tumour receptors tend to specifically overexpress GUCY2C protein 
genes and suggested that Anti-GCC mAbs could be utilized as a specific target to 
actively enhance therapeutic drug delivery. Thus, the linkage of targeting moieties 
such as Anti-GCC mAb to NP-PS conjugates, could possibly enhance the active 
delivery of PSs in CRC cells and so promote PDT treatment.    
However, studies by Wei et al. (2014) have revealed that CRC stem-like cells 
(CSCs) exhibit high resistance to PDT, leading to its possible recurrence after 
treatment. Thus, an effective therapy for advanced types of CRC often requires 
treatment of both primary tumours and secondary systemic disease that may not 
be apparent at initial diagnosis. Studies by Shams et al. (2015) have shown that 
stimulation of the host immune system can elicit anti-tumour immune responses 
capable of controlling metastatic tumour growth. Thus, there is interest in the 
development of combination therapies that control both primary tumour growth 
such as PDT, as well as stimulate anti-tumour immunity for the control of metastatic 
disease and hinder subsequent tumour growth and spread. Studies by Aviello et 
al. (2012) investigated the chemo preventive in vitro effect of cannabidiol (CBD) (a 
compound from the Cannabis sativa plant) in mice CRC induced models and noted 
that it reduced cell proliferation though apoptotic cell death mechanisms, while 
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generating anti-tumour immune responses after treatment, and so aided within the 
control of CRC metastatic tumour proliferation and secondary spread.  
Despite significant efforts to develop PS modified nanostructures for the efficient 
PDT treatment of primary CRC, it currently remains a challenge to develop a 
nanostructured drug delivery system that is based on surface-functionalised 
AuNPs, which combines CRC targeted tumour molecular recognition, for effective 
PS cytotoxic species production under PDT irradiation, as well as allows for the 
simulation of a hosts anti-immunity in order to control secondary CRC metastatic 
spread.  
1.3 Aims of the Study  
The aim of this study was to combine an efficient cytotoxic oxygen generating 
hydrophilic tetra sulphonated metal based PS, (Zinc Phthalocyanine Tetrasulfonic 
Acid, ZnPcS4) with CRC-specific targeting antibodies (Anti-Guanylate Cyclase Ab 
(Anti-GCC)) on the surface of heterobifunctional PEG amine stabilized AuNPs to 
enhance the active PS uptake in CRC cells and so improve the primary PDT 
treatment of CRC. Moreover, to enhance this CRC targeted PDT treatment 
outcome and hinder its secondary reoccurrence, the final targeted PS 
nanoconjugate was administered in combination with CBD to in vitro cultured CRC 
cells (Figure 1). The efficiency of this combined therapeutic approach was 
evaluated post-PDT, by assessing the cellular uptake, cellular morphology, 
viability, cell death, DNA damage and proliferation cytotoxic effects it had on in 
vitro cultured CRC in comparison to control groups and normal human in vitro 
cultured fibroblast cells. This approach allowed investigators to determine if CBD, 
when applied in combination with the final targeted PS nanoconjugate PDT could 
possibly be used to more efficiently treat primary CRC tumors, as well as inhibit 
the secondary malignant spread of CRC, with negligible effect on healthy tissues, 
since this has not been accomplished to date. 
Objectives: 
• Chemical synthesis and characterization of final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC). 
• Assess sub-cellular localization targeting abilities of the final actively targeted 
PS nanoconjugate within in vitro cultured CRC and fibroblast cells. 
8 
 
• Determine the lowest possible concentration of ZnPcS4 PS and CBD which can 
be administered to CRC cells to yield 50% cell viability, in order to establish 
cell death induction potential, but still be able to determine cellular responses. 
• Investigate  cytotoxic PDT abilities within in vitro cultured CRC cells, which 
received the final actively targeted PS nanoconjugate versus cells which 
received a synergistic combination of final actively targeted PS nanoconjugate 
and CBD, by performing various cellular morphological, viability, proliferation, 






Figure 1 Hypothesized active targeted PS nano drug delivery system for the 
enhanced PDT primary treatment of CRC, using ZnPcS4–AuNP-PEG5000-SH-NH2–Anti-




LITERATURE REVIEW  
 
2.1  Cancer  
Despite recent medical advancements in diagnosis and management, cancer is a 
global health concern that continues to claim millions of lives (Senapathy et al., 
2011). Approximately 18.1 million new cancer cases and over 9 million cancer-
related fatalites occurred globally in 2018 (Yates et al., 2020). Cancer refers to a 
wide range of disorders characterized by erratic division of cells that can invade 
normal tissues and disseminate or migrate to other locations in the body via blood 
or lymphatic systems (Senapati et al., 2018). Cancer begins with the growth of an 
abnormal cell into a cell mass that can spread throughout the body to deter normal 
body functions as shown in Figure 2 (Pardee and Stein, 2011). 
Figure 2 The development of cancer (Tompa, 2011). 
 
Virtually all forms of cells in the body are likely to acquire mutations and become 
tumorous (Pardee and Stein, 2011). The process in which a normal cell becomes 
a tumour is known as carcinogenesis or tumorigenesis (Pardee and Stein, 2011). 
Tumours can either be malignant or benign (Rashid, 2017). Benign tumours are 
noncancerous slow-growing masses that compress rather than invade adjacent 
tissues (Rashid, 2017). Unlike benign tumours, cancerous malignant tumours grow 
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rapidly, invade and infiltrate adjacent tissues and metastasize to other areas of the 
body (Porth, 2015). 
2.1.1  Common Traits of Cancer Cells  
Although each cancer has its own unique characteristics and growth features, 
cancers have a common set of traits (Pardee and Stein, 2011). According to 
Hanahan and Weinberg, (2015), Rashid, (2017), and Gutschner and Diederichs, 
(2012), tumour cells differ from normal cells in at least six characteristics involving 
growth control:  
1. Tumour cells can continually proliferate without any external stimuli through 
modulation of negative feedback mechanisms or activation of downstream 
signaling pathways, making them independent of exogenous growth factors. 
Moreover, they have the ability to generate growth factors for themselves or 
manipulate healthy cells to generate subsidiary growth factors. Cancer cells 
modulate mitogenic signals by overexpressing growth receptor molecules on 
their surface, which in turn renders them hyperresponsive. 
2. Cancer cells have the ability to inhibit checkpoints that control cell proliferation 
either by inactivating tumour suppressor genes or by manipulating cell cycle 
checkpoints. There are two prototypical tumour suppressors, which initiate 
cells to proliferate or activate cell death pathways, retinoblastoma-associated 
(RB) proteins and TP53 gene. RB proteins integrate stimuli from various 
internal and external factors to determine whether the cell must proceed with 
cell growth cycle or not. TP53 genes receive signals from stress and 
abnormalities sensors to halt cell cycle progression during DNA damage and 
trigger apoptosis if the damage is irreparable.  
3. Cancer cells evade apoptosis by deterring signaling mechanisms that govern 
cell death.  
4. Cancer cells are immortal in existence as they constantly pass through infinite 
cycles of growth and division. 
5. Generally, cancer cells require nutrients and oxygen so excretion of metabolic 
waste and carbon dioxide by tumours increase. To meet these requirements, 
vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis to 
sustain uncontrollable tumorous growths. 
6. Cancer cells interfere with pathways that antagonize invasion and metastasis. 
They also tend to express low adherence factor (E-cadherin), to detach from 
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primary tumours so they can invade neighbouring tissues. The dissociated cells 
also enter blood and lymphatic system, as well as spread to other distant 
organs.  
2.1.2 Etiology and Pathogenesis of Cancer  
Fundamentally, all cancers arise as normal cells undergo genetic changes that 
cause them to proliferate aberrantly, escape cell cycle regulators, and avoid 
apoptosis (Pardee and Stein, 2011). Intrinsic and extrinsic factors are the main 
causes of cancer (Pardee and Stein, 2011; Rashid, 2017). Intrinsic factors include 
age, immune abnormalities, hormonal imbalances and inherited mutations, 
whereas extrinsic factors comprise of carcinogens, radiation, infections agents, 
unfavourable diet and lifestyle, smoking and excessive alcohol use leading 
alcoholism (Pardee and Stein, 2011; Rashid, 2017). Genetic alterations in cancer 
virtually occur in two classes of gene, oncogenes and tumour suppressor genes 
(Rashid, 2017). Abnormalities in these sets of genes facilitate carcinogenesis, by 
elevating tumour cell numbers through stimulating cell proliferation or the inhibition 
of apoptosis (Pardee and Stein, 2011). According to Rashid (2017), mutated 
oncogenes can enhance cell growth, division and survival. In addition, the genes 
responsible for cell cycle regulation, apoptosis, DNA repair, aging and 
immortalization, angiogenesis, and metastasis play a pivotal role in cancer. 
Therefore, mutated tumour suppressor genes lose their ability to detect 
unrepressed cell growth and stimulate DNA and initiation of cell cycle checkpoints. 
2.2  The Human Colon  
The mouth, oesophagus, stomach, small intestine, colon and rectum make up a 
human gastrointestinal tract (GI) (Azzouz and Sharma, 2018). The colon has four 
sections, namely the caecum and ascending colon, transverse colon, descending 
colon, and sigmoid colon (Azzouz and Sharma, 2018). It performs three pivotal 
functions: water and electrolyte absorption, vitamin production and absorption, as 
well as fecal formation and excretion (Sulaiman and Marciani, 2019). Figure 3 
shows the different layers of the intestinal wall that are burdened by CRC. The 
mucosa, submucosa, muscular layer, and serosa are the four layers which form 




Figure 3 Layers of the intestinal wall (Kulkarni et al., 2018). 
2.2.1  Colorectal Cancer (CRC) 
The term CRC refers to an insidious malignancy that erupts from either the colon 
or the rectum innermost layers (Marley and Nan, 2016). CRC is one of the deadliest 
malignancies contributing to alarming cases of cancer-related mortalities, 
accounting for 0.6 million deaths per year (Hodgkinson et al., 2017; Kruger and 
Abrahamse, 2019). Nearly all cancers that originate from the colorectal regions are 
categorized as adenomatous polyps (Marley and Nan, 2016; Hodgkinson et al., 
2017). However, the colon and rectum intestinal wall comprises of many layers 
(Kruger and Abrahamse, 2019) and the development of CRC polyps begins in the 
innermost mucosal stratums of the GI colon or rectum regions and this abnormal 
cell mass can then protrude into the intestinal lumen and spread (Simon, 2016).  
Other less frequent cancers immerging from the colorectal region include; 
carcinoid tumours (emerge from hormone-secreting epithelial cells), sarcomas 
(arises in the blood vessels), lymphomas (immune system malignancies originating 
from the colon or rectum), and gastrointestinal stromal tumours (arising from 
interstitial cells of Cajal) (Marley and Nan, 2016). The occurrence of CRC is 
associated with a range of environmental and genetic predisposition factors 
(Hodgkinson et al., 2017). An estimated 25% of CRC cases are associated with 
hereditary syndromes, while 75% of CRC cases occur due to external 
environmental factors (Kruger and Abrahamse, 2019).  
The most prevalent CRC inherited syndromes stem from familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC) (Kruger 
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and Abrahamse, 2019). Environmental factors such as fiber free diet, high 
consumption of fat and red meat, alcohol abuse, physical inactivity, deskbound 
occupations, obesity and cigarette smoking exacerbate the chances of suffering 
from CRC (Marley and Nan, 2016; Hodgkinson et al., 2017).  
Despite the significant improvements in CRC diagnosis and treatment, tumour 
recurrence and metastasis are major problems which delay a patient’s prognosis 
(Kruger and Abrahamse, 2019). CRC is frequently discovered in its advanced 
phases when symptoms become apparent (Mishra et al., 2013). Depending on the 
phase of the disease, roughly 25% of CRC patients already suffer from metastatic 
disease during diagnosis and 50% of CRC patients have high chances of 
developing metastases, either at presentation or during check-ups (Kruger and 
Abrahamse, 2019). 
2.2.2  Pathophysiology and Etiology of Colorectal Cancer 
Genetic abnormalities in oncogenes, tumour suppressor genes and genes 
associated with DNA repair processes result in the onset of CRC, as well as in 
other types of cancer (Mármol et al., 2017). CRC is mainly caused by abnormalities 
in the Wnt signaling pathway, which intensify signaling mechanisms (Mustafa et 
al., 2016). These carcinomas can be intermittent, inherited and familial based on 
the source of mutation (Mármol et al., 2017). Most CRC cases are sporadic with 
no evident hereditable trends or ancestral history (Mishra et al., 2013). Somatic 
mutation of adenomatous polyposis coli (APC) is a common feature in almost all 
patients with nonhereditary sporadic adenomatous polyposis (SAP) (Mishra et al., 
2013). The first genetic changes occur in APC, a tumour suppressor protein, 
initiating the development of adenomas known as polyps, non-malignant (Mármol 
et al., 2017). According to Mármol et al., (2017) diets, tobacco, environmental 
hazards, viruses, and unfavourable lifestyles cause APC mutation. The build-up of 
malformed products of the APC gene activate the Wnt/β-catenin signalling pathway 
resulting in the transcriptional activation of target genes (c-myc and cyclin D) 
(Mishra et al., 2013). The tumorigenesis process involves a sequence of genetic 
mutations, phenotypical and pathological changes like loss of the p53 tumour 
suppressor gene in invasive CRC, after initial genetic modification (Mishra et al., 
2013). The APC mutation is accompanied by mutations in KRAS, TP53 and DCC, 
respectively (Mármol et al., 2017). The TP53 gene produces the p53 protein to 
regulate cell division and eliminate cells within Wnt pathway abnormalities 
15 
 
(Mustafa et al., 2016). According to Mishra et al., (2013) patients with FAP inherit 
a germinal mutation of the APC gene and are more susceptible to CRC, with the 
lifetime incidence of 100%. HNPCC is a group of inherited CRC linked genes which 
mutate DNA repair mechanisms (Mármol et al., 2017). Similar genetic changes 
attributed to the development of hereditary CRC have also been identified in the 
development of sporadic non-hereditary colon cancer, and these comprise of APC 
(Wnt/βcatenin pathway), TGF-β, Notch and hedgehog (Hh) signalling pathways. 
Moreover, other signalling pathways including EGFR, the ras/raf / MAPK cascade 
and activation of Akt kinase and STAT3 transcription factors are presumed to 
initiate CRC carcinogenesis (Mishra et al., 2013). 
2.2.3  Stages and Prognosis of Colorectal Cancer 
Colorectal cancer (CRC) is categorized into four distinct stages together with the 
fifth stage named recurring (Mishra et al., 2013).  
Stage zero; is the beginning of the CRC cycle in which abnormal cells emerge from 
the mucosal membrane of the colon (Viswanath, 2016). At this stage, the 
neoplastic polyps are completely obliterated by polypectomy to prevent cancer 
from progressing to advance stages.  
Stage I is a phase in which the polys permeate muscularis mucosa to the 
submucosa and may extend to the muscularis propria (Viswanath, 2016). Surgical 
excision at this stage is usually the only treatment for CRC, as the malignant 
portion of the tissue is alienated from the non-cancer portion (Mishra et al., 2013).  
The patient’s survival rate is 95% at this stage (Mishra et al., 2013).  
Stage II is classified into three phases: Stage IIA; the cancer has extended to the 
outermost layer (serosa) of the colon wall through colon muscular layer 
(Viswanath, 2016). Stage IIB; the tumour has breached through the serosa of the 
colon wall without migrating to adjacent organs (Viswanath, 2016). Stage IIC; the 
malignancy has migrated to the neighboring organs through the serosa of the colon 
wall (Viswanath, 2016). Surgical excision is highly recommended at this stage of 
CRC and the overall survival of rate of patients is 85% (Mishra et al., 2013). At 
stage III, the cancer has infiltrated the whole wall of the colon and nearby lymph 
nodes, with a prognosis of approximately 30-60% (Mishra et al., 2013).  
This stage of cancer is subdivided into stage III A, B and C based on the cancer 
spread to the innermost, middle and outermost wall of the colon, as well as the 
16 
 
adjacent lymph nodes. The treatment of this stage is surgery along with high quality 
lymphadenectomy (Mishra et al., 2013). Other alternative treatments comprise of 
chemotherapy and radiation therapy (Mishra et al., 2013; Kruger and Abrahamse, 
2019). 
Stage IV; at this phase, the cancer has spread to other locations of the body and 
the prognosis is 3% (Mishra, 2013). In stage IVA, the cancer spreads via the colon 
walls, disrupting neighbouring organs or lymph nodes (Viswanath, 2016). It 
metastasizes to vital organs such as kidneys, liver or lungs or to a far lymph node. 
In stage IVB, the malignancy may have penetrated via the colon layers and 
reached adjacent organs or lymph nodes (Viswanath, 2016). It spreads to several 
organs distant from the colon or the lining of the abdominal wall (Viswanath, 2016). 
The recommended treatment at this stage is chemotherapy or targeted therapy 
combined with surgery (Hodgkinson et al., 2017).  
2.2.4  Clinical Features of Colorectal Cancer 
CRC is not symptomatic in the early stages and often goes undetected until 
tumours have reached a substantial size in the advanced stages, which may block 
the passage of faeces and cause cramping, pain, or bloody stools (Simon, 2016). 
Fatigue, unexplained weight loss, abdominal discomfort, anal mucus secretion, 
changes in bowel habits, rectal bleeding and anemia are the clinical symptoms of 
CRC (Hatch, 2016; Duineveld et al., 2016) 
2.2.5  Diagnosis and Conventional Modalities of Colorectal Cancer  
There are several screening tests available for CRC diagnosis. Colonoscopy is the 
main modality for CRC detection, which enables a patient's whole rectum and 
colon to be examined for polyps or cancer (Viswanath, 2016). This test 
simultaneously demonstrates therapeutic and diagnostic effects on polyps 
(Kuipers et al., 2016). Computed tomographic (CT) colonography uses low-dose 
CT scanning to capture the colon interior (Kuipers et al., 2016). It is an alternative 
in cases where a standard colonoscopy is not feasible due to the possibility of 
anesthesia or in patients with a blocked colon, which deters a full examination 
(Viswanath, 2016). In sigmoidoscopy, polyps, cancer and other deformities are 
examined by inserting a flexible luminous tube into the rectum and lower colon. 
Stool tests such as FIT and FOBT test kits are used for the detection of irregular 
blood and DNA markers. To detect blood, FOBT uses guaiac, while FIT uses 
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antibodies to find traces of blood in feces. Double-contrast barium enema consists 
of a barium sulphate suspension pumped with air into the rectum by means of a 
flexible duct, followed by the capture of X-ray images (Viswanath, 2016). 
Surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy 
are considered as conventional treatments for CRC (Viswanath, 2016). The choice 
of treatment depends on the condition of a patient, tumour size and location 
(Marley and Nan, 2016). Furthermore, combinative treatments can also be used 
based on the stage at which a patient is diagnosed (Kruger and Abrahamse, 2019).  
Surgery is a mainstay treatment for CRC and the type of surgical excision depends 
on tumour location, the presence and degree of metastasis (Marley and Nan, 
2016). It comprises laparoscopic surgery, colostomy and radiofrequency ablation 
(Viswanath, 2016). Surgical excision of a tumour is a critical first line of defence in 
CRC treatment, especially if the tumour is well defined (Viswanath, 2016). The 
outcome, however, depends on the quality of surgery, the precision of pre-
operative staging and treatment of choice (Kuipers et al., 2016). Generally, 
discomfort and tenderness in the operated area together with constipation or 
diarrhoea are the main drawbacks of surgery (Viswanath, 2016). Other reports 
indicated that surgery enhances the chances of metastatic disease in some 
patients due to the mechanical destruction of the tumour integrity, allowing it to 
spread (Viswanath, 2016). 
Radiation therapy (RT) employs radioactive substances to eliminate malignant 
cells and stall their development and division (Gianfaldoni et al., 2017). RT exerts 
its therapeutic effect through the destruction of DNA, thus resulting in cell death 
(Baskar, 2014). In CRC treatment, RT may be used prior to surgery, known as 
neoadjuvant therapy, to shrink tumours and facilitate their removal. It can also be 
used to eliminate any residual malignant cells after surgery (Viswanath, 2016). 
Radiation is applied internally or externally (Gianfaldoni et al., 2017). In external 
beam radiation, radioactive substances from the exterior of the body are directed 
to the targeted cancerous tissues, whereas in internal beam radiation, a radioactive 
source is implanted inside or adjacent to tumorous tissues (Gianfaldoni et al., 
2017). However, patients respond differently to ionizing radiation in relation to the 
degree of damage exerted to normal cells. In patients with hypersensitivity, 
radiation exposure may result in adequate DNA damage to cause further neoplasm 
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growth (Viswanath, 2016). Moreover, RT inflicts side effects such as bowel 
dysfunction, nausea, bladder impairment, fatigue, low libido and skin irritations 
(Miller et al., 2016; Kruger and Abrahamse, 2019). 
Chemotherapy is another treatment modality for CRC, whereby alkylating agents, 
plant phytochemicals, hormones, enzymes, anticancer antibiotics and biological 
response modifiers are applied to control or destroy cancer cells, halt tumour 
growth or its proliferation (Mishra et al., 2013). The standard chemotherapeutic 
regimens recommended for CRC patients include; the integration of leucovorin, 5-
fluorouracil (5-FU), and either oxaliplatin (FOLFOX protocol) or irinotecan 
(FOLFIRI protocol), capecitabine (Xeloda) and oxaliplatin (CAPEOX or CAPOX 
protocol) and leucovorin, 5-FU, oxaliplatin and irinotecan (FOLFOXIRI protocol) 
(Kuipers et al, 2016; Kruger and Abrahamse, 2019). In comparison with 
monotherapy fluoropyrimidine, combined chemotherapy regimens yield better 
antitumor results (Kuipers et al, 2016). Chemotherapeutic drugs eliminate cancer 
cells through cytotoxicity, which leads to tumour regression (Mishra et al., 2013). 
They hinder cell division mechanisms, including DNA replication and chromosomal 
separation and are not cancer-specific. Unfortunately, only a negligible dose of the 
drug reaches the affected tissues, while the rest of the drug causes adverse side 
effects on normal tissues (Mishra et al., 2013). Furthermore, patients receiving 
chemotherapy experience unwanted side effects such; nausea, vomiting, fatigue, 
neuropathy, as well as bone marrow and renal impairment (Viswanath, 2016; 
Benarba and Pandiella, 2018). The poor selectivity, low concentration in malignant 
tissues, and systemic toxicity of chemotherapy have led researchers to consider 
investigating other more targeted and localized therapies, which don’t cause such 
severe and unwanted side effects (Geng et al., 2017). 
Immunotherapy stimulates the host immune system to reject and eradicate cancer 
cells (Mishra et al., 2013; Wrobel and Ahmed, 2019). Cytotoxic T-lymphocyte-
associated antigen-4 (CTLA-4), programmed death 1(PD-1) and programmed 
death ligand 1 (PD-L1) immune checkpoints are pivotal to the immune system’s 
ability to control cancer growth (Lee et al., 2019). Malignant cells interact with these 
immune checkpoint proteins to evade immune system responses (Lee et al., 
2019). CTLA-4 and PD-1 counteract the activation of T-cell (Wei et al., 2018). 
When PD-1 receptor on the T cells binds to PDL-1 expressed by cancer cells, it 
hinders the T cells from destroying the cancer cells (Lee et al., 2019). CTLA-4 
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receptor expressed by CD4 and CD8 T cells, attenuates immune stimulation by 
attaching to B7 ligands on the antigen presenting cells (APCs) and blocking 
stimulus normally elicited by B7 binding to a CD28 receptor on T cells  (Lynch and 
Murphy, 2016). Therefore, immune checkpoint inhibition prevents the inhibitory 
mechanisms of T-cell activation, allowing tumour-reactive T cells to detect tumour 
antigens and restore antitumor immune responses (Lee et al., 2019). Immune 
checkpoints blockades include anti-PD-1 nivolumab and prembolizumab and anti-
CTLA-4 ipilimumab (Alsaab et al., 2017; Angelova et al., 2015). In comparison with 
other malignancies, immunotherapy has not shown great advances in CRC 
treatment (Kalyan et al., 2018). Furthermore, immunotherapeutic agents have 
shown side effects such as fatigue, diarrhoea, nausea, disorientation, enterocolitis, 
dehydration and hypotension (Kroschinsky et al., 2017).  
Targeted therapy is a form of treatment that modulates genes or specific proteins 
for cancer or the tissue environment that promotes carcinogenesis (Viswanath, 
2016). It concurrently inhibits cancer growth and metastasis, while reducing 
detrimental side effects to normal cells (Viswanath, 2016). Targeting agents are 
used in treatment of metastatic disease, together with combined regimens of 
chemotherapy (Kuipers et al, 2016). These biological agents in particular target 
angiogenic factors, including anti-EGFR; cetuximab and panitumumab monoclonal 
antibodies, anti-VEGF; bevacizumab and fusion proteins targeting multiple 
proangiogenic growth factors (e.g. aflibercept) and small molecular multikinase 
inhibitors (e.g. regorafenib) (Kuipers et al, 2016; Ohhara et al., 2016). Nearly all 
CRC tumours overexpress EGFR, which heightens risks of metastasis and 
mortality. Anti-angiogenic agents do not only inhibit tumour angiogenesis, but also 
normalize tumour blood vessels (Ohhara et al., 2016). Vessel stabilization 
facilitates drug uptake by the tumour, which in turn can improve the therapeutic 
efficacy of drugs (Ohhara et al., 2016). However, targeted therapy agents have 
side effects in patients, such as skin rash, neuropathy, kidney failure, bleeding 
disorders and hypertension (Hagan et al., 2013; Hamza et al., 2017). In addition, 
a review by Hagan et al., (2013) revealed that counteracting VEGF enhances 
tumour invasiveness and metastasis, arguing that bevacizumab may indirectly 
promote angiogenesis via VEGF-independent mechanisms. 
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2.2.6  Resistance to Therapies and Tumour Metastases  
Tumour resistance is a major drawback that hinders the efficacy of current 
therapies, and almost all patients diagnosed with CRC develop resistance to 
conventional therapies (Hu et al., 2016). Accruing evidence indicates that 
resistance to traditional cytotoxic therapies is attributed to poor drug delivery to 
cancer cells, either by high efflux out of the tumour cells facilitated by ATP-
dependent transporters, poor uptake into the tumour, or by alterations in metabolic 
enzymes, as illustrated in Figure 4 (Hammond et al.,2016).  
 
Figure 4 A demonstration of mechanisms behind tumour resistance to conventional 
treatments (Hodgkinson et al., 2017).  
 
Poor responses to target therapies arise from various factors such as upregulation, 
genetic abnormalities, or downregulation of signaling pathways in CRC patients 
(Hammond et al., 2016). Approximately 90% of patients with metastatic CRCs 
cannot respond well to therapeutic drugs due to metabolic-related resistance, such 
as fatty acid synthesis and glutamine metabolism, as well as elevated aerobic 
glycolysis, which in turn reduce the efficiency of drug-induced apoptosis 
(Hodgkinson et al., 2017).  
RT is usually applied prior to or after surgery and often coupled with chemotherapy 
to suppress tumour recurrence (Hodgkinson et al., 2017). Although, a portion 
of tumours are sensitive to radiation, a great number of patients still develop 
resistance to RT. Generally, the kinase Ataxia Telangiectasia Mutated (ATM) is 
activated to trigger DNA repair mechanisms after RT DNA damage occurs in 
tumours (Hodgkinson et al., 2017). However, ATM controls the pro-survival and 
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radio-resistance mechanisms in radiation-treated cells (Hodgkinson et al., 2017). 
The phosphatase of regenerative liver-3 (PRL-3) and surviving anti-apoptotic 
factors have also been found to be RT resistance factors, since they promote 
advanced CRC, hepatic and nodal metastases, high recurrence risks and low 
patient survival rates (Hodgkinson et al., 2017). In addition to drug resistance, 
metastasis is also a major health concern in CRC patients. Primary tumours are 
likely to acquire TGF-β, PIK3CA and TP53 gene mutations, which consequently 
stimulate clonal expansion, invasiveness and metastasis of CRC (Kruger and 
Abrahamse, 2019). Lastly, CRCs drug resistance and metastasis are associated 
with cancer stem cells (CSCs). They have unique properties such as self-renewal 
and a slow rate of cycling ability, possession of numerous drug efflux pumps and 
rapid DNA repairing capacities (Ji et al., 2018). These tumour-initiating cells resist 
standard treatment modalities, which consequently enhance the risks of tumour 
recurrence (Hodgkinson et al., 2017; Ji et al., 2018).  
As indicated earlier, conventional CRC treatments have a low impact on cure rates, 
report resistance and show adverse side effects. Therefore, novel unconventional 
treatments are required to conserve normal healthy cells, precisely annihilate 
cancer cells, in order to reduce unwanted side effects, as well as enhance the 
overall survival of patients (Sun et al., 2016).  
2.3  Conventional Treatments Versus Unconventional Treatments for 
Colorectal Cancer  
Conventional treatments such as surgical excision, radiation therapy and 
chemotherapy, have poor specificity for cancer tumours and therefore are required 
to be administered at high dosages to be deemed successful (Sun et al., 2016; 
Kruger and Abrahamse, 2018). These high doses tend to be detrimental to healthy 
tissues and are often accompanied by undesirable side effects (Kruger and 
Abrahamse, 2018). Additionally, most conventional cancer treatments encounter 
tumour heterogeneity, drug resistance and systemic toxicities (Kruger and 
Abrahamse, 2018). Thus, enormous efforts have been dedicated to exploring 
unconventional treatments such as photodynamic therapy (PDT) since they are 
noninvasive, have a high tumour specificity and conserve normal body cells 
(Hodgkinson et al., 2017). 
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PDT is a non-invasive treatment modality used in the management of various 
malignancies (Kwiatkowski et al., 2018). PDT involves the interaction between 
three fundamentals: a photosensitizer (PS), oxygen molecules within the cell and 
a specific wavelength of light (Kwiatkowski et al., 2018). PDT is a synchronized 
technology that involves intravenous, topical, intraperitoneal or oral administration 
of a PS to patient based on the location of a tumour (Mahmoudi et al., 2018; Kruger 
and Abrahamse, 2018). The PS compound then either passively or actively 
accumulates within cancerous cells or tissues depending on mechanism of delivery 
involved (Kruger and Abrahamse, 2018). Following a successful localization of a 
PS in tumorous tissues, it is irradiated at a specific wavelength of light, which 
results in an energy transfer to surrounding tumour tissue molecular oxygen and 
so generates reactive oxygen species (ROS) and singlet oxygen (1O2) species, 
which in turn eradicate cancer cells via apoptotic or necrotic cell death pathways 
(Hong et al., 2016). 
According to Kwiatkowski et al., (2018) cancer cells are able to passively absorb 
higher concentrations of PSs in comparison to normal tissues, due to low-density 
lipoproteins (LDL) and the enhanced permeability and retention (EPR) effect. One 
of the key roles of LDL is to provide cholesterol to tissues to promote cell division. 
Cancer cell proliferation markedly exhibits an elevated uptake of LDL, due to the 
rapid rate at which tumour cells divide. Since most PSs can preferentially combine 
with low-density lipoproteins (LDL) and cancerous tissues contain a significant 
amount of LDL, their passive uptake is promoted in tumours (Kwiatkowski et al., 
2018). In relation to the passive absorption of a PS due to EPR, all tumors have a 
somewhat leaky vasculature, poor lymphatic drainage and increased vessel 
permeability, these factors allow macromolecular drugs (such as PSs) to 
accumulate more selectively in tumor tissues than in normal tissues (Hodgkinson 
et al., 2017). Therefore, one of the most important advantages of PDT is the 
localized annihilation of diseased cells, avoiding systemic toxicity and harming 
healthy tissues (Hong et al., 2016; Kruger and Abrahamse, 2018).  
In comparison with conventional chemotherapy and radiation therapy, PDT-
mediated cancer treatment limits side effects and enhances the treatment 
specificity, since it only affects the localized irradiated lesion (Hong et al., 2016). A 
study by Kawczyk-Krupka et al. (2018) noted that PDT efficaciously annihilates 
cancerous tissues and has the ability to initiate multifaceted immune reactions and 
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anticancer immunity, which can possibly eradicate remaining cancer cells. A 
review by Kruger and Abrahamse (2019), stated that PDT therapy is a non-irritant 
and feasible alternative treatment for inoperative CRC with mildly advanced polyps 
and precarious tumours. Additionally, since it is feasible to reach the colon using 
an endoscope through an open rectum, colonoscopy not only can be used both for 
direct PS delivery to the cancerous sites, but also for the administration of a 
suitable wavelength of light to stimulate the PS agent (Figure 5) (Kruger and 








Figure 5 PDT in CRC treatment (Kruger and Abrahamse, 2019). 
 
2.3.1  PDT Mechanism of Action  
PDT molecular mechanisms depend on three non-toxic elements, which exert 
cytotoxic effects within pathological tissues (Kwiatkowski et al., 2018). A specific 
wavelength of light, a PS and oxygen are three essentials of PDT (Debele et al., 
2015). A PS molecule is in singlet ground state with two electrons with opposite 
spin, when irradiated with an appropriate wavelength of light, it triggers the 
excitation of one of the electrons into a higher-energy orbital  (Abrahamse and 
Hamblin, 2016). The PS molecule then moves from this ground state to a singlet 
excited state due to photon absorption (Abrahamse and Hamblin, 2016; 
Kwiatkowski et al., 2018). The excited singlet state PS, then undergoes 
intersystem crossing to transform into a more stable excited triplet state with 
parallel electron spins (Abrahamse and Hamblin, 2016). Meanwhile, the released 
energy from this occurrence is transmitted to the surrounding tumour oxygen 
molecules, which in turn produces either ROS or 1O2 species depending on the 




Figure 6 Photodynamic therapy mechanisms of action for Type 1 and 2 pathways. 
Following activation of the PS with an appropriate wavelength of light, it 
interacts with either molecular oxygen or biomolecules adjacent to the 
tumour cell, producing ROS or 1O2, which in turn induces apoptotic or 
necrotic cell death (Kruger and Abrahamse, 2018). 
 
Within a Type 1 pathway, the excited PS interacts with surrounding substrates and 
biomolecules to form active radicals that subsequently upset biological 
components, such as peptides, proteins, plasma membranes and nucleic acids 
(Debele et al., 2018). The transfer of either a hydrogen atom or an electron 
between the excited triplet state of PS and the tumorous tissue (substrate) results 
in the formation of free radicals and anions radicals (Kwiatkowski et al., 2018). 
These free radicals then interact with surrounding tumour molecular oxygen to 
generate ROS, such as superoxide and hydroxyl radicals (Kruger and Abrahamse, 
2018; Kwiatkowski et al., 2018). The radicals then activate a cascade of reactions 
which exerts a lethal oxidation stress on cancer cells and so destroys them 
(Kwiatkowski et al., 2018). 
In a Type 2 pathway, the stimulated triplet state PS transfers energy or electrons 
to surrounding tumour molecular oxygen, which converts the oxygen into an 
excited singlet state species (1O2), which in itself is cytotoxic to surrounding tumour 
cells (Abrahamse and Tynga, 2018). Direct transmission of energy between 
stimulated triplet state PS and tumour molecular oxygen is achievable, if they are 
both in a similar state (Abrahamse and Tynga, 2018). However, as surrounding 
tumour molecular oxygen depletes, a Type 1 photochemical reaction will dominate 
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(Kwiatkowski et al., 2018). Singlet oxygen species generation generally results in 
the photodamage of amino acids, fats and other biomolecules which are adjacent 
to PS after excitation (Kwiatkowski et al., 2018). It is hypothesized that a Type 2 
photochemical reaction is the most favorable and effective pathway to induce PDT 
cancer cell death (Kwiatkowski et al., 2018).  
Nevertheless, the occurrence of both pathways simultaneously, influenced by 
variables such as surrounding oxygen concentrations, tissue dielectric constant, 
pH and PS properties can produce favorable PDT induced cancer cell death 
(Kwiatkowski et al., 2018).  
2.3.2 PDT Tumour Cell Death Induction     
Depending on the intracellular localization of a PS the type of tumour cell death 
induced by PDT may be apoptotic or necrotic. Generally, the disruption of a tumour 
cells mitochondria can trigger apoptotic cell death, while the destruction of a tumour 
cell membrane, causes it to lose integrity and so necrosis is observed. However, if 
only lysosome or endoplasmic reticulum damage is induced, a less favorable 
autophagy cell death can occur, as tumour cells can recover from this form of cell 
death (Kwiatkowski et al., 2018).Therefore PDT has the ability to kill tumour cells 
obliterates via the induction of the three modes of cell death: apoptosis, necrosis 
and autophagy (Figure 7) (Abrahamse and Hamblin, 2016).  
Figure 7 PDT eradicates cancer cells via three different modes of cell death 
namely, apoptosis, necrosis and autophagy (Naidoo et al., 2018). 
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The mode and magnitude of cell death depend on various factors such as cellular 
morphology, immune responses, enzymatic action, intensity of light wavelength, 
oxygen concentration availability, PS structure and region of subcellular 
localization (Naidoo et al., 2018). These variables enforce whether the mode of cell 
death is programmed or not (Naidoo et al., 2018). However, many studies have 
reported that apoptosis is the most frequently induced cell death pathway by PDT 
(Rapozzi et al., 2015; Wang et al., 2015; Manoto et al., 2017). 
2.3.2.1 Apoptosis  
Apoptosis is a programmed cell death distinguished by nuclear condensation and 
overall cellular shrinkage, which includes a sequence of caspases, endonucleases, 
and other enzymes (Rapozzi et al., 2015; Kou et al., 2017). The induction of the 
process is triggered through stimulation of cell death receptors or the translocation 
of cytochrome c from the mitochondria to the cytoplasm (Mroz et al., 2011; Kou et 
al., 2017; Kessel and Oleinick, 2018). Apoptosis is elicited via intrinsic 
(mitochondrial) and extrinsic pathways (cell death receptors) (Rapozzi et al., 2015; 
Donohoe et al., 2019).  Both pathways trigger the caspase cascade known as 
executioner caspases (caspase-3, 6 and 7) (Mroz et al., 2011). The initiated 
executioner caspases cleave cellular substrates, resulting in biochemical and 
morphological features exhibited by dead cells (Mroz et al., 2011). Nuclear lamins 
cleavage leads to condensation of chromatin and nuclear shrinkage, while caspase 
activated deoxyribonuclease (CAD) cleavage and DNase inhibitors cause DNA 
fragmentation (Mroz et al., 2011).  In addition, cleavage of cytoskeletal proteins 
results in cell fragmentation and apoptotic body formation (Mroz et al., 2011).  
The B-cell lymphoma 2 (Bcl-2) protein family has at least 20 relatives, all of which 
have a commonly conserved Bcl-2 homology domain (Mroz et al., 2011; George 
and Abrahamse, 2016; Kou et al., 2017). This family consists of four other anti-
apoptotic proteins: BclXL, Bcl-w, A1 and Mcll, and two sets of proteins, which 
stimulate apoptosis: the Bax and the BH3 families (Mroz et al., 2011; Donohoe et 
al., 2019). Bcl-2 localizes in cellular mitochondria, endoplasmic reticulum, and 
nuclei, and it can counteract the release of cytochrome c, thus inhibiting apoptosis 
(George and Abrahamse, 2016).  
Studies argue that PDT exerts photodamage on Bcl-2 and other related 
antiapoptotic proteins, stimulating Bax and the BH3 proapoptotic members of this 
27 
 
family (Mroz et al., 2011; Kessel and Oleinick, 2018).  A study by Mroz et al., (2011) 
stated that changes in the expression of members of Bcl-2 family proteins, post 
PDT was observed in various CRC cell lines and tumours, and Bax was 
upregulated, promoting apoptotic cell death in these cells. 
2.3.2.2 Autophagy  
Autophagy is a sporadic form of programmed cell death characterized by a self-
degradative mechanism which enables cells to digest themselves (Liang et al., 
2016). It controls proteins, organellar homeostasis and biomolecular resource 
recycling, thus serving as quality control processes to promote cell survival and 
energy homeostasis (Garg et al., 2015). Autophagy conserves nutrients through 
the eradication of damaged subcellular components, thereby alleviating cellular 
stress (Garg et al., 2015). According to Chilakamarthi and Giribabu (2017), it is not 
evident whether autophagy promotes cell survival or eliminates cells via PDT.  
However, in general within mammalian cells, during physiological stress / 
starvation or elevated ROS levels, autophagy serves as a self-survival mechanism 
and so revives dysfunctional organelles (Chilakamarthi and Giribabu, 2017). In this 
case, a double membrane autophagosome engulfs dysfunctional organelles and 
misfolded proteins and combines them with lysosomes to form 
autophagolysosomes, whereby lysosomal enzymes lyse them and salvage them 
(Garg et al., 2015; Chilakamarthi and Giribabu, 2017). However, within PDT 
applications autophagy can function as a cytoprotective or cytotoxic cell death 
pathway and the outcomes followed is based on the nature of PS, the form of ROS, 
the presence of apoptotic machinery and the degree of photo damage 
(Chilakamarthi and Giribabu, 2017). PSs localized within mitochondria, 
endoplasmic reticulum (ER) and lysosome organelles generally potentiates 
autophagic cell death (Chilakamarthi and Giribabu, 2017). Several lines of 
evidence state that PDT may trigger autophagy by inactivating autophagic negative 
feedback mechanisms, such as Bcl-2 and mammalian target of rapamycin (mTOR) 
proteins, instead of stimulating essential autophagic pathways such as Beclin1, 
Atg5 and Atg7 (Chilakamarthi and Giribabu, 2017). 
Studies by Gard et al., (2015) noted that different types of PSs, have different 
affinities for particular tumour cell organelles, e.g. hypericin has high affinity for ER, 
whereas 5-aminolevulenic acid (5-ALA) exclusively targets the mitochondria and 
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so different modes of PDT induced cell death is observed. However, studies by 
Ouyang et al., (2018) revealed that even though Protoporphyrin IX (PpIX)-
mediated PDT (PpIX-PDT) induced autophagy, as well as apoptotic modes of cell 
death in human CRC HCT116 cells, that this promoted overall PDT treatment 
outcomes. The study went onto state that even though autophagy cell death was 
supposed to protect the CRC cells, the overall cytotoxic effects of the PpIX-PDT, 
counteracted the autophagy recovery in cells, via the promotion of proapoptotic 
factors and so altered autophagy cell death to a more favourable apoptotic cell 
death mode, enhancing the PDT treatments efficacy. Thus even though, 
autophagy is an undesirable cell death pathway, because it can either serve as a 
tumour suppressor or promoter, a study by Wei et al., (2014) concluded that 
autophagy endows resistant CRC to PDT, by promoting apoptosis and so should 
be considered a favourable CRC tumour suppressor mode of cell death. 
2.3.2.3 Necrosis 
Necrosis is a non-programmed, aggressive form of degeneration affecting an 
extensive population of cells by killing them off (Chilakamarthi and Giribabu, 2017). 
Necrosis is triggered by a physical or chemical damage to a cell and the 
decomposition is mainly facilitated by proteolytic activity, although the precise 
identities of the involved proteases and their substrates are not well-known (Mroz 
et al., 2011). It is morphologically distinguished by extensive swelling of cellular 
membranes, often with chromatin condensation and an atypical pattern of DNA 
degradation (Mroz et al., 2011; Escobar et al., 2015). The cytoplasmic membranes 
and membranous organelles of cells lose their integrity, and their increased 
swelling triggers the disintegration of the plasma membrane, which releases 
cytoplasmic material into extracellular compartments, causing cellular 
fragmentation (Escobar et al., 2015).  Accumulating evidence describes that the 
higher the administered concentration of a PS and fluency rate, the higher the 
cause of membrane disruption is and so a necrotic, rather than apoptotic cell death 
mode is often observed (Van Straten et al., 2017; Chilakamarthi and Giribabu, 
2017). Studies by Van Straten et al., (2017) reported that a PDT mediated photofrin 
PS, induces apoptosis when it accumulates in the cytoplasm, whereas it initiates 
necrosis, when incubation time was increased, since it then accumulated higher in 
cellular plasma membranes.  Thus, the generation of cytotoxic species post-PDT, 
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when a PS has favourably localized in a cell’s plasma membrane, will promote 
more necrotic modes of cell death (Chilakamarthi and Giribabu, 2017).  
In response to PDT, tumour necrosis factor (TNF) and Fas receptors cause 
necrotic cell death by activating receptor interacting protein 1 (RIP1) under 
caspase inhibition conditions. RIP1 forms a necrosome in conjunction with RIP3, 
which augments the catalytic effect of bioenergetics enzymes (Chilakamarthi and 
Giribabu, 2017).  
2.4  PDT Laser Light Irradiation 
Each PS is prompted by a particular wavelength of light and the intensity of the 
light fluency (Allison and Moghissi, 2013). When light penetrates tissues, it can 
scatter or get absorbed, based upon the type of tissue and wavelength of light 
applied (Yoon et al., 2013). As the wavelength of light increases, so the light 
absorption characteristics of a tissues decreases, hence the greater the 
wavelength of light applied, the deeper the depth of tissue penetration (Yoon et al., 
2013). Shorter wavelengths (< 650 nm) of light in PDT have a poor tissue 
penetration and are usually absorbed, leading to high skin photosensitivity (Yoon 
et al., 2013). Studies have revealed that longer wavelength absorption bands (> 
850 nm) are not able to transfer ground state oxygen molecules to the excited 
singlet state, leaving PDT treatments unsuccessful (Yoon et al., 2013). Thus, the 
maximum tissue depth penetration wavelength of light, with idealistic PDT 
treatment outcomes, occurs in the range of 650-850 nm, which is known as the 
‘’therapeutic window’’ index of PDT (Yoon et al., 2013; Hugo, 2015; Zhu and Finlay, 
2008). The energy generated within this range allows for maximum tissue depth 
penetration, to excite PS photons enough, to generate sufficient amounts of 
cytotoxic species for effective PDT cancer cell death induction (Zhu and Finlay, 
2008). Additionally, essential endogenous chromophores, such as hemoglobin and 
water are principal absorbers of visible and infrared light and so have led 
researchers to only apply PDT treatment within the optical window concept in 
tissues (i.e. ’therapeutic window’’) (Yoon et al., 2013; Hugo, 2015). Intriguingly, 
tissues exhibit the lowest optical absorption coefficients in the near Infrared (NIR) 
spectroscopy region, around 650-900 nm (Hugo, 2015). This is due to the fact that 
light within the NIR region is more transparent with enhanced 500 µm tissue 
penetration (Hugo, 2015). More importantly, NIR light is less detrimental to normal 
tissues and so reduces the chances of unwanted tissue damage (Hugo, 2015). 
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Clinically, 630 nm can penetrate tissue to presumably 0.5 cm, which enables 
irradiation for both surface and deeply located tumours (Allison and Moghissi, 
2013).  However, some PSs can be activated at higher wavelengths for deeper 
penetration, while others act efficiently at lower wavelengths for more superficial 
illumination (Allison and Moghissi, 2013). Therefore, it remains pivotal to choose a 
suitable PS and wavelength of light to optimize PDT outcomes, for the type of 
cancer treatment required, taking into consideration tissue depth penetration 
(Allison and Moghissi, 2013; Zhu and Finlay, 2008).  
Furthermore, the successful formation of PDT induced cytotoxic species is also 
highly dependent on the mode of light delivery and so researchers often investigate 
varying approaches (Hugo, 2015). Generally, the most common light sources used 
in PDT applications include: broadband light beam generated by incoherent lamps, 
focused light beam with a particular wavelength yielded by lasers, light emitting 
diodes (LEDS) and fluorescent light sources (Hugo, 2015). Broadband light is often 
used for illumination of large lesions, due to its high portability and low cost (Hugo, 
2015). The treatment of deep internal organs is performed by the use of 
endoscopes and optical fibers for coordinated light delivery (Hugo, 2015).  
PDT involves the administration of a specific dose of a PS (per body weight), in a 
clinical setting, followed by the application of a fixed amount of light fluency (J/cm²) 
(James et al., 2018). However, the outcomes for each individual type of cancer and 
tumour vary due to physiological factors, such as local tissue optical 
characteristics, tumour oxygenation and absorbed PS dose (James et al., 2018). 
Additionally, these factors may also vary during PDT treatment. For instance, PS 
photobleaching may suppress cytotoxic species production, which leads to the 
depletion of molecular oxygen, if the reperfusion ability of the tissue is exceeded 
by instant photochemical reaction (James et al., 2018). Thus, critical pretreatment 
planning, online monitoring and dosimetry approaches during PDT must be taken 
into consideration (James et al., 2018).  
There are three clinical dosimetry techniques used in PDT, namely the direct, 
explicit and implicit dosimetry (Zhu and Finlay, 2008; James et al., 2018). Direct 
dosimetry directly quantifies cytotoxic species production, either by its own 
phosphorescence emission or through singlet oxygen sensitive chromophores 
(Zhu and Finlay, 2008). Explicit dosimetry encompasses techniques and 
instrumentation to evaluate the three fundamentals of PDT (i.e. light, PS and 
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oxygen) separately and independently in the tissue (James et al., 2018). Lastly, 
implicit dosimetry measures the fluorescence photobleaching of the PS, which 
indirectly determines the amount of generated cytotoxic species (Zhu and Finlay, 
2008; James et al., 2018).   
2.5  Limitations of PDT in CRC Treatment  
Despite many advances in PDT cancer treatment, PDT is still hampered by 
inherent properties of PSs in the clinical settings, due to their low solubility, mode 
of delivery and targeted tumour tissue selectivity (Hong et al., 2016; Kruger et al., 
2018). Most types of PSs are hydrophobic and tend to aggregate in physiological 
environments, considerably reducing the amount of cytotoxic species produced 
(Hong et al., 2016). Full obliteration of tumour cells requires high quantum yields 
of cytotoxic species, which depends on the uptake and intensity of PS localized in 
tumorous cells (Kruger et al., 2018).  
Generally, unmodified conventional PS drugs passively accumulate in tumour 
sites, limiting the overall potency of PDT (Kruger et al., 2018). The residual 
amounts of PS either invades surrounding healthy tissues and so can cause 
unwanted side effects or is eradicated by the bodies immunological barriers 
(Kruger et al., 2018). Even within some modified PS, for enhanced water solubility, 
their normal tissue preservation remains insufficient for clinical application (Hong 
et al., 2016). Furthermore, the delivery of enough light to localized tumours is a 
major challenge, since deep tissue malignancies often reflect light, weakening the 
overall treatment outcomes (Zhou et al., 2016). Another drawback is that PDT can 
only be sued from the treatment of non-hypoxic tumours, since its cytotoxic 
mechanism of action is highly dependent on the tumour surrounding oxygen 
concentration (Zhou et al., 2016). According to Zhou et al., (2016) solid tumours 
profusely proliferate beyond their blood supply, due to an impaired vascular 
system, leaving portions of the tumour in a hypoxic microenvironment, affecting 
overall PDT treatment outcomes. 
2.6 Photosensitizers for CRC PDT Treatment  
PSs are natural or synthetic chemicals that can absorb light at a particular 
wavelength and induce cytotoxic photochemical or photophysical reactions (Li et 
al., 2018; Kwiatkowski et al., 2018).  
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An ideal PS should possess a strong absorption peak within the red to near-
infrared spectral region (650-800 nm), to avoid patient photosensitivity prior to PS 
activation and light absorption by other endogenous chromophores of the body 
(Kruger et al., 2018; Abrahamse and Hamblin, 2016). Since the penetration of light 
into the tissues intensifies with wavelength, long wavelength parameters promote 
light absorption for maximum PS stimulation and cytotoxic species formation, as 
well as ideal tissue penetration within localized tumour sites (Kruger et al., 2018; 
Abrahamse and Hamblin, 2016). Preferably, a PS should be highly aqueous and 
show a high affinity to passive absorption by cancerous tissues (Kwiatkowski et al., 
2018). Furthermore, slow clearance from localized tumour areas and quick 
removal from healthy tissues are of great importance, to avoid unwanted side 
effects (Kwiatkowski et al., 2018). Lastly, PSs should exhibit a high degree of 
chemical purity for improved storage and stability (Abrahamse and Hamblin, 2016).  
PSs are classified into four basic structures, such as porphyrin, chlorin, 
phthalocyanines and bacteriochlorin. Then there are other types of PS dyes, such 
as methylene blue, toluidine blue, rose bengal and hypericin (Figure 8) (Baskaran 
et al., 2018). PSs can also be divided into four groups based on their functionality 
(Kruger et al., 2019). 
Figure 8 The four basic structures of PSs (Mesquita et al., 2018). 
First-generation type PDT PSs do demonstrate high stability, however they show 
photosensitivity in patients, with poor tissue penetration due to their relatively short 
wavelengths of activation (e.g. hematoporphyrin and photofrin derivatives) 
(Kwiatkowski et al., 2018; Kruger et al., 2019).  
Second-generation PSs exhibit improved properties, such as high chemical purity, 
with higher cytotoxic species generation and enhanced penetration in deeply 
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seated tumours, due to their strong absorption peaks within the 650-800nm 
wavelength range (Kwiatkowski et al., 2018). Additionally, second-generation PSs 
demonstrate less unwanted side effects, due to their preferential selective affinity 
for neoplastic tissues and rapid clearance from normal cells (Kwiatkowski et al., 
2018; Kruger et al., 2019). Currently, the grouping of second-generation PSs 
comprises of hematoporphyrin derivatives and synthetic PSs, such as 5-
aminolevulinic acid, benzoporphyrin derivatives, texaphyrins, thiopurine 
derivatives, chlorin, as well as bacteriochlorin analogues and phthalocyanines 
(Kwiatkowski et al., 2018). However, one of the major downsides of second-
generation PSs, is their poor water solubility and this greatly reduces their overall 
passive and concentrated uptake in tumour tissues (Kwiatkowski et al., 2018).  
Thus, in an attempt to overcome the obstacles second-generation PSs face, third-
generation PSs have been developed (Kou et al., 2017). Basically, third-generation 
PSs are second-generation PSs, which have been chemically modified, 
functionalized or encapsulated  into nanoparticles (to enhance their solubility and 
passive cellular uptake) or bound to targeting agents (such as monoclonal 
antibodies, peptides and aptamers) in order to promote actively targeted 
localization within specific tumour sites (de Freitas and Hamblin, 2016; Kruger and 
Abrahamse, 2019).  
Lastly, some recent novel research is also focused on the development of fourth-
generation PSs, which are composed of second-generation PSs conjugated to a 
nanoparticle carrier system, making them third-generation PSs, however they are 
additionally co-encapsulated within small-molecular inhibitor systems, which 
circumvent any tumour survival pathways post-PDT to prevent tumour relapse 
(Kruger and Abrahamse, 2019). 
In general, porphyrin PS derivatives have a planer aromatic ring structure with 
great photophysical properties for PDT applications (Figure 8), however they have 
a relatively low cytotoxic species yield and so are often modified into second- and 
even third-generation classes to try and enhance their overall PDT efficacy  
(Mfouo-Tynga and Abrahamse, 2015). Phthalocyanines (Pcs) PSs originate from 
porphyrins and so have properties that generally resemble porphyrin precursors 
(Figure 7) (Mfouo-Tynga and Abrahamse, 2015). However, Pcs can elicit even 
higher cytotoxic species yields in PDT applications, when compared to porphyrins, 
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since they have longer absorption peaks of activation within the red spectrum of 
light (Li et al., 2018). Furthermore, according to Mfouo-Tynga et al., (2015) 
phthalocyanine-mediated cancer PDT treatment stimulates autophagy and 
caspase-3 activation for enhanced apoptotic modes of cell death. Moreover, 
metallized Pcs are even more potent inducers of PDT cytotoxic damage in cancer 
cells, due to their additional photothermal properties, which are produced under 
laser light irradiation (Mfouo-Tynga and Abrahamse, 2015).  
Table 1 below summarizes the various PSs studied for CRC in vitro and in vivo 
PDT treatment, along with their functional parameters and the outcomes of each 
study.  
Table 1 The outcomes and parameters of PSs which have been investigated for 
the in vitro and in vivo PDT treatment of CRC. 
 PS Parameters  CRC  Results Ref.  
Chlorin e6 (Ce6) Wavelength: 
650nm 
Fluency: 6 J/cm² 
[PS]: 8μg/ml 
 
SW480 Ce6-PDT reduced migration and colon 
formation capacity of SW480 in a dose-
dependent manner and resulted in a 
substantial apoptotic rate of 75%. Moreover, 
the cell survival rate also declined in a dose-
dependent manner, revealing a significant  
20% cell survival rate at 8μg/ml. 
Li et al., 
2014 
Chlorin e6 (Ce6) Wavelength: 
650nm 
Fluency: 6 J/cm² 
[PS]: 1μg/ml 
SW620 Ce6-PDT induced apoptosis and autophagy. 
Ce6 was mainly localized in the endoplasmic 
reticulum and 1µg/ml resulted in 50% 
apoptotic cell population 
Yang et al., 
2018 




C26 C26 xerograph mouse tumours revealed a 
15% reduction in size following PDT and a 
decline in the expression of invasion-related 
proteins. 












Sub lethal dose of ALA-PDT (1000μM) 
reduced SW620 cell viability by 80% and 
SW480 by 93%. In hypoxia like settings, 
apoptosis percentage of SW620 cells was 
6.4, while in SW480 cell line was 3.0. In 
addition, ALA-PDT counteracted the release 
IL-6, 8 & 10 from, essentials factors for 










[PS]: 250 mg/kg. 
HT29 5-ALA elicited tumour inhibition rate of 88% 
in mice bearing HT-29 colon cancer cells. 
Hatakeyam






Fluency: 10 J/cm² 
[PS]: 0.5mM 











HT-29 cells were more resistant to PPa than 
SW480 cells with lower ABCG2 levels. The 
cell viability (relative) following the treatment 
of cells with 100nm of PPa was 0.6 and 0.9 
for SW480 and HT-29 respectively. 
 
 













PpIX-PDT triggered apoptosis and 
autophagy, decreasing cell viability in a 
concentration and light dose-dependent 
manner. 2μg/ml PpIX exerted phototoxic 
effects on HCT116 cells, resulting in 








Fluency: 10 J/cm² 
[PS]: 100 ng/mL 
HCT11
6 
Significant phototoxic and antiproliferative 
effects were noted.  100 ng/mL DVDMS led 
to 73.8 % apoptotic cell population in 
HCT116 cells. 














11.6µM m-THPC resulted in an apoptotic 
rate of 65 and 25% in SW480 and SW620, 
respectively. The colony formation and 
migration ability of both cell lines revealed a 
declining trend when the concentration of m-
THPC was increased. 
Abdulrehm














H2TFPC-SGlc-mediated PDT significantly 
suppressed tumour growth in xenograft 
tumour models through induction of apoptotic 
cell death. Tumour volume exhibited a 3-fold 














A significant apoptotic cell population was 
noted in CaCo-2 and DLD-1, accounting for 
70% and 60% respectively.   
Sekhejane 
et al., 2014 
Hypericin Wavelength: 580–
740nm 
Fluency: 14 J/cm² 
[PS]: 50µM 
CT26 A low dosage of hypericin-PDT completely 














HT29 Administered 0.3mg/kg of mTHPC and 
5mg/kg of bevacizumab to xerograph mouse 
model. mTHPC-PDT (2nd generation) 
exerted 45.1% tumour growth inhibition, 
however when combined with bevacizumab 
a 79% (3rd generation) growth inhibition was 
reported, due to combinative antibody effect 
which reduced VEGF and cytokines 
expression in tumours. 
Peng et al., 
2018 
 
As can be seen from the findings in Table 1, second-generation PSs, such as 
phthalocyanines, 5-aminolevulinic (ALA) and Chlorin e6 (Ce6) have the potential 
to provide cytotoxic effects on CRC tumours and could be the cornerstone in the 
treatment of primary CRC (Nkune et al., 2020). However, from a lot of these studies 
it was found that second-generation PSs, when used alone do not have the ability 
to efficiently and passively accumulate in high enough concentrations in CRC 
tumours for effective PDT treatment outcomes. Hence, it was recommended that 
researchers concentrate on the further investigation of these second-generation 
PSs, however within a modified actively targeted third-generation form in order to 
enhance their cellular uptake and so potentially improve CRC PDT treatment 
outcomes (Nkune et al., 2020; Baskaran et al., 2018).  
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2.6.1 Zinc Phthalocyanine (ZnPc) PSs for CRC PDT Treatment  
Phthalocyanines (Pcs) are planar aromatic macrocyclic compounds made up of 
four isoindole rings linked by hydrogen atoms (Li et al., 2017; Yalazan et al., 2019). 
Pcs are widely used second-generation PSs due to their long absorbance and high 
extinction coefficients (Yalazan et al., 2019). Pcs are capable of binding to different 
metal ions to form metallophthalocyanine (MPc) compounds (Yalazan et al., 2019). 
MPc compounds have attracted considerable attention owing to their strong 
absorption within the far-red spectral range, which promotes high triplet state 
quantum yields and long triplet lifetimes (Yalazan et al., 2019).  
Zinc phthalocyanine (ZnPc) is a favorable second-generation PS for cancer PDT, 
with desirable photophysical and photochemical properties (Yu et al., 2018). 
Studies by Roguin et al., (2019) noted that ZnPc has excellent properties such as 
low dark toxicity, selective passive accumulation in tumour tissues, high chemical 
and photochemical stability, improved therapeutic efficacy, negligible skin 
photosensitivity and excitation at wavelengths greater than 630 nm, which enables 
deep tissue light penetration. ZnPc has a massive photodynamic activity (PD) as it 
possesses a central zinc-diamagnetic metal ion that simultaneously increases the 
triplet-state quantum yield of ROS production, produces photothermal energy upon 
irradiation and prolongs triplet state lifetimes (Moon et al., 2012). Despite many 
merits, ZnPc is poorly soluble in organic solvents and so in order to overcome this 
problem, anionic derivatives containing sulphonic (ZnPcS), phosphonic and 
carboxylic groups have been developed, to not only enhance water solubility, but 
also improve its passive cellular absorption (Roguin et al., 2019).  
Mfouo-Tynga and Abrahamse, (2015) reported that a mixed sulfonated 
metallophthalocyanine (ZnPcSmix) containing zinc as the central atom effectively 
enters cancerous cells and accumulates in pivotal organelles like mitochondria, 
lysosomes and Golgi apparatus, producing desirable apoptotic forms of PDT 
induced cell death. In a study by Manoto et al., (2012), ZnPcSmix PS was incubated 
with DLD-1 CRC cells and irradiated at 680 nm with a fluency of 20 J/cm². In vitro 
studies noted a significant 40% apoptotic cell death, when treated with 20 μM 
ZnPcSmix, and only showed dark toxicity above 40 μM PS concentration. 
Furthermore, studies by Brozek-Pluska et al. (2020), utilized Raman imaging and 
spectroscopy to characterize and differentiate normal and cancerous colon tissues 
using a chemically pure tetra-sulphonated form of Zinc sulfothiolphthalocyanine 
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(ZnPcS4) and its vibrational features. The study found that ZnPcS4 PS noted a 
higher affinity passive subcellular localization uptake in CRC cells (when compared 
to normal cells) and noted excitation wavelengths within the 689 nm range, 
suggesting that this PS could  be applied within PDT applications for CRC, however 
required further investigation. 
Thus, within this particular study the chemically pure form of ZnPcS4 was used as 
the PS for the PDT treatment of in vitro cultured CRC cells, since it is a 
tetrasulphide derivative and so has 4 SH / thioacetate groups, which enhances 
solubility (Siriwandana et al. 2014). Furthermore, ZnPcS4 PS allows for easy 
chemical modification to promote passive nanoconjugate directed tumour uptake, 
as well as allows for functionalization for active tumour targeting (Siriwandana et 
al. 2014). Additionally, ZnPcS4 has three major Q bands of emission (583, 634, 
674 nm) within the far-red spectral range for maximum tissue light depth 
penetration and PS excitation for effective PDT treatment (Abramczyk et al.  2017). 
2.6.2 Nanoparticle PS Drug Carrier Platforms for PDT Applications 
Nanoparticles (NPs) allow anticancer agents (such as PSs) to permeate effectively 
and selectively into tumour tissues, through passive or active targeting, mitigating 
unwanted side effects in healthy tissues (Tang et al., 2017). A study by Patra et 
al., (2018) stated that NPs can fundamentally remould solubility, drug release 
profiles, diffusion, bioavailability and immunogenicity, which can lead to convenient 
routes of administration, reduced toxicity, fewer side effects, enhanced 
biodistribution and prolonged drug life cycle. Since NPs exhibit hydrophilic 
properties, the incorporation of NPs in PDT applications increases the overall 
solubility of PSs, as well as promotes their passive cellular uptake properties 
(Kruger and Abrahamse, 2018). Additionally, NPs drug carriers are able to infiltrate 
tiny spaces between tumour cells, thereby suppressing lymphatic filtration, which 
in turn enhances PS cellular uptake via the EPR effect (Kruger and Abrahamse, 
2018). In addition, NPs tend to mimic or modulate biological processes and so 
evade immune system barriers, which in turn preserves therapeutic drugs and so 
enables enhanced tumour cell passive drug delivery and absorption (Rizvi and 
Saleh, 2018; Kruger and Abrahamse, 2018). 
According to Rizvi and Saleh, (2018) NPs are small, and have a huge surface area 
to volume ratio to absorb high volumes of therapeutic drugs. Therefore, they can 
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accumulate efficiently in tumour cells and so deliver high enough quantities of 
drugs to enhance cancer cell treatments. Kruger and Abrahamse, (2018) also 
added that NPs are easy to synthesise and their surface properties enable 
modifications. In order to improve the selectivity of PSs towards tumour cells, NPs 
are covalently conjugated to PSs to form third-generation PSs (Saini et al., 2016). 
However, the main concern of PDT is to selectively annihilate cancer cells and 
improve PS selectivity towards cancer cells while sparing healthy tissues. In this 
sense, researchers are now developing third-generation actively functionalized NP 
PS target delivery systems, by binding specific cancer targeting moieties to already 
conjugated PS-NP passive delivery systems, to further enhance PS uptake in 
cancer tumour cells. In these models PS-NP conjugates are coupled with 
monoclonal antibodies (MAbs), against tumour-associated antigens (TAAs) 
specifically expressed by cancer cells (Saini et al., 2016). 
2.6.3 Nanoparticle Photosensitizer Carrier Platforms and Targeting 
Strategies for Cancer Treatment 
The application of nanomaterials within the PDT modality has paved new avenues 
for the treatment of cancer by offering effective nanoscale PSs delivery 
mechanisms and minimizing unwanted PDT-associated side effects (Mesquita et 
al., 2018). Studies demonstrate that NPs not only can promote passive or active 
uptake of PSs in tumour cells, but also can enhance solubility, stability of the PSs 
and so minimize nonspecific toxicity (Roblero-Bartolon and Ramon-Gallegos, 
2015). 
NPs are broadly classified into organic and inorganic NPs. Their physiochemical 
characteristics can be rendered by modifying their composition, shape and surface 
properties (Lombardo et al., 2019). Examples of nanocarriers include liposomes, 
polymer micelles, silicon dioxide, carbon nanotubes, dendritic polymers, gold, 




Figure 9 Examples of various organic and inorganic NPs used in cancer PDT 
treatment (Zhou et al., 2017). 
2.6.4 Passive Nanoparticle Photosensitizer Carrier Platforms for PDT 
Treatment of CRC 
As discussed, previously NPs passively target diseased tissues via EPR effect 
depending on factors, such as the surface properties of NPs, immunogenicity and 
tumour characteristics (Zhou et al., 2017) (Figure 9). Numerous organic and 
inorganic nanomaterials, such as liposomal, micellar polymeric, silica and gold 
NPs, are used to deliver sufficient PS volumes to targeted tumour sites 
(Hodgkinson et al., 2017).The application of NPs in PDT improves its lethality, 
allows for the passive accumulation of the PS in malignant tissues, with fewer side 
effects, as well as decreases the dark toxicity of PSs (Hodgkinson et al., 2017).  
Table 2 below, lists effective NP carrier platforms which have been studied for the 
effective passive PS delivery in CRC tumours, as well as their PDT outcomes.  
Table 2 The outcomes and parameters of passive PS nanoconjugates which have 
been investigated for the in vitro and in vivo PDT treatment of CRC. 




β-cyclodextrin β-CDs reduced the absorption of the 
PS in the skin and muscles and 
increased its accumulation in HT29 
tumours in mice. 
Yankovsky 






Chitosan The drug was absorbed and confined in 
the endocytic vesicles of HCT116/LUC 
xenograft models and epitomized high 
efficacy of PDT treatment. 
 











PTHPP-PHA complex had phototoxic 
effects on HT-29 cancer cells following 








PEG-Chito-5-ALA stimulated necrotic 
and apoptotic cell death in CT26 cells 
and demonstrated an immense drug 
delivery capacity. 




Chitosan CaCo-2 cells demonstrated a better 
uptake of 5-ALA and chitosan 
conjugate compared to 5-ALA alone. 
Yang et al., 
2009 
Chlorin e6 (Ce6) Methoxy poly(ethylene 
glycol) (MePEG) 
Accelerated cellular uptake, 
phototoxicity and ROS yield in in vitro 
cell culture. In addition, they promoted 
tumour tissue penetration and 
accumulation in vivo animal model 
Ryu et al., 
2018 
Chlorin e6 (Ce6) Polyvinyl alcohol (PVA) Ce6-PVA enhanced cellular uptake and 
reported a considerable tumour 
regression and necrotic cell death in 
CT26 xenograft models. 
Gavrina et 
al., 2018 
Chlorin e6 (Ce6) Doxorubicin (DOX)-
loaded micelles and 
lipoic acid (LA) 
conjugated methoxy-
poly(ethylene) glycol 
In vitro CT-26 and HCT-116 cell 
cultures were treated with PS coupled 
with an anticancer agent. This 
combination therapy triggered 
apoptosis and suppressed tumour 
growth in CT-26 tumours in mice. 
Kim et al., 
2018a 
Diaryl-porphyrin Core-shell poly-methyl 
methacrylate NPs 
(PMMA) 
PS-PMMA displayed high phototoxicity 
on HCT116 CRC cells. 
Ballestri et 
al., 2018 
Dimeric zinc (II) 
phthalocyanine 
Mesoporous silica Elicited a significant intracellular 
fluorescence and photocytotoxicity in 
HT-29 cells. 
Wong et al., 
2017 
Hypericin P123 micelles P123 stimulated cellular uptake of 
hypercin and achieved 90% 




Indocyanine Green Super carbonate 
apatite 
HT-29 showed a significant decrease in 
growth. 
Tamai et al., 
2018 
IR780 iodide Pluronic-coated gold Demonstrated an increased 
phototherapeutic and photothermal 
effect with no dark cytotoxicity in C26 in 
vitro cell cultures 
Nagy-Simon 






Increased uptake of PS with increased 
phototoxicity in in vitro SW480 CRC 
cells and drastic tumour-inhibiting effect 
in four-week athymic female mice were 
observed. 







HT-29 showed an increased absorption 
of m-THPC encapsulated in FosPeg®, 
which led to high phototoxicity. 





Polyethylene glycol and 
polylactic acid block 
copolymer (PN-Por) 
An enhanced cellular uptake and a 
sustainable release of ppIX-DME from 
PN-Por within in vitro cultured C26 
CRC cells were noted. In Addition, a 
substantial and highly efficacious anti-










DC PC with PEGylated 
lipid 
Enhanced cellular uptake and 
increased therapeutic efficacy in mice 
bearing HT-29 cells, and Colon-26 
BALB / c mice presented no tumour 
relapse up to 100 days. 




PS NP Results Ref. 





Chemo drug and PS synergistically 
enhanced in vivo antitumor effect of 
PDT in HT-29 colon cancer xenografts 
over a single treatment. 
Yang et al., 
2017 
Protoporphyrin IX (Pp IX) Silica The study showed accelerated ROS 
production, with 100% cell death. In 
vivo, Pp IX silica showed increased 
accumulation and high affinity for HCT 
116 tumours in mice. 








The synergistic effect of SN-38 and 
CSBC subdued tumour growth and 
achieved 60% tumour regression in HT-
29 xenograft model after 3 trials. 




Liposomal After 120 days, Sonodynamic therapy 
(SDT) and PDT caused 20% tumour 
shrinkage in CT26 tumours treated with 
liposomal zinc phthalocyanine. 
Bakhshizade
h et al., 2017 
Zinc phthalocyanine 
(ZnPc) 
Titanium dioxide (TiO2) Not only did ZnPc- TiO2 exerted high 
phototoxicity, but it also showed an 
increased accumulation and specificity 
for in vitro CRC (HT29) cells. 
Yurt et al., 
2017 
Zinc Protoporphyrin N-(2-hydroxypropyl) 
methacrylamide 
copolymer 
20 mg/kg of the nanodrug was 
illuminated at the fluency of ≥20 
J/cm2 induced necrosis and obliterated 
more than 70% of colon cancer 
tumours in mouse. 
Fang et al., 
2015 
Zinc (II) phthalocyanine Tetronic® 1107 
polymeric poloxamine 
micelles (T1107) 
The study demonstrated increased cell 
uptake and apoptotic cell death in 2D 
and 3D murine colon adenocarcinoma 






Nanocarriers loaded with 5-FU 
exhibited enhanced uptake and a 
noticeable reduction in cell viability in 
HT29 cells. 
Radu et al., 
2019 
Cisplatin Gold nanoparticles 
(AuNPs) 
AuNPs efficiently enhanced the delivery 
of cisplatin and suppressed tumour 
growth by decompressing CRC 
vessels. 
Zhao et al., 
2018 
 
From Table 2, it can be observed that nanocarriers, most definitely enhance the 
passive uptake of PSs in CRC tumors, in relation to accumulation and affinity 
towards CRC cells, decreasing the unwanted PDT side effects on normal healthy 
surrounding tissues. However, studies argue that passive NP targeting has some 
drawbacks, since it depends on tumour vascularization and angiogenesis, which 
is not sometimes apparent for all tumour types (Aftab et al., 2018). Furthermore, 
studies have noted that sometimes PSs may be unevenly disseminated in tumours, 
due to high interstitial fluid pressure (IFP) in the tumour, hampering the effective 
PDT obliteration of cancer cells (Aftab et al., 2018).  Thus, to circumvent any of 
these issues from being experience PS nanocarriers are often further 
functionalized into third-generation models, which are capable of active PS 
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delivery, as to ensure selective and improved PS absorption in target cancer cells 
occurs only with improved distribution (Aftab et al., 2018). 
2.6.5 Active Nanoparticle Photosensitizer Carrier Platforms for PDT 
Treatment of CRC 
Active targeting is a non-invasive approach, whereby a therapeutic drug is 
precisely delivered to target diseased tissue by combining it with specific ligands, 
which are exclusively overexpressed on the targeted tissues surface, as to ensure 
specific uptake (Aftab et al., 2018) (Figure 10).  
Figure 10 Enhanced cellular uptake of PDT PS nanoconjugates via passive and 
active drug delivery mechanisms (Kruger and Abrahamse, 2019). 
 
In relation to PDT applications, targeting ligands are generally bound to either a 
PS surface directly or are bound to NP PS carriers, in order to recognize and 
specifically bind to correlated antigens or receptor molecules which are 
overexpressed by tumour cells and not normal healthy cells (Shirasu et al., 2013). 
In this regard, active targeting promotes specific accumulation PSs in target tumour 
sites and so improves the specificity of PDT, as well as its overall treatment 
outcomes (Li and Yan, 2018). Numerous specific moieties comprising of 
antibodies, aptamers, peptides, carbohydrates and vitamins have been widely 
used for the active targeting modification of PS nanoconjugates in order to promote 
PDT cancer treatment outcomes (Aftab et al., 2018). Table 3 below lists some of 
the most recent studies which have exploited various targeting moieties to improve 
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PS nanoconjugate carriers uptake within in vitro and in vivo CRC tumours 
(Hodgkinson et al., 2017; Kruger and Abrahamse, 2019). 
Table 3 The outcomes and parameters of active PS nanoconjugates which have 
been investigated for the in vitro and in vivo PDT treatment of CRC. 





HER2 receptor or 







Both nanoparticle conjugates were supremely 
phototoxic in HT-29 cells, resulting in 80-90% 
cell death, and were slightly confined within the 
acidic organelles signifying enhanced targeted 
PDT attributed to receptor mediated 
endocytosis  
Obaid et al., 
2015 




Tf-IR780 NPs demonstrated narrow size 
distribution, high photo-stability and 
photothermal effect, as well as increased ROS 
yield. Furthermore, Tf-IR780 significantly 
shrank CT26 tumours in xenograft models with 
enhanced tumour-to-background ratio. Thus, 
the Tf-IR780 NPs exhibit notable targeted PDT 
and theranostic potential in cancer treatment.   
Wang et al., 
2016 
Chlorin e6 (Ce6) Imiquimod (R837), 
a Toll-like-receptor-




UCNP-Ce6-R837 conjugate did not only 
obliterate CT26 tumours in mice, but also 
elicited profound anticancer immune 
responses that suppressed the growth of 
residual tumours post-PDT via its interaction 
with CTL4 checkpoint blockade. Furthermore, 
these multifaceted conjugated showed 
enhance cellular uptake and effectively 
eliminated irradiated primary tumours and 
inhibited deeply seated tumors that were not 
exposed to light, thus preventing tumour 
relapse via the immune memory effect.   
Xu et al., 
2017 





The study noted HANP-Ce6 was effectively 
taken up by CRC cells and significantly 
suppressed tumour growth by 9.61 ± 1.09-fold 
in human colon HT29 cell line and murine 
tumor model without hampering normal 
tissues.   












PHPP-SMNPS showed a high bioavailability 
with no dark toxicity, but significant ROS 
production and exceptional PDT efficacy in 
SW480 cells. 









The study discovered that PHPP-MTCNPs 
were localized within SW480 CRC cells in vitro 
and in vivo, without posing any risk to normal 
tissues, signifying that it is an efficacious drug 
delivery paradigm with great PDT efficacy.  
Sun et al., 
2009 
Chlorin e6 (Ce6) Anti-colon cancer 
monoclonal 
antibody 17.1A 
Cationic Photo immunoconjugate 
demonstrated enhanced Ce6 delivery, as well 
as a 90% reduction in cell viability within in 
vitro  cultured HT-29 CRC cells 
Del 
Governatore, 








Cationic DMPC effectively delivered m-THPC 
to COLO206 cells and showed enhanced 





PS Active PS NP 
System 
Results Ref. 
Chlorin e6 (Ce6) and 
indium complex  
Vitamin B7 to target 
biotin receptors  
The study noted an increased uptake of 
biotinylated chlorin and indium complexes by 





Chlorin e6 (Ce6) Glycoconjugated 
chlorin (G-chlorin) 
G-chlorin demonstrated a superior affinity for 
CT26 cells and effectively subdued tumour 
growth in a xenograft model 
Tanaka et 
al., 2016 




HY-NaPB-mediated PDT severely disrupted 
the mitochondrial membrane of HT-29 and 
HCT 116 cells, achieving at least 70% 
dissipation with enhanced uptake. Moreover, 
the study noted that tumour suppressor 
CDKN1A gene expression was upregulated   
Halaburková 






PDT of m-THPC combined with Avastin 
exhibited antiangiogenic and antineoplastic 
effects in murine model by suppressing VEGF 
and inducing cell death via ROS formation.  
Peng et al., 
2018 






The drug showed high uptake and a significant 
photothermal-induced cell death in CRC cells 
Azhdarzade
h et al., 2018 
5-Fluorouracil (5-FU) Eudragit S100 
coated Citrus Pectin 
Nanoparticles (E-
CPNs) 
5-FU was effectively deposited to HT-29 cells 
both in vitro and in vivo. In vitro cytotoxicity 
assay reported 1.5-fold greater cytotoxicity 
potency of the conjugate in comparison with 5-










The study observed an increased Uptake in in 
vitro cultured DLD-1 CRC cells, with 
suppressed growth and PDT dose-dependent 
apoptotic cell death. 








DBC-UIO caused tumour regression in HT29 
and CT26 xenograft models with an improved 
uptake. Moreover, the drug induced apoptotic 
and immunogenic cell death in in vitro cultures. 
Lu et al., 
2015 
IR700 PDGFRβ to target 
tumour pericytes  
PDT massively eliminated Human CRC cell 
LS174T that expressed PDGFRβ protein. The 
treated tumour masses were 20-30% lesser 
than the control, suggesting that pericyte-
target PDT is efficacious for cancer treatment  
Shi, et al., 
2017 
Camptothecin (CPT) iRGD- PEGylated 
nanoparticle (iRGD-
PEG-NPs) 
IRGD enhanced tumour accumulation and 
cellular uptake of NPs by Colon-26 cells. 
Moreover, the resultant iRGD-PEG-NPs 
significantly augmented the therapeutic 
efficiency of CPT in vitro and in vivo by 
exhibiting an increased toxicity in relation to 
the control groups. 
Ma et al., 
2017 
2.6.6 Gold Nanoparticles (AuNPs) PS Platforms for PDT Treatment of CRC  
Gold nanoparticles (AuNPs) possess extraordinary physiological and optical 
characteristics, which have been extensively investigated for various medical 
diagnostic and therapeutic purposes (Dreaden et al., 2012). AuNPs have 
exceptional stability, high scattering energy, high biocompatibility, strong 
absorption within the NIR region, and easy surface functionalization (Hong and 
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Rao, 2019). In PDT applications , they can act as photothermal agents and PS 
transport systems, owing to their surface plasmon resonance (SPR) effect, which 
facilitates the conversion of light to heat, promoting tumour cell obliteration (Kim et 
al., 2018b). Additionally, their facile thiolation chemistry enables them to be further 
functionalized with numerous targeting moieties, enhancing their active tumour 
targeting abilities (Kim et al., 2018b).  
According to many scientists, AuNPs enhance 1O2 generation in PDT applications, 
due to their localized plasmon resonance (LSPR) of the metallated NPs and so 
promote treatment outcomes (Yao et al., 2016). However, Yao and colleagues 
demonstrated that the overall PDT induced tumour cellular destruction, is  
principally due to AuNPs’ effective passive PS delivery. Therefore, the 
incorporation of AuNPs and PSs, promotes PS passive uptake in tumour cells, as 
well as synergistically exerts both photothermal therapy (PTT) to overall promote 
PDT effects on malignant cells (Yao et al., 2016).   
Studies by Obaid et al., (2015) reported that PEG-coated AuNPs enhanced tumour 
accumulation and cellular uptake of zinc phthalocyanine (C11Pc) PS in HT-29 
CRC cells, and induced a significant 80-90% cell death. Three years later Zhao 
and peers demonstrated that AuNPs effectively improved cisplatin PS delivery in 
CRC cells, as well as inhibited tumours growth through vessel dilation and 
destruction (Zhao et al., 2018).  
Thus, within this particular study, after careful consideration of the various 
nanoplatforms that are available for adaptation to enhance PS passive delivery in 
CRC cells in order to promote PDT outcomes, it was decided that AuNPs seemed 
to be the best option, since AuNPs show a high efficiency in passive PS delivery 
with enhanced synergistic PTT and PDT cell death induction within various cancers 
(Yao et al., 2016; Kruger and Abrahamse, 2018). 
 
2.7 Anti-Guanylate cyclase C: Specific Monoclonal Antibody for Active 
Targeting of Guanylyl cyclase C Receptor in CRC Cells 
Guanylyl cyclase C (GCC) is a transmembrane protein receptor, which is 
overexpressed in all metastatic CRCs, but not by extra gastrointestinal tissues 
(Almhanna et al., 2016: Gallery et al., 2018). According to Almhanna et al., (2016) 
GCC is overexpressed in 95% of all primary and metastatic CRCs. GCC controls 
the intestinal electrolyte balance and plays a crucial role in the mucosal blockade 
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functions, inflammation and regulation of intestinal cell proliferation (Danaee et al., 
2017). Recent studies have exploited GCC transmembrane proteins as a specific 
target for new CRC therapeutic drugs (Danaee et al., 2017). Hence, Anti-
Guanylate Cyclase (Anti-GCC) mAbs can be utilized to preferentially target GCC 
receptors in CRC tumour cells, to enhance a therapeutic drugs active uptake, while 
conserving healthy tissues. Thus, since Anti-GCC mAb (Anti-GCC ) has a high 
affinity to CRC tumour receptor overexpressed protein GUCY2C gene, it could 
possibly be incorporated within NP-PS molecules, to facilitate actively targeted PS 
delivery in CRC cells, to perhaps enhance the overall efficacy of PDT, since this 
has never been done before. 
2.8 Cannabis sativa 
Cannabis sativa L. is a plant belonging to Cannabaceae family and it is widely 
distributed throughout the world (Pellati et al., 2018). This rapidly growing plant is 
accentuated by its multipurpose applications; however, the focus is more on its 
medicinal aspects, due to its phytochemical properties and bioactivities which can 
be utilized to improve human health (Andre et al., 2016). The characteristic and 
the psychoactive effects of the plant are due to its classes of metabolites, the 
cannabinoids, mainly Δ⁹-tetrahydrocannabinol (THC), which is formed primarily in 
the leaves and flower buds of the plants (ElSohly et al., 2017). However, besides 
THC, there are also non-psychotropic cannabinoids with diverse medicinal 
properties, such as cannabidiol (CBD), cannabichromene (CBC), cannabigerol 
(CBG), and other non-cannabinoid compounds belonging to distinct clusters of 
natural products (ElSohly et al., 2017). Cannabinoids are lipophilic ligands that 
interact with cell-surface cannabinoid receptors (CB) (Śledziński et al., 2018). This 
class of compounds is categorized into three main groups, namely 
phytocannabinoids, endocannabinoids, and synthetic cannabinoids (Elbaz et al., 
2015). Presumably, 100 phytocannabinoids have been identified of which THC is 
the main psychoactive constituent (Śledziński et al., 2018). Cannabidiol (CBD) is 
a non-psychoactive phytocannabinoid, which has drawn a lot of medical attention 
(Śledziński et al., 2018).   
Cannabinoids exert their effects mainly by interacting with specific cannabinoid 
receptors CB1 and CB2 (Fisher et al., 2016). Cannabinoid CB1 receptors have a 
widespread distribution in the central nervous system (CNS), with rare peripheral 
expression, while CB2 receptors are primarily located in the immune system, with 
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much lower and more restricted distribution in the CNS (Massi et al., 2013). 
However, CBD has a low affinity for these receptors and acts on other receptors 
such as transient receptor potential channel subfamily V member 1 (TRPV1), 
orphan G-protein coupled receptor (GPR55), or peroxisome proliferator-activated 
receptors (PPARs) (Śledziński et al., 2018). 
2.8.1 Cannabidiol (CBD) 
Cannabidiol (CBD) is the most abundant cannabinoid derived from Cannabis 
sativa, free of psychoactive effects (Elbaz et al., 2015). Several lines of evidence 
state that CBD possesses several pharmacological properties comprising 
neuroprotection, anticancer, antipsychosis, immune modulatory and anti-
inflammatory effects (Wu et al., 2018). CBD has been reported to induce apoptotic 
cell death in different cancers (Elbaz et al., 2015). In addition to its potential to 
induce cell death directly, it can disrupt intracellular signaling pathways such as 
P13K/AKT/mTOR and ERK, making certain cancer cells respond to additional 
combinative treatments (Kenyon et al., 2018). Furthermore, recent studies indicate 
that CBD counteracts metastatic factor (ID1) and upregulates pro-differentiation 
(ID2) (Elbaz et al., 2015).  
A study by Nallathambi et al. (2018) demonstrated that CBD reduced cell 
proliferation in CRC cell lines. They discovered that CBD reduced preaberrant 
crypt foci (ACF) lesions, polys, and tumour growth, as well as suppressed CRC-
related gene expressions. Angiogenesis is the formation of new blood vessels from 
preexisting ones and it is crucial for tumour growth and dissemination (Bielenberg 
and Zetter, 2015). Honarmand et al., (2019) reported that CBD exhibits a 
counteractive effect on angiogenesis, tumour progression, and metastasis through 
inhibiting VEGF gene expression, reducing cytokines, and activation of antioxidant 
enzyme activities.  
A study conducted by Solinas et al. (2012) indicated that CBD showed 
antiproliferative effects on human umbilical vein endothelial cell development 
(HUVEC) and effectively counteracted metastasis and invasion via cytostatic 
mediation, devoid of in vitro cell death induction. CBD also interfered with the 
differentiation of endothelial cells into tubular capillaries and the projection of 
HUVEC capillary-like structures in vitro. Furthermore, they proved that CBD 
provided proanti-angiogenic effects within an in vivo matrigel sponge model. The 
48 
 
research concluded that CBD modulated the expression of genes which promoted 
angiogenesis such as uPA, endothelin, PDGF-AA, CXCL16, MMP2 and MMP9. 
According to recent findings by Jeong et al. (2019a) CBD induced apoptosis 
facilitated by Noxa-ROS signaling pathway within in vitro and in vivo CRC cells, 
without affecting healthy colonic cells. 
2.8.2 Cannabidiol Mechanism of Action  
The endocannabinoid system (ECS) comprises of receptors, endogenous ligands 
(endocannabinoids) and metabolic enzymes which play a key role in different 
physiological and pathological mechanisms (Dariš et al., 2019). 
Phytocannabinoids and synthetic cannabinoids modulate cellular pathways 
through their interaction with constituents of the ECS, thereby altering the 
progression of diseases (Dariš et al., 2019). Accumulating evidence corroborates 
that the chemo preventive activity of CBD is not attributed to direct interactivity with 
CB1 and CB2 receptors, TRPV1, adenosine A2A receptor (A2A) or the peroxisome 
proliferator-activated receptor gamma (PPR γ) (McAllister et al., 2015). According 
to studies by Aviello et al. (2012) CBD elicits an anti-inflammatory effect, reducing 
intestinal contractility and inflammation, which is associated with CRC. Moreover, 
CBD may counteract fatty acid amide hydrolase (FAAH) and so cause an 
antioxidant effect in CRC cells, lowering their metastatic potential (Aviello et al., 
2012). Figure 11 gives an overview of presumed receptors (TRPV, 5‐HT1A, 
GPR55 and PPARγ) which bind with CBD to exert antiproliferative and pro-
apoptotic effects, as well as impedes angiogenesis, adhesion and invasion (Massi 
et al., 2013). 
 
Figure 11 Hypothesized protein complexes which interact with CBD and so mediate 
anticancer activities (Massi et al., 2013). 
2.8.3 CBD Non-Conventional Treatment for CRC 
CBD has been reported to have antiproliferative and pro-apoptotic effects by 
altering tumorigenesis mechanisms in various cancers including CRC (Pellati et 
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al., 2018). Aviello et al. (2012) studied the chemo preventive effect of CBD in 
azoxymethane-induced (AOM) colon cancer models in mice. AOM treatment 
triggered ACF, polyps, tumour growth, upregulated of phosphor-Akt, iNOS and 
COX-2 and down-regulated caspase-3. CBD noticeably shrank ACF, polyps and 
tumours and negated phospho-Akt and caspase-3 changes. Furthermore, Aviello 
and peers noted that within in vitro studies, CBD preserved DNA from oxidative 
stress, boosted endocannabinoid levels, which in turn decreased cell proliferation 
in a CB1-, TRPV1- and PPARγ-antagonist sensitive manner. The study concluded 
that CBD exerts anticancer effects in vivo and suppresses cell proliferation through 
the modulation of multiple cancer survival pathways (Aviello et al., 2012). 
Raup-Konsavage et al., (2018) evaluated the cell growth inhibitory effect of 10 µM 
cannabinoids on seven CRC cell lines (SW480, SW620, HT29, DLD-1, HCT115, 
LS174, and RKO). The study noted that CBD massively dropped the cell viability 
of SW480 below 50% and it was slightly more effective on HCT116 cells compared 
to THC. In addition, Raup-Konsavage and peers argued that cells with mutated 
APC genes (SW480, HT29 and DLD-1) were more sensitive to CBD compared to 
cells with abnormalities in the β-catenin gene (HCT116 and LS174), which showed 
cell viability above 50%. The highly resistant metastatic cell line SW620 tolerated 
CBD, suggesting that CBD is likely to stifle the action of Wnt/β-catenin pathway 
prior to the translocation of β-catenin into the nucleus. 
Ramano et al. (2014) investigated the anti-proliferative effects induced by pure 
CBD and standardized cannabis sativa extract with high levels of CBD (CBD BDS) 
i.e. cannabidiol botanical drug substance, within in vivo CRC xenograft models 
(DLD1 and HCT116) and healthy colonic cells. Pure CBD and CBD BDS 
demonstrated antiproliferative effects on tumorous cells without affecting normal 
healthy cells. In this study, selective antagonists of CB1 and CB2 receptors were 
employed to counteract the activity of CBD BDS. The results demonstrated that 
pure CBD elicited its antiproliferative in a CB-1 sensitive manner. Moreover, the 
binding assays indicated that CBD BDS exhibited high binding affinity for CB1 and 
CBD2 in comparison with pure CBD. Ramano and colleagues noted that CBD BDS 
efficiently reduced AOM-induced preneoplastic lesions and polyps, as well as 
tumour development in mice. The research concluded that CBD BDS yielded 
anticancer activities via its interaction with CB1 and CB2 receptors, proposing the 
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implementation of Cannabis-derived medicine in cancer treatment (Ramano et al., 
2014). 
Honarmand et al., (2019) investigated the antiangiogenic and antitumor activity 
exerted by CBD in mice bearing CT26 human CRC cells. The study indicated that 
5 mg/kg of CBD exhibited antiangiogenic and anti-metastatic effects by 
significantly reducing the expression of VEGF. They also noted that CBD reduced 
the inflammatory cytokines (IL-6 and IL-8), which in turn affected cell proliferation, 
angiogenesis, and metastasis, since inflammation plays a key role in 
tumorigenesis and development. In addition, CBD reduced malondialdehyde 
(MDA) and stimulated antioxidant enzyme activity. On the other hand, CBD 
induced apoptosis and decreased cellular pleomorphism. Therefore, it was 
concluded that CBD could be a novel CRC drug based on its inhibitory 
mechanisms on angiogenesis, tumour development, and metastasis through 
reducing VEGF gene expression, suppressing cytokines, and accelerating 
antioxidant enzyme activities (Honarmand et al., 2019).  
According to Carr et al., (2016) tumour necrosis factor-related apoptosis-inducing 
ligand (TRAIL) is a death receptor (DR) ligand that specifically triggers apoptosis 
in cancer cells without disturbing healthy normal tissues. Furthermore, Gong et al., 
(2019) reported that TRAIL restrained the aggression of CRC and induced 
apoptosis. In light of these speculations Kim et al., (2019) investigated the 
anticancer synergistic effect caused by CBD and TRAIL on HCT116, HT 29 and 
DLD-1 CRC cell lines, as well as within in vivo xenograft models. The results 
revealed that the combined effect of CBD and TRAIL exerted anticancer effects on 
CRC cells and normal colonic cells (CCD-18Co) remained unaffected. It was noted 
that CBD-treated cells acquired some form of endoplasmic reticulum stress (ER 
stress), due to the high levels of ER stress-associated proteins that were 
expressed, such as phosphorylated protein kinase RNA-like ER kinase (PERK) 
and C/EBP homologous protein (CHOP), as well as the  upregulation of DR5. The 
study revealed that the knockdown of DR5 hampered the synergistic effect of CBD 
and TRAIL, suggesting that CBD activated ER stress via upregulation of DR5, 
which in turn made CRC cells highly sensitive to TRAIL-induced apoptosis. 
Furthermore, the synergistic effect of TRAIL and CBD reduced tumour progression 
in xenograft models. Kim and colleagues concluded that CBD stimulated TRAIL-
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induced apoptosis through the upregulation of DR5 and suggested that CBD was 
a promising agent to promote CRC treatment.  
Recent studies by Jeong et al., (2019b) showed the potential of CBD to 
incapacitate oxaliplatin resistance in CRC cells via autophagy, in designed 
oxaliplatin-resistant cell lines DLD-1 R and Colo205 R, respectively derived from 
DLD-1 and Colo205 parent cells. This was due to the fact that the phosphorylation 
of nitric oxide synthase 3 (NOS3) in oxaliplatin-resistant cells, was higher than in 
comparison to parent cells. The integration of CBD and oxaliplatin decreased the 
levels of phosphor-NOS3 and nitric oxide (NO) yields and so led to ROS formation 
by decreasing superoxide dismutase 2 levels (an antioxidant that preserves 
mitochondria), and so triggered mitochondrial disruption. Overall, this study noted 
that increased phosphorylation of NOS3 promoted oxaliplatin resistance. In 
conclusion, they stated that the incorporation of oxaliplatin and CBD reduced 
NOS3 phosphorylation, which in turn triggered autophagic cell death, by 
stimulating ROS via mitochondrial impairment, thus overcoming CRC oxaliplatin 
resistance (Jeong et al., 2019b). 
2.8.4 Cannabidiol-induced Cell Death Facilitated by NOXA Activation in 
CRC 
Noxa is a member of the pro-apoptotic B-cell lymphoma 2 (BCL-2) family, which 
plays a crucial role in the regulation of mitochondrial pathways, and induces both 
apoptotic and autophagic cell death through its interaction myeloid cell leukemia-1 
(MCL-1) (Wang et al., 2018). Noxa is triggered by various conditions, such as ROS 
production, low oxygen levels, mitogenic instigation, etoposide and ultraviolet 
radiation, and so subsequently induces Bax-mediated mitochondrial damage by 
inhibiting BCL-2 anti-apoptotic proteins (Jeong et al., 2019a). During apoptosis, 
activated Noxa relocates to the mitochondria, stimulating the release of 
cytochrome c, a protein that induces apoptotic cell death via caspase-9 activation 
(Figure 12) (Jeong et al., 2019a).  
Jeong et al., (2019a) studied the apoptotic activity exerted by CBD on CRC cells 
(HCT116, DLD-1, and normal colonic cells CCD-18Co), focusing on its alterations 
on the novel pro-apoptotic Noxa-ROS signaling pathway. The study unveiled that 
CBD induced apoptosis within in vitro CRCs through the generation of vast 
amounts of mitochondrial ROS and ER stress, was due to the consequent 
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stimulation of Noxa. CBD also reduced tumour volumes and stimulated apoptosis 
in vitro within CRC tumour xenograft models. Jeong and colleagues also evaluated 
the link between Noxa and CBD-induced apoptosis by blocking Noxa with siRNA, 
which resulted in a significant reduction of apoptosis expression markers. The level 
of Noxa declined after ROS generation was nullified, signifying that ROS is crucial 
in the modulation of Noxa. Therefore, the study concluded that CBD induced 
cytotoxicity in a Noxa-ROS dependent manner in CRC cells without affecting 
normal colon cells, suggesting it is a reliable, as well as novel anticancer drug, that 
could be utilized in combinative treatment therapies (Jeong et al., 2019a).  
Figure 12 Apoptotic cell death mediated by NOXA-ROS pathway in CRC cells 
treated with CBD (Nkune et al., 2020). 
2.9 Summation 
CRC continues to be a health concern with more than one million new CRC cases 
reported worldwide each year (Hodgkinson et al., 2017). CRC is the world's third 
most prevalent cancer, accountable for 0.6 million cancer-related deaths annually, 
and this is due to its limited response to currently available conventional 
treatments, especially when cancer has metastasized (Hodgkinson et al., 2017; 
Kruger and Abrahamse, 2019). This chapter concluded that neither conventional 
nor nonconventional monotherapies can fully obliterate CRC cells, without 
disrupting healthy tissues and therefore it is imperative to investigate new 
combinative therapies, which can more effectively treat CRC in a localized manner, 
as well as limit unwanted side effects 
Although in recent years, PDT has elicited promising results for the primary 
treatment of CRC treatment, the administration of PSs alone has not shown 
53 
 
promising results (Table 1). Thus, the integration of CRC PDT with PS 
nanoconjugates for improved passive PS delivery were investigated (Table 2). 
Even though nanocarriers, most definitely enhance the passive uptake of PSs in 
CRC tumors and improved PDT outcomes, reducing the unwanted PDT side 
effects on normal healthy surrounding tissues, some drawbacks, such as 
vascularization and angiogenesis, can cause uneven PS distribution and so can 
effect treatment outcomes (Aftab et al., 2018).  Thus, to overcome any of these 
issues from being experienced, PS nanocarriers are often further functionalized 
into third-generation models, which are capable of active PS delivery, to promote 
PS distribution and absorption in target cancer cells only, as well as ensure 
localized enhanced PDT treatment outcomes with null unwanted side effects 
(Table 3) (Aftab et al., 2018). 
According to Calavia et al. (2018), conjugation of zinc phthalocyanines (ZnPcs) 
and gold nanoparticles (AuNPs) could enhance passive cancer drug delivery and 
demonstrate superior PDT efficacy, with more triplet lifetimes than unbound ZnPc 
PSs. This is because ZnPcs are inherently lipophilic and normally aggregate in 
aqueous medium, hampering their photodynamic activity (Calavia et al., 2018). 
However, the pure sulphonation of ZnPc (ZnPcS4) can improves its solubility and 
with the addition of AuNP carriers this PS can become more hydrophilic, for 
improved tumour uptake (Calavia et al., 2018). Studies by Sukumar et al., (2013) 
noted that AuNPs enabled ZnPcs to effectively pass through the lipophilic 
membrane via enhanced endocytosis compatibility and so intensify PS intracellular 
accumulation. Furthermore, studies by Colombeau et al., (2016), stated that PSs 
and AuNP conjugates were capable of escaping biological barriers, which 
consequently increased their longevity in vivo for improved and enhanced passive 
cellular uptake via the EPR effect. Additionally, studies by Danaee et al. (2017), 
noted that CRC tumour receptors tend to specifically overexpress the GUCY2C 
protein gene and stated that Anti-GCC mAbs could be bound to NP-PS molecules, 
in order to enhance selective active targeting of CRC cells for improved PDT 
treatment outcomes. 
Studies by Bostad et al. (2015) have noted that CRC cells have normal stem-like 
cell features known as colorectal cancer stem cells (CSCs) or tumour initiating cells 
(TICs), and these are presumed to accelerate tumour progression, therapy 
resistance and metastasis. Moreover, studies by Bostad et al., (2015) and Wei et 
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al., (2014) indicated that CSCs tend to develop resistant cells to PDT, which can 
lead to tumour relapse and secondary systemic spread post treatment. Thus, CRC 
is an intricate disease, and despite vast therapeutic advances, it is evident that 
monotherapy is only effective in the management of the primary tumour, and is 
ineffective for systemic spread (Shams et al., 2015). Studies by Shams et al., 
(2015) emphasized the necessity to invent PDT regimens that inhibit primary 
tumour growth, as well as secondary disease by triggering host anticancer immune 
responses which can halt metastatic tumor growth. A review by Massi et al., (2013) 
described CBD as a potent anticancer drug, since it generated anti-proliferative 
and pro-apoptotic effects that disrupt tumour angiogenic pathways, 
metastasization, adhesion and invasion, and is therefore likely to impede 
secondary systematic spread of cancer. Recent studies have noted 
antiproliferative and pro-apoptotic effects of CBD within numerous types of cancer 
in both vitro and in vivo CRC tumours and cells (Lukhele and Motadi, 2016).  
Despite significant efforts to develop PS modified nanostructures for efficient PDT 
treatment of primary CRC, it currently remains a challenge to develop a 
nanostructured drug delivery system that is based on surface-functionalized gold 
nanoparticles (AuNPs), which combines CRC targeted tumour molecular 
recognition, for effective PS ROS production under PDT irradiation, as well as 
allows for the simulation of a hosts anti-immunity in order to control secondary 
metastatic tumour spread.  
Thus, the aim of this study was to combine a ZnPcS4, with CRC specific targeting 
antibodies –Anti-GCC on the surface of heterobifunctional PEG amine stabilized 
AuNPs, in order to enhance PS passive / active drug delivery and specificity in 
CRC cells, so primary CRC can be effectively treated. However, to possibly 
enhance CRC PDT primary treatment outcomes and try and hinder its secondary 
reoccurrence, this final target PS nanoconjugate was administered to in vitro 
cultured CRC in combination with CBD. This study was initiated in order to 
determine if CBD, when applied in combination with the final target PS 
nanoconjugate, could possibly be used to more efficiently treat primary CRC 
tumors, as well as inhibit its secondary malignant spread, with negligible effect on 






3.1 Study Design 
Appendix A outlines the methodical workflow of this study in a form of a flow 
diagram. This research study was approved by the Higher Degrees Committee 
(HDC-01-2019) and the Research Ethics Committee (Ethical Clearance Reference 
Number REC-01-27-2019) of the Faculty of Health Sciences, University of 
Johannesburg as indicated in Appendix B. Appendix C is a compilation of all 
consumables used in this study including the catalogue numbers and the 
manufacturer they were purchased from. In addition, Appendix D lists all 
chemicals, reagents and media utilized in this study. Appendix E shows all the 
formulas and calculations implemented within this study. 
To ensure the integrity, validity and reliability of the results, as well as safeguard 
the health and safety of the laboratory personnel, it was of paramount importance 
to adhere to the Good Laboratory Practices (GLP) guidelines throughout this study. 
Therefore, to minimize contamination, all necessary equipment and lab 
consumables were sterilized before use and constant aseptic disinfection 
techniques were upheld by spraying 70 % ethanol (D1). Furthermore, appropriate 
personal protective equipment (PPE) (such as lab coats, surgical mask safety 
goggles, gloves, disposable sleeve protectors) were always worn and all 
experiments were conducted under sterile conditions using a biosafety level 2 
cabinet. Lastly, all solid and liquid waste was disposed of in the appropriate 
biological waste containers, which was removed and disposed of by the University 
in the appropriate manner. 
 
3.2 Aim of Study  
The aim of this study was to develop a PDT targeted PS nanoconjugate based 
system that was capable of actively enhanced and specific ZnPcS4 PS drug 
delivery within in vitro cultured CRC cells for improved primary treatment, as well 




3.3 Chemical Composition of Actively Targeted PS Nanoconjugate  
3.3.1  Zn (II) Phthalocyanine tetrasulfonic acid (ZnPcS4) PS 
Zinc (II) Phthalocyanine tetra-sulphonic acid (ZnPcS4) was the PS used in this 
study and it was purchased from Santa Cruz® Biotechnology (sc-264509A, 
molecular weight 898.15 g/mol). ZnPcS4 is a typical phthalocyanine PS which has 
two typical major absorption bands, one at 350 nm (B or Soret band) and one 
between 600-700 nm (Q band), which is typical for phthalocyanines (Brozek-
Pluska et al., 2015). ZnPcS4 powder can be solubilized in distilled water or 0.001M 
Phosphate buffered saline (PBS) and three major Q bands of emission can be 
noted at 583, 634, and 674 nm within the far-red spectral range (Brozek-Pluska et 
al., 2015). Moreover, ZnPcS4 is a tetra-sulphide derivative and so has 4 thioacetate 
groups, seen as sulphur-hydrogen (SH) bonds in its chemical composition. These 
sulphide derivatives allow for a ligand exchange process to be used to link the 
ZnPcS4 PS to AuNP-PEG5000-SH-NH2 and so form a strong gold-sulphur bond 
(Au-S) (Siriwandana et al., 2014) (Figure 13). Additionally, a ligand absorption 
process can also occur, whereby the PS ZnPcS4 sulphonated groups can link to 
the polyethylene glycol (PEG5000-SH) surface coating of the AuNP-PEG5000-SH-
NH2, forming weak di-sulphide bonds (Nombona et al., 2011; Siriwandana et al., 
2014). 
Figure 13 Chemical structure of Zn (II) Phthalocyanine tetrasulfonic acid (ZnPcS4). 
3.3.2  Gold Nanoparticles PEG5000-SH-NH2 Functionalized (AuNP-
PEG5000-SH-NH2) 
Gold nanoparticles (AuNP) of approximately 10 nm in diameter which were amine 
(NH2) functionalized and Polyethylene glycol (PEG 5000 SH) coated were 
purchased from (Sigma-Aldrich 765309). They have a maximum peak of 
absorption at 520nm, molecular weight of 18.02 g/mol and concentration optical 
density of 50, which equates to 2.85 X 1015 particles per ml dispersed in water.  
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The commercially purchased AuNPs employed in this study were amine (NH2) 
functionalized in order to facilitate the linkage of an antibody for enhanced targeted 
delivery of the ZnPcS4 PS to CRC tumour sites (Figure 14). The attachment of the 
target antibody to the AuNP was achieved via EDC (1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride) and NHS (Dihydroxysulfo-
succinimide sodium salt) chemistry. This chemical bonding approach was used to 
establish amide bond formation by activating the carboxyl group of the c’ terminus 
of the target antibody to interact and so bind with the amine functionalized AuNPs. 
Moreover, the AuNPs were PEG 5000 coated to enhance stability and ligand 
exchange, within the final actively targeted PS nanoconjugate (Siriwandana et al., 
2014). 
Figure 14 Chemical structure of PEG5000-SH-NH2 functionalized AuNP. 
Since, Hong et al. (2015) noted that AuNPs can be further functionalized with 
targeting biomolecules (such antibodies) that are overexpressed in tumour cells, 
causing a nano drug carrying system to only actively and specifically bind to 
targeted receptor tumour sites and studies by Conde et al. (2012) noted that in 
PDT applications AuNPs have laser light induced theranostic properties, which 
assist in tumour annihilation, this NP seemed to be an excellent choice as a 
nanocarrier platform. 
3.3.3  Anti-Guanylate Cyclase Antibody (Anti-GCC Ab)  
Guanylyl cyclase C (GCC) is a cancer mucosa antigen universally overexpressed 
by primary and metastatic human CRCs, suggesting its unique utility as an 
antigenic determinate active target site for NP-PS active drug delivery (Danaee et 
al. 2017). Anti-Guanylyl cyclase C antibody (Anti-GCC Ab) was purchased from 
Abcam (ab122404) and was conjugated to the bound AuNPs and ZnPcS4 
nanoplatform for active PS delivery and enhanced PDT, since it has tissue 
specificity for all  types of CRC cells (Almhanna et al., 2016). 
3.3.3.1 Anti-GCC Ab Purification  
Commercially available antibodies often contain impurities (e.g. Bovine serum 
albumin, glycine, Tris (hyodroxymethyl)aminomethane, and sodium azide (NaN3)) 
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that interfere in molecular bonding reactions. BSA functions as a blocking agent to 
prevent the non-specific binding of the antibody and Tris serves as antibody 
stabilizer. The AbSelect™ Purification System (Expedon: 860-0010) was used to 
remove the azide contaminates from the commercially purchased Anti-GCC Ab, 
following the recommended manufacturers protocol. Briefly, the method involves 
capturing the antibody on the AbSelect Protein A resin. Protein A resin has a high 
affinity for the Fc regions of antibodies. Once the antibody has bound to the Protein 
A resin, unwanted substances can be removed by simply washing the resin. The 
antibody is then eluted and neutralized.  
The eluted, neutralized and purified Anti-GCC Ab’s from the AbSelect protein 
collection tubes were pooled into a final volume of 300 ul.  The Jenway Genova 
Nano Plus Life Science Spectrophotometer protein direct UV option was utilized to 
determine the antibodies concentration before and after purification. The 
antibodies concentration after purification was found to be 457.7 ug/ml. Then the 
purified Anti-GCC Antibody was diluted to 200 µg/ml (D2) with 0.69 ml of 0.001 M 
PBS (D3). This working concentration of the diluted Anti-GCC Ab was then stored 
at -20°C, in frozen aliquots and only thawed upon use.  
 
3.4  Chemical Synthesis of Actively Targeted PS Nanoconjugate 
3.4.1 Zinc(II) Phthalocyanine tetra-sulphonic acid (ZnPcS4) Solubilization 
In order to solubilize ZnPcS4 and make a stock concentration of 0.0005M, 0.0006 
g of ZnPcS4 powder was added to 1.25 ml of 0.001M Phosphate Buffer Solution 
(PBS) (D4). The ZnPcS4 stock solution was then mixed well, wrapped in aluminum 
foil (as it is a light sensitive and exposure to light before required laser light 
irradiation activation can result in premature oxidation and so render it ineffective) 
and stored in the dark at room temperature. To make a working stock concentration 
of 0.000125 M or 125 µM (D5), 1 ml of ZnPcS4 stock solution (0.0005M) was diluted 
with 4 ml of 0.001M PBS and mixed to make a diluted 0.000125 M or 125 µM 
concentration which was used throughout the experimentation, this concentration 
was determined in ZnPcS4 PDT dose response assays (Section 3.10.1). 
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3.4.2  Conjugation of ZNPcS4 to AuNP-PEG5000-SH-NH2: Ligand Adsorption 
and Exchange on Pegylated Gold Nanoparticle Surfaces  
1 ml of AuNP-PEG5000-SH-NH2 which contained 2.85 X 1015 AuNPs per ml were 
added to 1 ml of 0.000125 M working stock ZnPcS4 (D5) in a micro tube, which 
was covered with tin foil to prevent premature light exposure. The micro tube 
contents were mixed at room temperature overnight using a multifunction vortex 
mixer set (DAIHAN-brand® MVM-10 with a Microtube Platform Head purchased 
from Celsius), at 1500 rpm, in order to enhance gentle mixing of both compounds 
with a constant circular, oscillating movement to promote spontaneous ligand 
exchange and adsorption within both chemicals through gentle agitation. Studies 
by Woehrle and colleagues (2005), noted that a ligand exchange and absorption 
reaction time is highly dependent on the thiol ligand and chain length of molecular 
conjugate and so the time required for this process to occur can range from 30 
minutes up to 24 hours. During the ligand exchange process the intention was that 
the gold (Au) of the AuNP and the sulphur groups on the ZnPcS4 would create a 
strong Au-S bond (Siriwandana et al., 2014). Additionally, the hope was that the 
ligand absorption process would occur between the sulphonated ZnPcS4 and the 
SH group on the AuNP-PEG5000-SH to create weak di-sulphide bonds 
(Stuchinskaya et al., 2011).  
The next day the mixture was purified by micro-centrifugation using a B115-18R - 
NovaFuge High Speed refrigerated centrifuge with a 0112022/18 - Fixed Angle 
Rotor - 12 x 2,2ml from Celsius Scientific at 4°C, 18000rpm / 20860xg for 1 hour. 
Note: such a high centrifugation speed was required in order to ensure that the 10 
nm AuNPs could successfully be pelleted out of solution (24000g for 45min for 
10nm size particles). The supernatant was then removed in order to discard any 
unbound ZnPcS4 that remained free in solution. The pellet which contained the 
conjugated ZnPcS4 and AuNP-PEG5000-SH-NH2 was re-suspended in 1 ml of 
0.001 M PBS (D3). 
The re-suspended conjugated ZnPcS4 – AuNP-PEG5000-SH-NH2 was then further 
utilized in experiments below, as well as subjected to molecular characterization 




3.4.3 Conjugation of Anti-GCC Ab to AuNPPEG5000-SH-NH2 - ZnPcS4: 
Amide Bond Formation  
In order to successfully bind the previously purified Anti-GCC Ab (Section 3.3.3.1) 
to the above conjugated ZnPcS4 – AuNP-PEG5000-SH-NH2 (Section 3.4.2) amide 
bonding formation was needed.  
This amide bond was achieved by covalent mode carbodiimide crosslinker two-
step coupling chemistry utilizing EDC and NHS coupling chemistry methods, which 
were adapted from Decker and Oldenberg (2017), Stuchinskaya et al. (2011) and 
Vashist et al. (2012). This two-step coupling chemistry allowed for the activation of 
the carboxylic group on the c’ terminus of Anti-GCC Ab (Jazayeri et al., 2016). This 
activation converted the carboxylic moiety of Anti- GCC Ab to a succinimidyl ester, 
which then reacted with the amine group (NH2) on the functionalized AuNPs in the 
ZnPcS4 – AuNP-PEG5000-SH-NH2 conjugate, forming a stable amide bond 
between the ZnPcS4 – AuNP-PEG5000-SH-NH2 and the Anti-GCC Ab (Jazayeri et 
al., 2016). The working concentration of 200 µg/ml of the previously purified and 
diluted Anti-GCC Antibody (D2) that was stored at -20°C, in frozen aliquots and 
was thawed upon use.  
0.4 mg of EDC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride and 
1.1 mg of N-Hydroxysulfosuccinimide sodium salt ≥ 98 %, were added to 500 µl of 
the thawed 200 µg/ml Anti-GCC Ab (D2). The mixture was then gently vortexed 
until all reagents became solubilized. The mixture was then incubated at room 
temperature for 30 minutes with gentle agitation at 1500 rpm (using the 
multifunction vortex mixer set) to allow for activation of the carboxyl groups on the 
Anti- GCC Ab c’ terminus. Then 10 µl of quencher (50 % w/v hydroxylamine) (D6) 
was added to deactivate any active NHS-esters and the mixture was then vortexed 
and incubated at room temperature for 10 minutes with gentle agitation again. The 
mixture was then subjected to 13 500 rpm micro-centrifugation at 4°C for 5 minutes 
in order to concentrate and collect the activated Anti-GCC Ab. The pelleted Anti-
GCC Ab was then re-suspended in 0.001 M PBS (D3) to bring its final 
concentration to 200 µg/ml, which was confirmed using the Jenway Genova Nano 
Plus Life Science Spectrophotometer protein direct UV option.  This activated Anti-
GCC Ab (200 µg/ml) was then added to the ZnPcS4 – AuNP-PEG5000-SH-NH2 in 
1 ml 0.001 M PBS, which was synthesized above and vortexed. The mixture was 
then gently agitated overnight at 1 500 rpm to encourage and promote Anti-GCC 
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Ab attachment to the amine functionalized groups of the PEG coating on the 
AuNPs. The next day the mixture was purified to discard any antibody that 
remained free in solution by micro-centrifugation at 15 200 rpm, 4°C for 1 hour. 
The supernatant was removed, and the pellet was re-suspended in 1 ml 0.001 M 
PBS (D3). The final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab) was then subjected to molecular 
characterization assays (Section 3.5).  When not in use it was stored in the dark at 
4°C.  
Note: To ensure the efficient conjugation of the Anti-GCC Ab to primary amines on 
AuNPs all experiments were performed at physiologic pH. Moreover, it must be 
mentioned that only the Ab (and not the AuNP-PEG5000-SH-NH2) was treated with 
EDC/NHS carbodiimide crosslinker coupling chemistry. This was done to ensure 
that only the carboxyl c’ terminus of the Anti-GCC Ab was activated and so could 
bind to the amide functionalized group on the AuNPs PEG coating, allowing the n’ 
terminus of the Ab to remain unbound and unaffected during the conjugation 
process, in order to preserve the Abs n’ terminus active targeting for effective and 
specific PS uptake targeting. The EDC/NHS chemistry could have been applied to 
the Ab and AuNPs, however this would have also activated the carboxylic group 
on the PEG coated AuNP, causing the n’ terminus of the Abs to bind to the 
activated carboxyl’s on PEG, blocking their active sites. This would have impaired 
the function of the Anti-GCC Ab antigenic binding sites, sterically blocking them 
upon conjugation to the AuNP-PEG5000-SH-NH2 and so effective PS targeting of 
CRC cells would have been unachievable. Thus for this reason, only the Anti-GCC  
Ab was activated with EDC/NHS chemistry, to ensure the correct orientation of the 
Ab attachment (i.e. c’ terminus bound to AuNP-PEG5000-SH-NH2 and n’ terminus 
free for active site targeting), to the PS carrying molecule (ZnPcS4 – AuNP-
PEG5000-SH-NH2) in order to produce a bio-active Ab targeting NP for effective 
PS delivery. 
3.5  Molecular Characterization of the Final Actively Targeted PS 
Nanoconjugate 
In order to validate the effective binding of Ab and PS to functionalized AuNP 
surfaces as well as the stability of the multicomponent active nano-PS molecular 
drug conjugate the following molecular characterization tests were performed; 
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3.5.1 UV-Visible Spectroscopy 
In order to substantiate the successful binding of the antibody and PS to the 
surface of the AuNPs, as well as PS photostability and ROS generation, the final 
actively targeted PS nanoconjugate underwent UV−Vis spectral analysis.  
The UV-Visible absorption and fluorescent spectra of the final actively targeted PS 
nanoconjugate (AuNP-PEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab) and various 
controls (AuNP-PEG5000-SH-NH2, ZnPcS4, Anti-GCC Ab, AUNP-PEG5000-SH-
NH2 - ZnPcS4) were measured using a Jenway Genova Nano Plus Life Science 
Spectrophotometer. A spectral blank was recorded with 0.001M PBS (D3), 2 ul of 
well-mixed samples devoid of bubbles were loaded onto the sample pedestal. The 
absorption and fluorescent spectra were analysed by spectrum/purity scan mode 
within the 198 to 800nm spectral region and 220nm protein direct UV option.  
The protein and ZnPcS4 PS concentration, as well as number of bound AuNP of 
the final actively targeted PS nanoconjugate was confirmed by comparing original 
spectra of unbound chemical components (ZnPcS4, AuNP-PEG5000-SH-NH2, 
Anti-GCC Ab) at known concentrations with final spectra obtained from the bound 
final actively targeted PS nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab) (Tan et al., 2015).  
3.5.2 Fourier Transform Infrared (FTIR) Spectroscopy  
Fourier Transform Infrared (FTIR) spectroscopy is an analytical technique used to 
identify the occurrence of different types of chemical bonds present in a sample by 
yielding an infrared absorption spectrum as a molecular “fingerprint” (Athar, 2015). 
FTIR is a method used to detect the chemical bonding occurring in organic 
complexes (Athar, 2015). It is used for the quantification of components in an 
unknown mixture (Athar, 2015). The wavelength of light absorbed signifies a 
particular chemical bond in a molecule (Athar, 2015). Molecular bonds vibrate at 
different frequencies dependent on types of bonds and elements involved (Athar, 
2015).  
FTIR analysis was therefore performed on the AuNPPEG5000-SH-NH2 - ZnPcS4 
conjugate for confirmatory ligand exchange and absorption bond analysis, by 
noting and identifying the existence of strong Au-S and weak disulphide bonds in 
FTIR spectra when compared to AuNPPEG5000-SH-NH2 alone. Furthermore, the 
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final actively targeted PS nanoconjugate (AuNPPEG5000-SH-NH2 + ZnPcS4 + 
Anti-GCC Ab) was also subjected to FTIR analysis for confirmatory amide bond 
analysis, by noting and identifying the formation of amide bonds when compared 
to the FTIR spectra of AuNPPEG5000-SH-NH2 alone. 
In order to ensure the accuracy of PerkinElmer FT-IR spectrometer, the liquid 
samples were solidified into a powder form so that the instrument could not only 
detect the peaks of the 0.001M PBS solvent. Thus, 50 µl was removed from each 
sample to be analyzed and kept in a -80 ºC freezer overnight. The following day 
the frozen samples were kept in a freezer dryer for 2 days to solidify. Thereafter, 
the solidified samples were ground into a fine powder ready to be analyzed. 
Prior to running the samples, the PerkinElmer FT-IR spectrometer was cleaned 
with acetone and blanked with potassium bromide (KBr). Each sample was mixed 
with KBr and the mixture was compressed using a hydraulic press to form a pellet. 
The pellet was then placed on sodium chloride plate of the FT-IR spectrometer for 
analysis. The infrared spectra results were recorded using far infra-red solution 
software at frequencies ranging from 400 to 4000 cm-1 with 25 scans.  
3.5.3 Dynamic light scattering (DLS) and Zeta potential (ZP) 
Size distribution and surface charge of therapeutic drug delivery systems are 
paramount parameters which require investigation, as they influence in vivo 
kinetics and interactions with cellular and biological membranes and so allows one 
to determine the overall efficiency of the delivery systems (Rahdar et al., 2019). 
Dynamic light scattering (DLS) and Zeta potential (ZP) are convenient and 
reproducible techniques used to establish particle size distribution, shape, surface 
charge, purity and functionalization (for active targeting), as well as assist in 
identifying successful biomolecular conjugation (Bhattacharjee ,2016). 
DLS and ZP measurements were performed in triplicate with 15 runs each, using 
the Malvern Zetasizer Nano ZS (Malvern Instruments, Malvern UK), which has a 4 
mW He-Ne laser of 633 nm wavelength. Twelve microliters of each sample were 
loaded into a clean, scratch free plastic Zeta 3 x 3 mm dip cell cuvette, which had 
in-built electrodes capable of DLS and Zeta measurements. All analyzed samples 
were heterogeneous or homogenous 10 to 50 µg/ml diluted suspensions in water, 
which were free of any form of precipitation. All experiments were performed at 
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25°C, at a 13° and 173° angle. Samples to be analyzed and compared consisted 
of AuNP-PEG5000-SH-NH2, ZnPcS4, ZnPcS4 – AuNP-PEG5000-SH-NH2, Anti-
GCC Ab and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab. 
However, studies by Brozek-Pluska et al. (2016) stated that chromatic or 
fluorescent samples, such as the ZnPcS4 PS drug investigated within this final 
actively targeted PS nanoconjugate study possess fluorophores, which absorb at 
350nm and emit at 583,634 and 674nm range. The one emission wavelength of 
ZnPcS4 lies within the range used by DLS for data acquisition, slightly above the 
633nm laser wavelength, and therefore possible interference with the results could 
be reported (Geißler et al., 2015). Hence, additional UV-Vis and FTIR spectra 
techniques (as discussed above) were used to further validate the successful 
conjugation of all components within the final actively targeted PS nanoconjugate. 
3.5.4 Presumptive ROS Generation  
Considering that the final actively targeted PS nanoconjugate contained ZnPcS4 
which absorbs at 350nm (Soret Band) and emits at 583, 634 and 674nm range (Q 
band) in PBS (Brozek-Pluska et al., 2016), it should have the capacity to generate 
ROS. However, it is argued that the conjugation of PSs to NPs may result in a 
quenched fluorescence and so reduced ROS production (Wu et al., 2017). 
Thus, in order to presumptively substantiate if the final actively targeted PS 
nanoconjugate was capable of yielding ROS prior to conducting PDT experiments, 
its UV-Visible absorption and fluorescent spectra were captured, before and after 
laser irradiation exposure.  
Laser irradiation experiments consisted of transferring 1ml of the final actively 
targeted PS nanoconjugate solution in a small cell culture dish and subjecting it to 
laser light from a Roithner 1000mA 673nm high power diode laser (Arryo 4210) at 
a fluence of 10 J/cm2, for approximately 10 minutes in the dark, while vigorously 
stirring it and then measuring its UV-Vis absorption post-irradiation. UV-Vis 
absorption and fluorescent spectra readings were recorded using a Jenway 
Genova Nano Plus Life Science Spectrophotometer, using the spectrum/purity 
scan mode within the 198 to 800nm spectral region. Small increments of 2 µl of 
well-mixed samples, which were free of bubbles, were loaded onto the sample 
pedestal, after recording a spectral blank with 0.001M PBS (D3).  
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The presumptive production of ROS of the final actively targeted PS 
nanoconjugate was determined by comparing the decay in absorbance intensity of 
the UV-Vis Q band in the known 634 and 674 nm range of ZnPcS4, pre and post 
laser irradiation with that of a previously run control sample of ZnPcS4 alone.  
3.5.5 Photostability Analysis 
Photostability testing of drugs is a crucial parameter in the pharmaceutical industry, 
as several drugs are sensitive to light and may degrade during production, storage 
and administration (Ahmad et al., 2016). Therefore, this may hamper the potency 
and therapeutic efficacy of the drug, as well as cause unwanted biological effects 
(Ahmad et al., 2016).  
In PDT, an ideal therapeutic PS should be stable and remain in the triplet state for 
a relatively long time (Rojkiewicz et al., 2013). Only upon irradiation, should it 
transform into an excited state, transfer its energy to adjacent molecules and then 
decay back to the ground state (Rojkiewicz et al., 2013). Sometimes PS can 
degrade overtime and so lose their absorption and excitation properties. This 
degradation many be due to many external properties, such as the solvent they 
have been suspended in, storage conditions, additional substituents being present 
or aggregation (Rojkiewicz et al., 2013). 
In order to determine the photostability of the final actively targeted PS 
nanoconjugate the Soret and Q bands values were measured prior to laser light 
irradiation experiments over the duration of experimental assays with a UV-Vis 
spectrophotometer (Genova Nano Plus Life Science Spectrophotometer - 
Jenway), using the spectrum/purity scan mode within the 198 to 800 nm spectral 
region. Three microliters of well mixed samples, that were free of bubbles were 
loaded into the machines mechanism head, after recording spectral blank with 
0.001 M PBS (D3). The results were captured and reported over an 8-week period, 
to note any changes within its UV spectra. Any obvious changes in the UV spectra 
would suggest that the compound had become unstable, and any shift changes 
within the high absorption (350 nm - Soret Band) and emission (583, 634 and 674 
nm - Q band) peaks would indicate that the ZnPcS4 within the final actively targeted 
PS nanoconjugate had quenched.  
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3.6 Cannabidiol (CBD) 
10 mg/ml of Cannabidiol solution (CBD) solubilized in 1ml 99.8% ethanol with a 
molecular mass of 314.46 g/mol, was commercially obtained from Sigma Aldrich 
(90899-1ml). Upon receipt, CBD was further diluted with 19 ml of 99.8% of ethanol 
to make a stock concentration of 0.5 mg/ml (E1). CBD stock solution was stored in 
a refrigerator covered in tin foil since it is a light sensitive compound. Various 
studies have shown that CBD is able to disrupt different stages of tumorigenesis, 
it can impede cancer cell metastasis and adhesions, as well as exerts anti-
proliferative, pro-apoptotic and anti-invasive effects through various mechanisms 
(Kis et al., 2019). Thus, in a quest to improve the primary PDT treatment of CRC, 
as well as combat its secondary spread, CBD was administered to CRC cells in 
pre-PDT treatment.   
3.7 Cell Culture 
3.7.1 Human CRC (CaCo-2) Cell Culture 
Commercially purchased Human CRC cells (CaCo-2 Cellonex Cat SS1402 CCAC-
FL; CCAC-C) were used in this study. A vial of frozen CaCo-2 cells was retrieved 
from the liquid nitrogen storage. The vial was thawed under strict aseptic conditions 
by gentle agitation in a 37ºC water bath for approximately 3 minutes. To reduce 
any potential contamination, 70% ethanol (D1) was used to disinfect the vial before 
taking it to the BSL-2 laminar-flow hood. Thereafter, the cells were cultivated in a 
75 cm2 (E2) culture flask containing complete pre-warmed DMEM Media, enriched 
with 10% Foetal Bovine Serum (FBS), 4mM sodium pyruvate, 4mM L-glutamine, 
2.5 g/ml amphotericin B, and 100 U Penicillin 100 g/ml streptomycin solution (D7). 
The re-constituted cell culture was incubated at 37ºC in 5% CO2 and 85% humidity. 
The cells were observed daily macroscopically and microscopically using inverted 
light microscopy (Wirsam Olympus CKX41) to monitor morphology (Figure 15), 
confluence, growth rate, media pH (yellowing) and to ensure the cell culture was 
free from contamination. After every 48 hrs, old medium was removed and 
replaced with fresh pre-warmed complete growth medium, after rinsing twice with 
10 ml of Hanks Bank Salt solution (HBSS). Upon reaching 90% confluence, the 
monolayers of cells were detached from the flask by adding 5 ml of Tryple Express 
(TE) and incubated at 37 ̊C for 5 minutes with gentle agitation to detach the cells 
from the cell culture flask. Microscopic observation of cells was performed to 
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confirm this detachment and the cellular suspension was then aspirated into a 50 
ml centrifuge tube and centrifuged at 2200 rpm for 4 minutes at 20ºC, after which 
the supernatant was then discarded. The pellet was then re-suspended in 1 ml of 
complete cell growth medium and transferred to a T175 flask to yield enough cells 
for experimentation. 
Figure 15 Ovoid shaped morphology of Human CRC (CaCo-2) cells (40x 
magnification). 
At 90% confluency, the cells were washed twice with HBSS and 10 ml of Tryple 
Express (TE) was added to the flask in order to dissociate monolayer cells and so 
yield a cellular suspension. The cellular suspension was aspirated into a 50 ml 
falcon tube and centrifuged at 2200 rpm for 4 min at 20 ̊C, after which the 
supernatant was discarded. The pellet was then re-suspended in 1 ml of complete 
cell growth medium and 20 µl of this cellular suspension was removed to perform 
the Trypan Blue Exclusion Test in order to quantify the number of viable cells per 
ml (Section 3.12.2.1). After quantification, the cells were seeded at a density of 6 
X 105 cells/ml (E3) into 3.4 cm diameter cell culture plates, which contained 3ml of 
completed cell culture media (D7) and used for various biochemical assays 
discussed below.  
The remaining cells were cultured into a T175 flask at a high subculture ratio (1:3 
or 1:4) or cryopreserved in 2 ml cryovials at a density of 5 X 106 cells/ml (E4) in bio 
freezing medium and first placed in the -80°C freezer for 24 hours, before being 
stored in liquid nitrogen for later re-constitution. 
3.7.2 Normal Human Fibroblasts (WS1) Cell Culture 
Commercially purchased WS1 Human Skin Fibroblasts were obtained from the 
American Type Culture Collection (ATTC CRL-1502). A vial of frozen WS1 cells 
was retrieved from the liquid nitrogen storage. The vial was thawed under strict 
aseptic conditions by gentle agitation in a 37ºC water bath for approximately 3 
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minutes. To mitigate contamination, 70% ethanol (D1) was used to sanitize the vial 
before taking it to the BSL-2 laminar-flow hood. Thereafter, the cells were cultivated 
in a 75cm2 culture flask (E2) containing complete pre-warmed MEM Media, 
enriched with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential 
amino acids, 10% FBS, 2.5 g/ml amphotericin B and 100 U Penicillin 100 g/ml 
streptomycin solution (D8). The re-constituted cell culture was incubated at 37ºC 
in 5% CO2 and 85% humidity. 
 
Figure 16 Spindle shaped morphology of WS1 Human Skin Fibroblasts cells (40x 
magnification). 
The cells were observed daily macroscopically and microscopically using inverted 
light microscopy (Wirsam Olympus CKX41) to monitor morphology (Figure 16), 
confluence, growth rate, media pH (yellowing) and to ensure the cell culture was 
free from contamination. After every 48 hrs, old medium was removed and 
replaced with fresh pre-warmed complete growth medium, after rinsing twice with 
10 ml of Hanks Bank Salt solution (HBSS). Upon reaching 90% confluence, the 
monolayers of cells were detached from the flask by adding 5 ml of Tryple Express 
(TE) and incubated at 37 ̊C for 5 minutes with gentle agitation to detach the cells 
from the cell culture flask. Microscopic observation of cells was performed to 
confirm this detachment and the cellular suspension was then aspirated into a 50 
ml centrifuge tube and centrifuged at 2200 rpm for 4 minutes at 20ºC, after which 
the supernatant was then discarded. The pellet was then re-suspended in 1 ml of 
complete cell growth medium and transferred to a T175 flask to yield enough cells 
for experimentation. 
At 90% confluency, the cells were washed twice with HBSS and 10 ml of Tryple 
Express (TE) was added to the flask in order to dissociate monolayer cells and so 
yield a cellular suspension. The cellular suspension was aspirated into a 50 ml 
falcon tube and centrifuged at 2200 rpm for 4 min at 20 ̊C, after which the 
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supernatant was discarded. The pellet was then re-suspended in 1 ml of complete 
cell growth medium and 20 µl of this cellular suspension was removed to perform 
the Trypan Blue Exclusion Test in order to quantify the number of viable cells per 
ml (Section 3.12.2.1). After quantification, the cells were seeded at a density of 3 
X 105 cells/ml (E3) into 3.4 cm diameter cell culture plates, which contained 3 ml 
of complete cell culture media (D8) and used for various biochemical assays as 
discussed below.  
The remaining cells were cultured into a T175 flask at a high subculture ratio (1:3 
or 1:4) or cryopreserved in 2 ml cryovials at a density of 5 X 106 cells/ml (E4) in bio 
freezing medium and first placed in the -80°C freezer for 24 hours, before being 
stored in liquid nitrogen for later re-constitution. 
3.8 Sub Cellular Localization Confirmation of Final Actively Targeted PS 
Nanoconjugate 
Subcellular localization studies were performed in order to confirm if the final 
targeted PS nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab) 
was able to actively and specifically localize in CRC cells only and not in normal 
human cells (such as WS1 fibroblasts).  
Colon cancer (CaCo-2) cells or normal human fibroblasts (WS1) cells were 
detached from cell culture flasks and seeded in culture plates (which already had 
sterile cover slips inserted into their base) at a density of 6 x105 cells/ml for CaCo-
2 and 3x105 cells/ml for WS1. The culture plates were incubated at 37ºC for 4hrs 
to allow for cellular attachment to the coverslips. After 4 hrs of incubation, the 
complete growth medium from the culture plates was removed and discarded. 
The culture plates produced were then divided into various experimental and 
control groups, as per Table 4 and received varying volumes of completed cell 
culture media with either ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-NH2 or 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab. *Note: the concentration of 
0.125 µM ZnPcS4 was pre-determined in Section 3.10.1, since results in Section 
4.4.1.5 showed that the minimum inhibitory concentration of ZnPcS4 to induce 50 
% cellular destruction was found to be 0.125 µM. Thus, the volumes of ZnPcS4 – 
AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab 
that were added to each plate were corrected as to ensure that the control and final 
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PS nanoconjugate contained 125 µM ZnPcS4 after UV molecular characterization 
experiments, to ensure result comparability, the calculations showing these 
concentration corrections have been described in Section 4.4.1.5.  
 
Table 4 Description of sub-cellular localization experimental and control cell culture 
plate groups.  
Plate  
No. 
Contents of Culture 
Plates 







1 WS1 or CaCo-2 cells only 0 µl  3000 µl Control 
2 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4  
3 µl of 125 µM ZnPcS4 
PS working stock (D5) 
2 997 µl Control 
3 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 
*6.7 µl of bound 
0.0000555 M / 56 uM 
ZnPcS4 + AuNP stock 
2 993.3 µl  Control 
4 WS1 or CaCo-2 cells with 
0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-
GCC  Ab 
*10.71 µl of final bound 
0.000035 M final PS 
nanoconjugate stock 
2 989.29 µl  Experimental  
 
The complete cell culture media with allocated plate number contents were mixed 
thoroughly and were all covered with tin foil (due to light sensitivity of the ZnPcS4 
PS) and incubated again at 37ºC for an additional 20 hrs. Note: all experimentation 
that followed was conducted in the dark in order to ensure that the integrity of the 
ZnPcS4 PS and subcellular localization fluorochromes did not become 
photobleached.   
After incubation the complete culture media from each culture plates were 
discarded. The culture plates were then placed on ice and rinsed once with 1 ml 
ice-cold 0.01 M PBS (D9), which was then discarded. The cultured cells were then 
fixed to their coverslips by the addition of 1 ml of 3.7% (v/v) Formaldehyde solution 
(D10) to each of the coverslips. All the culture plates were incubated on ice at room 
temperature in the dark for 10 minutes, to induce cellular fixation. After this 10-
minute incubation the formalin solution was removed from each culture plate and 
discarded, then the coverslips in each culture dish was rinsed briefly with 1 ml 0.01 
M PBS (D9) and then shortly afterwards with 1 ml tap water. Both rinsing solutions 
were immediately discarded.    
Then 1 ml ice-cold 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide 
buffer solution (D11) was briefly added to the culture plates and then discarded. 
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Then 200µl of a diluted primary Ab [2 µg/ml ICAM-1 Mouse Monoclonal IgG1 Ab 
diluted in 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer 
solution in a ratio 1:500 (D12)] was added onto each coverslip of the cultured cells 
and incubated for 30 minutes at room temperature on ice. After 30 minutes the 
primary Ab was discarded, and each culture plate was rinsed two times with 1 ml 
ice-cold 0.01 PBS in 1% (w/v) BSA and 0.01% (w/v) sodium azide buffer solution 
(D11). Then 200µl of a diluted secondary Ab [5 µg/ml Goat Anti-Mouse IgG-FITC 
human absorbed, fluorescein conjugated antibody, diluted in 0.01 M PBS in 1% 
(w/v) BSA and 0.01% (w/v) Sodium Azide Buffer Solution in a ratio 1:400 (D13)] 
was added onto each coverslip of the cultured cells and incubated for 30 minutes 
at room temperature on ice. After 30 minutes the primary Ab was discarded, and 
each culture plate was rinsed two times with 1 ml ice-cold 0.01 PBS in 1% (w/v) 
BSA and 0.01% (w/v) sodium azide buffer solution (D11). Then 50µl of 1µg/ml 40-
6-Diamidino-2-phenylindole (DAPI) (D14 -15) was added to each coverslip and the 
culture plates were incubated for 5 min at room temperature, after which they were 
rinsed with 1ml HBSS. The coverslips were then carefully removed from the culture 
plates and inverted onto glass microscope slides to which 50 µl of Fluoromount™ 
Aqueous Mounting Medium (D16) had previously been added to them. The 
coverslip boarders were then sealed with nail varnish and the slides were 
examined using the filter settings of a Carl Zeiss Axio Z1 Observer immuno 
fluorescent microscope.  
The 358Ex / 461Em filter was used to detect blue DAPI counter stained nuclei in 
cultured cells, while the 495Ex / 519Em filter was used to detect any green FITC 
stained ICAM-1 membrane proteins in cultured cells. According to studies by 
Kotteas et al. (2014), Intracellular Adhesion Molecule 1 (ICAM-1) proteins are 
found to be expressed on the surface layers of various endothelial cells. Thus, 
ICAM-1 proteins may be used to indirectly (when conjugated to a fluorochrome, 
such as FITC) to counter stain endothelial cells membranes and so easily locate 
and view them when conducting immuno fluorescent microscopy experiments. 
Lastly, the 589Ex / 610Em filter was used to detect any Cy5 red auto fluorescent 
signal that was produced from the ZnPcS4 PS alone or within the control and 
experimental molecular conjugates, which were added to cultured cells in order to 
determine if the final targeted PS nanoconjugate was capable of active PS delivery 
in CRC cells only and had no effective uptake in fibroblast cells.  
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3.9 PDT Laser Parameters, Final Actively Targeted PS Nanoconjugate, 
CBD and Controls Addition to Culture Plates and Laser Irradiation  
3.9.1 PDT Laser Parameters 
After 24 hours of incubation, the cells were irradiated using the Roithner 1000mA 
673nm high power diode laser (Arryo 4210) obtained from National Laser Centre 
of South Africa (Figure 17). Laser parameters are shown below in Table 5.   
 
Figure 17 A Roithner 1000mA diode laser (Arryo 4210) emitting at a wavelength of 
673 nm was used to irradiate cells. 
Table 5  Laser Parameters of the 673 nm diode laser. 
Variable  Parameter 
Laser Type Semiconductor (diode) 
Wavelength  673.2 nm 
Spectrum  Red (Visible) 
Pulsed or Continuous  Continuous Wave 
Spot area 9.1 cm2 
Power density (Average) 9.40 mW/cm2 
Power output (Average)  74,95 mW 
Spot size 9.1 cm2 
Energy density (Fluences) 10 J/cm2 
Number of exposure 1 exposure on day 2 
Duration of exposure 16 mins 8 secs 
 
Cell culture plates were irradiated in the dark uncapped at a fluency of 10 J/cm2 
and untreated irradiated cells served as laser control. Prior to cell culture plate 
irradiation, the laser was switched on and allowed to stand for 10 minutes to 
stabilize and reach maximum power output. The photons which were released from 
the laser were directed through an optical fibre in order to reach the culture plates 
which required laser irradiation. The power output of the laser was measured using 
a power meter (Coherent Fieldmate Model 1098297). In order to obtain a fluence 
of 10 J/cm2 an irradiation time was calculated for the 673 nm laser. On average the 
power output for the 673 nm laser was 75 mW and therefore the time calculated to 
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deliver a fluence of 10 J/cm2 to the cell culture plate requiring laser irradiation was 
16 minutes and 8 seconds (E5). 
3.9.2 Final Actively Targeted PS Nanoconjugate, CBD and Controls 
Addition to Culture Plates 
Referring to Section 3.7.1 various groups of experimental and control culture plates 
seeded with human CRC CaCo-2 and WS1 cells were prepared for both CBD 
(Section 3.10.2) and ZnPcS4 (Section 3.10.1) PDT PS dose response assays or 
for final actively targeted PS nanoconjugate PDT response assays and final 
actively targeted PS nanoconjugate PDT plus CBD combinative response assays 
(Section 3.11).  
The cell culture plates were incubated for 4 hours to allow for cellular attachment, 
and thereafter their growth media was discarded. The control and experimental 
group cell culture plates, which were not treated with either  ZnPcS4, CBD, ZnPcS4 
– AuNP-PEG5000-SH-NH2 or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
as well as of these treatments in combination with CBD, had their growth media 
replaced with 3ml of fresh pre-warmed complete cell culture media. Whereas, the 
groups of cell culture plates which were treated with ZnPcS4, CBD, ZnPcS4 – 
AuNP-PEG5000-SH-NH2 or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
as well as of these treatments in combination with CBD had their 3 ml of complete 
fresh growth media replacement volumes adjusted to accommodate for the 
administered PS or CBD concentrations they required. Freshly added cell culture 
media in both control and experimental cell culture plates, particularly those 
containing administered PS or CBD concentrations, were thoroughly mixed to 
disperse the PS and CBD throughout the cell culture plate and covered with tin foil 
(due to light sensitivity of the ZnPcS4 and CBD). After this the cell culture plates 
were incubated at 37ºC in 5% CO2 and 85% humidity for an additional 20 hrs. 
3.9.3 Photo-Irradiation  
All experiments were conducted in the dark to avoid premature activation and 
photobleaching of the ZnPcS4 PS and to preserve the integrity of light-sensitive 
CBD prior to laser irradiation.  
After 24 hrs of incubation, groups of experimental and control cell culture plates of 
human CRC CaCo-2 cells for ZnPcS4 (Section 3.10.1) and CBD PDT PS (Section 
3.10.2) dose response assays or for final actively targeted PS nanoconjugate PDT 
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response assays (with WS1 cells) with and without CBD response assays (Section 
3.11), had their complete growth medium discarded. Thereafter, the cells were 
rinsed twice with 1ml of Hanks' Balanced Salt Solution (HBSS) to remove all traces 
of cell culture media, as well as any unabsorbed (PS / CBD / final conjugate or 
control). 3 ml of fresh pre-warmed complete cell culture media (D7) was used to 
replace the culture media in the control and experimental group cell culture plates, 
which did not require laser irradiation. Control and experimental cell culture plates 
which required laser irradiation received 1 ml of 0.01 M PBS (D9), to prevent cells 
from drying out, as well as prevent any light scattering, to ensure that the laser 
beam directly reached the monolayer of cultured cells. The cell culture plates to be 
irradiated were uncapped and all irradiation experiments were conducted in the 
dark. After irradiation, the 1 ml of 0.01 M PBS was discarded from the culture plate 
and replaced with 3 ml of fresh complete cell culture media (D7). All control and 
experimental culture plates were then covered with tin foil and incubated for an 
additional 24 hours. Following laser irradiation and an additional 24 hours of 
incubation, the cell culture plates underwent various biochemical cellular test 
assays (Section 3.12).  
3.10  Dose Response Studies  
3.10.1  CaCo-2 ZnPcS4 PS PDT Dose Response Assays  
These experiments were conducted in order to establish the lowest inhibitory 
concentration (ICD50) that was required to be administered to cells in order to 
induce 50% cytotoxicity post-PDT, as some cells were still required to be viable in 
order to determine various biological cellular responses post-PDT treatment. 
0.0006 g ZnPcS4 powder was solubilized in 0.001M Phosphate Buffer Solution 
(PBS) (D4) to make a stock concentration of 0.0005M. To make a working stock 
concentration of 0.000125 M or 125 µM (D5), 1 ml of ZnPcS4 stock solution 
(0.0005M) was diluted with 4 ml of 0.001M PBS (D4). This working stock 
concentration of ZnPcS4 was further diluted in order to acquire the four varying 
dose concentrations (0.0312; 0.0625; 0.125; 0.25 µM) (E6).   
In vitro CaCo-2 cultured cells received four varying dose concentrations (0.0312; 
0.0625; 0.125; 0.25 µM) of ZnPcS4 PS, after 4 hrs of attachment (Table 6) within 
their adjusted complete cell culture media of 3ml (Section 3.7.1). The various 
experimental and control groups were then incubated for an additional 20 hrs, 
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where after those that required laser irradiation, received irradiation (Section 
3.9.3), and all culture plates were then incubated for an additional 24hrs, before 
being subjected to various biochemical assays (Table 6) (Section 3.12).  
Table 6 Description of various volumes and concentrations which experimental 
and control groups of CaCo-2 cell culture plates received for ZnPcS4 PS 
PDT Dose Response Assays. 
Plate 
No. 






1 Cells only - 3000 µl Control 
2 Cells plus irradiation  - 3000 µl Control 
3 Cells plus 0.0312 µM ZnPcS4 0.75 µl 2999.25 µl Control 
4 Cells plus 0.0625µM ZnPcS4 1.5 µl 2998.5 µl Control 
5 Cells plus 0.125µM ZnPcS4 3 µl 2997 µl Control 
6 Cells plus 0.25 µM ZnPcS4 6 µl 2994 µl Control 
7 Cells plus 0.0312 µM ZnPcS4 and 
irradiation (PDT) 
0.75 µl 2999.25 µl Experimental 
8 Cells plus 0.0625µM ZnPcS4 and 
irradiation (PDT) 
1.5 µl 2998.5 µl Experimental 
9 Cells plus 0.125µM ZnPcS4 irradiation 
(PDT) 
3 µl 2 997 µl Experimental 
10 Cells plus 0.25 µM ZnPcS4 and 
irradiation (PDT) 
6 µl 2994 µl Experimental 
Note: the calculations for the various volumes and concentrations of ZnPcS4 PS which was 
added to cell culture plates have been shown in Appendix E6.  
 
The ICD50 dose response of ZnPcS4 PS after PDT treatment that induced 50% 
cytotoxicity was found to be 0.125 µM (Section 4.4.1.5). Once this had been 
established then further PDT final actively targeted PS nanoconjugate induced 
experimental studies could be conducted utilizing the final synthesized conjugate 
at the recommended (ICD50) adjusted dose of 0.125 µM ZnPcS4 PS concentration 
(Section 3.11). This was done in order to compare ZnPcS4 PS PDT cytotoxicity 
alone versus final actively targeted PS nanoconjugate (AuNPPEG5000-SH-NH2 - 
ZnPcS4 - Anti-GCC Ab) PDT induced cytotoxicity and so determine if the 
multicomponent active nano PS drug conjugate actually enhanced PDT. 
3.10.2  CaCo-2 CBD Dose Response Assays 
These experiments were conducted in order to establish the lowest inhibitory 
concentration (ICD50) that was required to be administered to cells in order to 
induce 50% cytotoxicity when treated with CBD alone or post-laser irradiation, as 
some cells were still required to be viable in order to determine various biological 
cellular responses post-laser irradiation treatment.  
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A CBD stock concentration of 0.5 mg/ml in 99.8% ethanol was prepared (E1), it 
was stored in the fridge and covered with tin foil due to its light sensitivity. This 
working stock concentration of CBD was further diluted in order to acquire the four 
varying dose concentrations (0.5, 1, 1.5 and 2 µM) (E1).   
In vitro CaCo-2 cultured cells received four varying dose concentrations (0.5, 1, 
1.5 and 2 µM) of CBD, after 4 hrs of attachment (Table 7) within their adjusted 
complete cell culture media of 3ml (Section 3.7.1). The various experimental and 
control groups were then incubated for an additional 20 hrs, where after those that 
required laser irradiation, received irradiation (Section 3.9.3), and all culture plates 
were then incubated for an additional 24hrs, before being subjected to various 
biochemical assays (Section 3.12). In addition, there was also a control group of 
CRC cells treated with ethanol only, which was included as to ensure that it had 
no significant cytotoxic effects on CRC treatment, since the CBD utilized in this 
study was solubilized in ethanol. 
Table 7 Description of various volumes and concentrations which experimental 




CaCo-2 Culture Plate 
Contents 
Volume of CBD Volume of Cell 
Culture Media 
Group Type 
1 Cells only - 3000 µl Control 
2 Cells plus irradiation  - 3000 µl Control  
3 Cells plus 4 µl Ethanol  - 2986 µl Control  
4 Cells plus 0.5 µM CBD 20 µl 2980 µl Control 
5 Cells plus 1µM CBD 40 µl 2960 µl Control 
6 Cells plus 1.5 µM CBD 60 µl 2940 µl Control 
7 Cells plus 2 µM CBD 80 µl 2920 µl Experimental 
8 Cells plus 0.5 µM CBD and 
irradiation  
20 µl 2980 µl Experimental 
9 Cells plus 1µM CBD and 
irradiation  
40 µl 2960 µl Experimental 
10 Cells plus 1.5 µM CBD and 
irradiation  
60 µl 2940 µl Experimental 
11 Cells plus 2 µM CBD and 
irradiation  
80 µl 2920 µl Experimental 
Note: the calculations for the various volumes and concentrations of CBD which was added to cell 
culture plates have been shown in Appendix E1. 
The ICD50 dose response of CBD treatment alone that induced 56% cytotoxicity 
was found to be 1uM and the ICD50 dose response of CBD after laser irradiation 
treatment that induced 44% cytotoxicity was found to be 1uM, suggesting that laser 
irradiation had a negligible effect on CBD result outcomes and so it could be utilized 
in combination with PDT or without to induce cytotoxic effects on CRC cells 
(Section 3.10.2 and Section 4.4.2.5). Once this had been established then further 
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PDT final actively targeted PS nanoconjugate induced experimental studies could 
be conducted utilizing the final synthesized conjugate at the recommended (ICD50) 
adjusted dose of 0.125 µM ZnPcS4 PS concentration (E1). This was done in order 
to compare if the final actively targeted PS nanoconjugate PDT induced more or 
less cytotoxicity, versus the final actively targeted PS nanoconjugate PDT 
treatment plus combinative CBD and so determine if CBD did actually have the 
ability to improve the overall primary targeted CRC PDT treatment outcomes, as 
well as limit its secondary spread.  
3.11  Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with and without CBD Treatment 
These assays were to determine if the final actively targeted PS nanoconjugate 
(ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) was capable of enhanced 
PDT induced cell death, due to its functionalized active Ab targeting abilities and 
AuNP passive promoting nanocarrier, when compared to ZnPcS4 PS drug 
administration alone, as well as evaluate if its combinative treatment with CBD can 
exert even more improved cytotoxicity and in turn limit secondary CRC.  
Therefore, human CRC cells and WS1 were harvested from a T-175 cell culture 
flask and seeded into cell culture plates and incubated for 4hrs for attachment 
(Section 3.7.1), after which they were divided into various control and experimental 
groups.  The control or experimental groups of cell culture plates consisted of 
irradiated and non-irradiated cells, treated with ZnPcS4, CBD, ZnPcS4 – AuNP-
PEG5000-SH-NH2 or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, as well 
as of these treatments in combination with CBD (Table 8).  
Table 8 Various volumes and concentrations which experimental and control 
groups of CaCo-2 cell culture plates received for final actively targeted PS 
nanoconjugate PDT response assays with and without CBD treatment. 
Plate 
No. 
CaCo-2 or WS1 Culture Plate 
Contents  
*Volume  










1 Cells only / / 3 ml  Control 
2 Cells plus irradiation / / 3 ml Control 
3 Cells plus 0.125 µM ZnPcS4 3 µl / 2 997 µl Control  
4 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 
6.7 µl / 2 993.3 µl Control  
5 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab 


















6 Cells plus 0.125 µM ZnPcS4 
and irradiation 
3 µl / 2 997 µl Control  
7 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation 
6.7 µl / 2 993.3 µl Control  
8 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab and irradiation  
10.71 µl /  2 989.29 µl  Experimental  
9 Cells only + 1uM CBD / / 3 ml Control  
10 Cells only + 99.8% Ethanol (40 
µl) 
/ / 3 ml Control  
11 Cells plus irradiation + 1uM 
CBD 
/ 40 µl 2 960 µl Control  
12 Cells plus 0.125 µM ZnPcS4 + 
1uM CBD 
3 µl 40 µl 2 957 µl Control 
13 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 + 
1uM CBD 
6.7 µl 40 µl 2 953.3 µl  Control 
14 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab + 1uM CBD 
10.71 µl 40 µl 2 949.3 µl  Control  
15 Cells plus 0.125 µM ZnPcS4 
and irradiation + 1uM CBD 
3 µl 40 µl 2 957 µl Control 
16 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation + 1uM CBD 
6.7 µl 40 µl 2 953.3 µl  Control  
17 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab and irradiation + 
1uM CBD 
10.71 µl 40 µl 2 949.3 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10.1, since results in Section 
4.4.15 showed that the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular destruction was 
found to be 0.125 µM. Thus, the volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC  Ab that were added to each plate were corrected as to ensure that the 
control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV molecular characterization 
experiments, as to ensure result comparability, the calculations showing these concentration corrections 
have been shown in E7. 
#Note: The ICD50 dose response of CBD treatment alone that induced 56% cytotoxicity was found to be 
1uM and the ICD50 dose response of CBD after laser irradiation treatment that induced 44% cytotoxicity 
was found to be 1uM (Section 3.11), suggesting that laser irradiation had a negligible effect on CBD result 
outcomes and so it could be utilized in combination with laser irradiation or without to induce cytotoxic 
effects on CRC cells (Section 4.4.2.5).  
 
In addition, there was also a control group of cells treated with ethanol only, which 
was included as to ensure that it had no significant cytotoxic effects in treatments, 
since the CBD utilized in this study was solubilized in ethanol. After cell culture 
plates had the various experimental and control drugs administered to them, they 
were incubated for an additional 20 hrs. After incubation cell culture plate groups 
which required irradiation were irradiated and incubated for an additional 24 hrs 
(Section 3.9.3). Post incubation, cell culture plates were then subjected to various 
biochemical assays (Section 3.12).  
79 
 
3.12  Post-Irradiation Biochemical and Cellular Response Assays 
Inverted light microscopy was used to analyze morphological changes in all cell 
culture control and experimental groups prior to and post-laser irradiation; digital 
images were recorded and analyzed (Section 3.12.1). 50 µl of complete culture 
growth medium was aspirated from all control and experimental cell culture plates 
and added to 96 well plates used for cellular cytotoxicity assessment in triplicate 
(Section 3.12.2.3). The remaining cell culture media was discarded for all cell 
culture plates, and the cells were rinsed twice with 1 ml of pre-warmed HBSS. 
Thereafter, 500 µl of Tryple Express (TE) was added to each culture plate and 
incubated at 37ºC for 5 minutes with gentle agitation to detach the cells. The culture 
plates were then visualized under the inverted light microscope to confirm the 
detachment of the cells, and the cellular suspensions were aspirated into the 
Eppendorf tubes. Furthermore, each plate was rinsed with 500 µl of HBSS, which 
was also added to the cellular suspensions in the Eppendorf tubes (this was done 
to clear any remaining cells from the cell culture plates, as well as counteract any 
further effects from the TE). The contents were then centrifuged at 2,200 rpm 
(Tomy Micro Vac MV-100) for 4 minutes at 20ºC. 1 ml of HBSS was used to 
resuspend the cellular pellets once the supernatants were discarded. From the 
various control and experimental cellular suspension groups (from Section 3.10 
and 3.11), cellular quantification assays such as cellular viability, proliferation and 
cytotoxicity were investigated (Section 3.12.2).  
Additionally, the different control and experimental cellular suspensions only from 
Section 3.11 - Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with and without CBD Treatment, were subjected to cell death pathway (Section 
3.12.3) and DNA damage (Section 3.12.4) analysis. Each experiment was 
repeated six times in duplicate, graphically presented and statistically analysed 
(Section 3.13).  
3.12.1  Morphological Assessment by Light Microscopy 
Morphological changes in CaCo-2 and WS1 cells prior to and post-laser irradiation 
were observed at a 100x magnification using the inverted microscope (Olympus 
CKX41) that had a built-in digital camera (Olympus C5060-ADUS). The images 
were captured in a dark room. Captured images of cell structure were evaluated 
based on the cells distinct shape and changes such as size, shape and presence 
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of apoptotic bodies. Viability and non-viability were contrasted by assessing the 
amount of lysis and debris as indicators of cell death. 
3.12.2  Cellular Quantification, Viability and Cytotoxicity Assays 
3.12.2.1  The Trypan Blue Exclusion Test 
The Trypan Blue Exclusion test is a vitally important stain used to quantify the 
number of viable cells present in the cell suspension. This assay is based on the 
principle that viable cells do not take up the trypan blue dye, due to their intact cell 
membranes, whereas nonviable cells do so, due to their damaged membranes 
(Avelar-Freitas et al., 2014). Therefore, a viable cell will have a clear cytoplasm, 
while a nonviable cell will have blue cytoplasm (Strober, 2015). Following the 
detachment of the cells from either a culture flask or cell culture plate, the quantity 
of viable cells was assessed using an automated cell counter, Countess® II FL 
(Invitrogen). 20µl of cell suspension was well mixed in an equal volume of 0.4% 
trypan blue solution (Sigma Aldrich: T8154) in a 1ml test tube and left for 5 minutes 
to allow for effective staining of cells. After staining, 10 µl of the sample was loaded 
into both chambers of the Countess® cell counting slide. After inserting the slide 
to the slide reader, the instrument automatically focuses sample slides and so 
captures and displays the cell quantification results as total number, percentage 
viability and concentration of viable and non-viable cells. The Trypan Blue 
Exclusion Test was performed for various cell-seeding ratios, such as culturing 
flasks (E2), when making cell culture plates (E3) or cryopreserving cells (E4). The 
cellular viability of CaCo-2 and WS1 cells post-irradiation for the various control 
and experimental groups of dose responses and the final actively targeted PS 
nanoconjugate, with and without CBD was determined and the differences were 
graphically presented. 
3.12.2.2  Adenosine Triphosphate (ATP) Cell Proliferation Assay 
Metabolically active cells generate adenosine triphosphate (ATP), which signifies 
their viability. The CellTiter-Glo® luminescent assay (AnaTech: Promega, 
PRG7571) is a homogeneous method for determining cellular proliferation and the 
quantification of ATP present in metabolically active cells. This assay is based on 
the properties of a proprietary thermostable luciferase, which generates a stable 
luminescent and at the same time inhibits endogenous enzymes released during 
cell lysis (i.e. ATPases) which interferes with the accurate detection of ATP.  
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In compliance with the instructions of the manufacturer, 100 µl of the cellular 
suspension was added to an equal volume of the CellTiter-Glo® Reagent 
(Promega) (D17) in an opaque-walled 96 multi-well plate.  
 
A reference control plate well consisting of a 100 µl of complete growth media was 
also included so that background luminescence could be subtracted from the 
results obtained, in order to ensure the correct luminescent reading for only 
metabolically active cells was taken. The contents were mixed on a cell shaker for 
2 min to induce lysis. The contents were then incubated at room temperature, in 
the dark, for 10min to stabilize the luminescence signal. The luminescent signal 
was determined in Relative Light Units (RLU) using the Perkin-Elmer, VICTOR3 ™ 
Multilabel Counter (model 1420).  
The cellular proliferation of CaCo-2 cells post-irradiation for the various control and 
experimental groups of dose responses and the final actively targeted PS 
nanoconjugate, with and without CBD was determined and the differences were 
graphically presented. 
3.12.2.3  The Lactate Dehydrogenase (LDH) Cellular Cytotoxicity and 
Membrane Integrity Assay 
CytoTox 96® Non-Radioactive Cytotoxicity Assay was used to quantitatively 
measure lactate dehydrogenase (LDH), a cytosolic enzyme that is released upon 
cell lysis. The presence of LDH in the cell culture media indicates cell membrane 
damage and cellular toxicity. Healthy cells possess intact membranes that are 
impermeable to LDH, unlike damaged cells whose membranes allow LDH to leak 
into the extracellular fluid.  
Therefore, post-irradiation and 24 hours after incubation, 50 µl of culture media 
was removed from each culture dish and added to the wells in triplicate in a flat 
clear bottom 96 well plate. A culture medium background control was included to 
subtract background absorbance. 50 µl of LDH Reconstituted Substrate Mix (D18) 
was added to each well containing complete media. In order to determine the 
maximum release of LDH, a positive control was set-up by taking a 100 µl of 10x 
Lysis Solution and adding it to a cells only control culture plate, which contained 1 
ml culture medium. This control culture plate of cells only was incubated at 37ºC 
for an additional 45 minutes in order to induce cell lysis, so that a positive control 
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reading could be obtained for a comparable 100 % cell death result. After 
incubation the solution was aspirated from the positive control cell culture plate into 
a microcentrifuge tube and centrifuged at 2200 rpm for 4 minutes at 20ºC, to 
remove cellular debris. The pellet was then re-suspended in 50 µl of complete cell 
culture media and this supernatant was also added to the 96 well plate, with an 
additional 50 µl of LDH Reconstituted Substrate Mix (D18).  
The contents were incubated in the dark, covered in tin foil, at room temperature 
for 30 min. Then 50 µl of Stop Solution was added to each well to terminate further 
reactions and the resulting colour intensity was proportional to the number of lysed 
cells. The colour change was due to the conversion of tetrazolium salt (INT) into a 
red formazan product. Absorbance was read at 490 nm using a spectrophotometer 
(Perkin Elmer, Victor3, 1420 Multilabel Counter) and cell death and membrane 
damage was determined by calculating the percentage cytotoxicity. The 
percentage cytotoxicity was calculated initially by subtracting the background cell 
value from the LDH readings to obtain corrected LDH values. The corrected LDH 
values were divided by the maximum LDH release value to obtain the percentage 
cytotoxicity.  
The cellular cytotoxicity of CaCo-2 cells post-irradiation for the various control and 
experimental groups of dose responses and the final actively PDT targeted PS 
nanoconjugate, with and without CBD was determined and the differences were 
graphically presented. 
3.12.3  Flow Cytometry Annexin V-FITC/PI Cell Death Pathway 
Detection Assay 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
from necrosis cells, or cells remaining viable within experimental samples 24 hours 
post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate plus cannabidiol (ZnPcS4 
– AuNP-PEG5000-SH-NH2 – Anti-GCC Ab + CBD), was able to enhance PDT 
treatment, as well as limit secondary CRC more than ZnPcS4 PS drug 
administration alone, CBD treatment alone, or final actively targeted PS 
nanoconjugate treatment alone, by preparing various control and experimental cell 
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culture plates. This assay was also performed on WS1 in order to assess toxicity 
of this treatment in normal human cells. 
The membrane phospholipid known as phosphatidylserine is typically located in 
the inner surface of the cell membrane. During apoptosis, phosphatidylserine 
becomes translocated to the outer surface of the plasma membrane, exposing it to 
the external environment. Annexin V is a protein that has high affinity for exposed 
phosphatidylserine in the presence of calcium. To analyse the binding of the 
Annexin V to the phosphatidylserine, Annexin V conjugated to fluorescein 
isothiocyanate (FITC) was used to detect the apoptotic fluorescence of cells. 
Staining with Annexin V-FITC precedes the loss of membrane integrity, which 
accompanies the latest stages of cell death resulting from apoptotic processes. 
Therefore, staining with Annexin V was used in conjunction with a propidium iodide 
(PI), a pivotal and specific dye use to identify necrotic cells. This is because healthy 
cells with integral membranes exclude PI, while dead and damaged cells take up 
PI, due their disrupted membranes. Therefore, viable cells with intact cell 
membranes are both Annexin V and PI negative, whereas cells undergoing early 
apoptosis are Annexin V positive and PI negative, and cells that in late apoptosis 
are both Annexin V and PI positive and necrotic cells are only PI positive (Figure 
18). 
 
Figure 18 Flow cytometry scatter plot; Cells negative for both Annexin V-FITC and 
PI are viable (lower left quadrant), whereas cells positive for PI only 
indicate that cells are in necrosis (upper left quadrant). Cells positive for 
both Annexin V-FITC and PI represent late apoptosis (upper right 
quadrant). Cells positive for Annexin V-FITC and negative for PI are 




The maximum absorption of Annexin V-FITC is 492 nm and the maximum emission 
is 520 nm, whereas the maximum absorption for PI is 370 nm with an emission 
range of 560 to 680 nm. Thus, staining with both Annexin V-FITC and PI enables 
detection and differentiation of viable cells, cells in the early apoptotic or late 
apoptotic phases, as well as necrotic cells. 
In conformity with the manufacturer’s protocol, cellular suspensions in 
microcentrifuge tubes were centrifuged at 2,200 rpm for 4 minutes at 20ºC. The 
supernatants were pipetted out and cellular pellets were washed twice with cold 
0.01 M PBS (D9). Thereafter supernatants once again were pipetted out and 
cellular pellets were re-suspended in ice-cold 1x (v/v) Binding Buffer (D19) to 
approximately 5 X 105 cells/ml and the microcentrifuge tubes were kept on ice 
before analysing the samples.  
The various control and experimental group set ups for this assay have been 
described below and listed in Table 9. Then a 100 µl of each cellular suspension 
was removed and pipetted into a flow cytometry tube. To each cellular suspension 
5 µl of Annexin V-FITC solution and 5 µl of Reconstituted Propidium Iodide Staining 
Solution (D20) was added. The flow cytometry tubes, and their contents were 
gently vortexed and incubated at room temperature for 15 minutes in the dark. 
Then 400 µl of ice-cold 1x (v/v) Binding Buffer (D19) was added to all the flow 
cytometry tubes and cell preparations were analysed and interpreted using the 
Becton Dickinson (BD) AccuriTM C6 flow cytometer with appropriate filters. Prior to 
sample analyses all quality control procedures and calibrations were performed on 
the BD AcuriTM C6 flow cytometer C6 using a BD AccuriTM Flow Maintenance Kit 
(BD/653149) and BD Flow Cytometer Starter Kit (BD/653160). 
3.12.3.1  Flow Cytometry Annexin V-FITC/PI Controls and Experimental 
Groups 
Various negative and positive control cells groups consisting of human CRC cells 
(CaCo-2) or human fibroblasts (WS1) in cellular suspension were used to set up 
for flow cytometry compensation and various quadrant gating restrictions for the 
study (Table 9, plates no. 1 to 6).  
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Table 9 Description of various volumes and concentrations which experimental 
and control groups of CaCo-2 and WS1 cell culture plates received for final 
actively targeted PS nanoconjugate PDT response assays with and 
without CBD treatment for flow cytometry assays. 
Plate 
No. 














Flow Cytometry Controls 
1 Cells only / / 3ml No staining applied Negative 
Control 










4 Cells only / / 3ml 5 µl of Annexin V-




5 Cells only / / 1 ml media + of 3 % 
(v/v) Formaldehyde 
Solution 
5 µl of Annexin V-





6 Cells only / / 1 ml media + 500 µl of 
concentrated 
Hydrogen Peroxide 
5 µl of Annexin V-





(ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) PDT response assays 
7 Cells only / / 3 ml  5 µl of Annexin V-
FITC and 5 µl of PI 
staining solution 
Control 
8 Cells plus irradiation / / 3 ml Control 
9 Cells plus 0.125 µM 
ZnPcS4 
3 µl / 2 997 µl Control  
10 Cells plus 0.125 µM 
ZnPcS4– AuNP-
PEG5000-SH-NH2 
6.7 µl / 2 993.3 µl Control  




10.71 µl / 2 989.29 µl Control 
12 Cells plus 0.125 µM 
ZnPcS4 and 
irradiation 
3 µl / 2 997 µl Control  




6.7 µl / 2 993.3 µl Control  
14 Cells plus 0.125 µM 
ZnPcS4 – AuNP-
PEG5000-SH-NH2 – 
Anti-GCC Ab and 
irradiation  
10.71 µl /  2 989.29 µl  Experimental  
(ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) PDT + CBD response assays 
15 Cells only + 1uM 
CBD 
/ / 3 ml 5 µl of Annexin V-
FITC and 5 µl of PI 
staining solution 
Control  
16 Cells only + 99.8% 
Ethanol (40 µl) 
/ / 3 ml Control  
17 Cells plus irradiation 
+ 1uM CBD 
/ 40 µl 2 960 µl Control  
18 Cells plus 0.125 µM 
ZnPcS4 + 1uM CBD 
3 µl 40 µl 2 957 µl Control 




6.7 µl 40 µl 2 953.3 µl  Control 
20 Cells plus 0.125 µM 
ZnPcS4 – AuNP-
PEG5000-SH-NH2 – 
Anti-GCC Ab + 1uM 
CBD 
10.71 µl 40 µl 2 949.3 µl  Control  
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21 Cells plus 0.125 µM 
ZnPcS4 and 
irradiation + 1uM 
CBD 
3 µl 40 µl 2 957 µl Control 
22 Cells plus 0.125 µM 
ZnPcS4– AuNP-
PEG5000-SH-NH2 
and irradiation + 
1uM CBD 
6.7 µl 40 µl 2 953.3 µl  Control  
23 Cells plus 0.125 µM 
ZnPcS4 – AuNP-
PEG5000-SH-NH2 – 
Anti-GCC Ab and 
irradiation+ 1uM 
CBD 
10.71 µl 40 µl 2 949.3 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10.1, since results in Section 4.4.1.5 showed 
that the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular destruction was found to be 0.125 µM. Thus, the 
volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab that were added to 
each plate were corrected as to ensure that the control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV 
molecular characterization experiments, as to ensure result comparability, the calculations showing these concentration 
corrections have been described shown in E7. 
#Note: The ICD50 dose response of CBD treatment alone that induced 56% cytotoxicity was found to be 1uM and the ICD50 
dose response of CBD after laser irradiation treatment that induced 44% cytotoxicity was found to be 1uM (Section 3.11), 
suggesting that laser irradiation had a negligible effect on CBD result outcomes and so it could be utilized in combination with 
laser irradiation or without to induce cytotoxic effects on CRC cells (Section 4.4.2.5).  
Apoptosis positive control cells (Table 9, plate no. 5), untreated cells were 
stimulated to undergo apoptosis by adding 1 ml of 3% (v/v) Formalin Solution in 
0.01 M PBS (D10) to a cell culture plate containing 1 ml of complete cell culture 
medium and 5 x 105 cells/ml. The culture plates were then incubated at 37ºC for 
30 minutes to induce cellular apoptosis. Thereafter the apoptotic cellular 
suspension was dispensed into a microcentrifuge tube and centrifuged at 2,200 
rpm for 4 minutes at 20ºC, in order to obtain a pellet and the cells were stained.  
Necrosis positive control cells (Table 9, plate no. 6), induction of necrosis was 
established by adding 500 µl of concentrated Hydrogen Peroxide to a culture plate 
containing 1 ml of complete cell culture medium and 5 x 105 cells/ml. The culture 
plates were then incubated at 37ºC for 20 minutes in order for necrosis to be 
induced. After this the necrotic cellular suspension was dispensed into a 
microcentrifuge tube and centrifuged at 2,200 rpm for 4 minutes at 20ºC, in order 
for the cells to be pelleted out and the cells were stained.  
With reference to (Table 9) and (Figure 18) for the overall percentage of apoptotic 
(early stage and late stage), necrotic and viable cells to be calculated within 
experimental and control groups plate nos. 7 to 23, positive control groups (plate 
no. 4, 5 and 6) were used to define the basal level of viable, total apoptotic and 
necrotic cells within experimental set-up. The total percentage of viable cells within 
the experimental set up was calculated from the lower left quadrants of statistically 
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analysed scatter grams (Figure 18), by subtracting the percentage values of viable 
cells in experimental and control groups plate nos. 7 to 23, from the percentage 
value of viable cells obtained for experimental control group (plate no. 4). The total 
percentage of early stage apoptotic cells within the experimental set up was 
calculated from the lower right quadrants of statistically analysed scatter grams 
(Figure 18), by subtracting the percentage values of early stage apoptotic cells in 
experimental and control groups plate nos. 7 to 23, from the percentage value of 
apoptotic cells obtained for positive control group (plate no. 5). The total 
percentage of late stage apoptotic cells within the experimental set up was 
calculated from the upper right quadrants of statistically analysed scatter grams 
(Figure 18), by subtracting the percentage values of early stage apoptotic cells 
experimental and control groups plate nos. 7 to 23, from the percentage value of 
apoptotic cells obtained for positive control group (plate no. 5). The total 
percentage of necrotic cells within the experimental set up was calculated from the 
upper left quadrants of statistically analysed scatter grams (Figure 18), by 
subtracting the percentage values of necrotic cells in experimental and control 
groups plate nos. 7 to 23, from the percentage value of necrotic cells obtained for 
positive control group (plate no. 6). 
The type of cell death of CaCo-2 and WS1 cells post-irradiation for the various 
control and experimental groups of within the final actively targeted PDT PS 
nanoconjugate assays, with and without CBD was determined and the differences 
were graphically presented. 
3.12.4 Nuclear DNA Damage Examination by Hoechst 33258 
Hoechst 33258 bisbenzimide derivate fluorescent stain is a nuclear DNA staining 
method which is used for the detection and assessment of cellular nuclear DNA 
damage. It can seek out and place itself within the minor grooves of the double-
stranded DNA with binding affinity within the A-T rich regions of the DNA, allowing 
for the detection of nuclei cell damage (Chen et al., 2016). Hoechst 33258 is a blue 
fluorescent dye that is excited by ultraviolet light at a wavelength of 352 nm and 
has maximum fluorescence at 461 nm in the violet-blue region. Hoechst 33258 is 
a cell permeable nucleic acid stain and according to Chen et al. (2016) it can 
differentiate between live, necrotic and apoptotic cell stages, due to the degree of 
nuclear damage that is caused by DNA conformation and chromatin state of the 
cell and the stains sensitivity.  
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Thus, in order to confirm if the final actively targeted PS nanoconjugate 
combinative treatment with CBD was able to induce more notable PDT induced 
cellular DNA nuclear damage in CRC CaCo-2 cells, than when compared to the 
administration of CBD alone, ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-
NH2 alone or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab alone, Hoechst 
33258 bisbenzimide derivate fluorescent stain was performed.  
Therefore, human CRC cells (CaCo-2) were harvested from a T-175 cell culture 
flask and seeded into cell culture plates and incubated for 4hrs for attachment 
(Section 3.7.1), after which they were divided into various control and experimental 
groups.  The control or experimental groups of cell culture plates consisted of 
irradiated and non-irradiated cells, treated with ZnPcS4, CBD, ZnPcS4 – AuNP-
PEG5000-SH-NH2 or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, as well 
as of these treatments in combination with CBD (Table 10). All experiments were 
performed in the dark in order to minimize any photobleaching of PS drugs or 
immune fluorescent stains.  
Table 10 Description of various volumes and concentrations which experimental 
and control groups of CaCo-2 cell culture plates received for final actively 
targeted PS nanoconjugate PDT response assays with and without CBD 
treatment for Hoechst Staining. 
Plate 
No. 
CaCo-2 Culture Plate 
Contents  
*Volume  










1 Cells only / / 3 ml  Control 
2 Cells plus irradiation / / 3 ml Control 
3 Cells plus 0.125 µM ZnPcS4 
and irradiation 
3 µl / 2 997 µl Control  
4 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation 
6.7 µl / 2 993.3 µl Control  
5 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab and irradiation  
10.71 µl /  2 989.29 µl  Experimental  
6 Cells plus irradiation + 1uM 
CBD 
/ 40 µl 2 960 µl Control  
7 Cells plus 0.125 µM ZnPcS4 
and irradiation + 1uM CBD 
3 µl 40 µl 2 957 µl Control 
8 Cells plus 0.125 µM ZnPcS4– 
AuNP-PEG5000-SH-NH2 and 
irradiation + 1uM CBD 
6.7 µl 40 µl 2 953.3 µl  Control  
9 Cells plus 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – 
Anti-GCC Ab and irradiation+ 
1uM CBD 
10.71 µl 40 µl 2 949.3 µl  Experimental  
*Note: the concentration of 0.125 µM ZnPcS4 was pre-determined in Section 3.10, since results in Section 
4.4.1.5 showed that the minimum inhibitory concentration of ZnPcS4 to induce 50 % cellular destruction 
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was found to be 0.125 µM. Thus, the volumes of ZnPcS4 – AuNP-PEG5000-SH-NH2 and ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC  Ab that were added to each plate were corrected as to ensure that the 
control and final PS nanoconjugate contained 125 µM ZnPcS4 after UV molecular characterization 
experiments, as to ensure result comparability, the calculations showing these concentration corrections 
have been shown in E7. 
#Note: The ICD50 dose response of CBD treatment alone that induced 56% cytotoxicity was found to be 
1uM and the ICD50 dose response of CBD after laser irradiation treatment that induced 44% cytotoxicity 
was found to be 1uM (Section 3.11), suggesting that laser irradiation had a negligible effect on CBD result 
outcomes and so it could be utilized in combination with laser irradiation or without to induce cytotoxic 
effects on CRC cells (Section 4.4.2.5).  
 
Post laser irradiation and after 24 hours incubation the complete culture media 
from the culture plates was discarded. The culture plates were then placed on ice 
and rinsed once with 1 ml ice-cold 0.01 M PBS (D9), which was then discarded. 
The cultured cells were then fixed to their coverslips by the addition of 1 ml of 3.7% 
(v/v) Formaldehyde solution (D10) to each of the coverslips. All the culture plates 
were incubated on ice at room temperature in the dark for 10 minutes, to induce 
cellular fixation. After this 10-minute incubation the formalin solution was removed 
from each culture plate and discarded, then the coverslips in each culture dish was 
rinsed briefly with 1 ml 0.01 M PBS (D9) and then shortly afterwards with 1 ml tap 
water. Both rinsing solutions were immediately discarded.  
Then 1 ml of complete growth culture medium was added to each of the culture 
plates, ensuring that the entire surface area of each coverslip of cells was covered. 
Then each coverslip of cells was stained with 20 µg/ml of Hoechst Working Stock 
Solution Stain by adding a pre-determined amount of 20 µl of 1.0 mg/ml Hoechst 
33258 Fluorescent Dye Stock Solution Stain (D21). The culture plates were all 
wrapped in tin foil in order to minimize light exposure and were incubated at 37ºC 
for 30 minutes. 
After this incubation period the culture medium containing the Hoechst staining 
solution was removed from each culture plate and discarded. Then each coverslip 
was rinsed four times with 1 ml pre-warmed 0.01 M PBS (D9) for 5 minutes at room 
temperature. The rinsing solution was then discarded and each coverslip was 
carefully removed with a sterilized forceps and placed cell side down onto a 
labelled glass microscope slide, which had 50 µl of Fluoromount™ Aqueous 
Mounting Medium (Sigma Aldrich, F4680) (D16) pipetted onto it prior to the 
coverslip being inverted onto it. All the coverslip borders were sealed with clear 
nail polish on the microscope slide and each slide was examined using the 
358Ex/461Em DAPI filter to detect the blue Hoechst 33258 stain fluorescence’s on 
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a fluorescent microscope (Axio Observer Z1, Carl Zeiss). The Hoechst 33258 stain 
was viewed under the fluorescent microscope at 400x magnification using the 
broad band DAPI filter set, with an excitation wavelength of 352 nm and an 
emission wavelength of 455 nm. The blue Hoechst 33258 stained nuclei within the 
cells allowed for cellular orientation to be identified and the DNA damaged to be 
assessed in accordance with the size of the nuclei, as well as nuclear 
fragmentation.  
3.13  Statistical Data Analysis 
Data points shown on the graphs represent the mean and the standard deviation 
(+SD) of the biochemical assays done in duplicate for six independent experiments 
on different cell populations (n=6). Statistical analysis was performed using Sigma 
Plot software to determine the mean, standard deviation, standard error and 
significant changes of data. The distribution of the groups was confirmed using the 
Levene’s test for homogeneity of variances. The Students t-test and one-way 
analysis of variances (ANOVA), for comparing two or more means, was used for 
normal distributed data whereas the Mann-Whitney test was used for non-normal 
distributed data. These tests were used to determine the significance difference 
between the control and the experimental groups where values in the 95% 
confidence interval (P < 0.05*, P < 0.01** or P < 0.001***) were accepted as 
statistically different. 
3.14  Ethical Considerations 
This research project made use of commercially purchased, CaCo-2 and WS1 
cells in order not to violate Human Tissue Act 65 of 1983. Special reference to 
section 18 of the Act which states that no tissue, blood or gamete shall be removed 










RESULTS AND DISCUSSION 
4.1  Bond Chemical Synthesis of Final Actively Targeted PS 
Nanoconjugate 
4.1.1  Conjugation of ZnPcS4 to AuNP-PEG5000-SH-NH2: Ligand Adsorption 
and Exchange on Pegylated Gold Nanoparticles 
Studies by van Lith et al. (2018) reported that current PS have poor water solubility 
and dark toxicity. Surface functionalization of NPs plays a crucial role in particle 
solubility and reactivity (Siriwandana et al., 2014). This raises the question of 
functionalization efficiency and can new methods probe the degree of surface 
coverage. Ligand exchange is an equilibrium reaction associated with Nernst 
distribution, which often leads to incomplete surface functionalization following 
“standard” literature protocols (Kluenker et al., 2018). However, methods by 
Kluenker et al. (2018) show that the surface coverage with a ligand depends on 
the (i) repeated exchange reactions with large ligand excess, (ii) size of NPs 
(curvature and reactivity) (iii) molecular size of the ligand and (iv) surface 
functionalization, during ligand exchange and can be improved upon when a thiol 
chemisorption driven ligand exchange method it utilized AuNPs to improve surface 
functionalization via tight binding. 
Studies by Siriwandana et al. (2014) noted PEG5000-SH molecules with a 
molecular weight equal to or larger than 2000 g/mol adopt a mushroom-like 
configuration on AuNP surfaces in water and that a large fraction of the AuNP 
surface under the PEG5000-SH mushroom caps is available for ligand adsorption 
in order to form weak disulphide bonds. Moreover, this same study noted that this 
PEG5000-SH mushroom-like configuration on AuNP surfaces in water, also 
exposes the actual AuNPs core to undergo ligand exchange and so form strong 
Au-S bonds. Therefore, since the amine functionalized AuNPs, which were 
purchased for this study were pegylated with a molecular weight of 5000 g/mol, the 
possibility of the ligand adsorption and exchange process occurring between the 
sulphides and PEG5000-SH existed. 
Thus, theoretically, sulphides can be adsorbed onto pegylated AuNPs through one 
or more of the following three pathways: firstly, by occupying the AuNP surfaces 
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that are under the PEG5000-SH “mushroom cap” and so form strong Au-S bonds; 
secondly, by displacing PEG5000-SH molecules previously attached to AuNPs 
and so form weak di-sulphide bonds; or lastly, by binding to the PEG5000-SH 
overlayer on the AuNPs through possible intermolecular interactions between 
PEG5000-SHs and the ligand molecules (Siriwandana et al., 2014). These 
interactions can namely be hydrogen bonding, van der Waals forces, electrostatic 
interactions and possibly even physical entanglement (Siriwandana et al., 2014). 
Since the ZnPcS4 PS which was used in this study is a tetrasulphide derivative 
which has 4 SH / thioacetate groups, the possibility of a ligand exchange process 
occurring between it and the AuNP-PEG5000-SH-NH2 to form strong Au-S bond, 
as well as a ligand absorption process occurring between it and the AuNP-
PEG5000-SH-NH2 to form weak di-sulphide bonds was a strong possibility 
(Nombona et al., 2011; Siriwandana et al., 2014; Sakamoto and Ohno-Okumura 
2009). With reference to Figure 23, the ZnPcS4 PS and AuNP-PEG5000-SH-NH2 
formed a strong Au-S bond via ligand exchange, as well as weak di-sulphide bond 
occurred between them via ligand absorption process. 
4.1.2 Conjugation of Anti-GCC Ab to ZnPcS4 - AuNP-PEG5000-SH-NH2: 
Amide Bond 
According to studies by Stuchinskaya et al. (2011), AuNPs Ab targeted delivery 
conjugates have been effectively used in various PDT PS delivery applications, in 
order to enhance PS uptake and adsorption into target cancer cells. 
With referral to studies by Jazayeri et al. (2016), there are various physical and 
chemical interactions that can be used for attaching Abs to AuNP surface. Physical 
interactions between Abs and AuNPs depends on three phenomena: (1) ionic 
attraction between the negatively charged gold and the positively charged Ab; (2) 
hydrophobic attraction between the Ab and the gold surface; and (3) dative binding 
between the gold conducting electrons and amino acid sulphur atoms of the Ab. 
Additionally, chemical interactions between Abs and NP surface are achieved in 
the number of ways like chemisorption via thiol derivatives; through the use of 
bifunctional linkers; or through the use of adapter molecules like Streptavidin and 
biotin. Thus, when conjugating Abs to AuNPs, both covalent and non-covalent 
immobilization modes can be used by integrating these physical and chemical 
interactions (Jazayeri et al., 2016).  
93 
 
Non-covalent immobilization is whereby Abs are non-specifically or spontaneously 
adsorbed onto the AuNPs surface through a combination of ionic and hydrophobic 
interactions between the Ab and AuNP surface (Figure 19) (Jazayeri et al., 2016). 
Ionic interactions are formed between Ab’s positively charged groups, such as the 
amino acids and the N-terminal, and the negatively charged surface of AuNPs 
(Jazayeri et al., 2016) (Figure 19). Hydrophobic interactions involve the attraction 
between the hydrophobic parts of an Ab and the metal surface of the AuNP 
(Jazayeri et al., 2016) (Figure 19). According to Jazayeri et al. (2016) non-covalent 
modes have several major weaknesses, these include the necessity of a high 
concentration of Ab’s for the preparation of Ab - AuNPs conjugates, random 
orientation of Abs on the AuNP surface and within biological environments they 
can become uncoupled, due to external electrostatic forces, as well as changes in 
environmental pH (Figure 19). Therefore, fixed covalent modes are the most often 
used to bind Abs directly onto the AuNPs surface, through the use of bi-functional 
linkers in order to form a stable and strong bond (Jazayeri et al., 2016).  
Figure 19 Interactions between an Ab and AuNP surface. A- hydrophobic interaction, 
B- ionic interaction, C- covalent bonding due to dative binding. 
 
Within this study, the purchased AuNPs surface were functionalized with an amine 
PEG bi-functional linker in order to facilitate fixed covalent bonding of the Ab to its 
surface. However, in order to facilitate the bonding of the Abs c’ terminus to the 
AuNPs amine group and so form a stable amide bond, the Abs n’ terminus had to 
be correctly orientated outward from the AuNPs surface, in order to be freely 
available for the target Ab to bind to the antigen or over-expressed receptor sites 
on the CRC cells and so allow for active PS delivery. Only the c’ terminus carboxyl 
group was activated for binding through the use of EDC/NHS carbodiimide 
crosslinker coupling chemistry. When an Ab is exposed EDC/NHS its c’ terminus 
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carboxyl group becomes activated by forming amine reactive-sulfo-NHS esters, 
and when exposed to primary functionalized amine groups, a stable amide 
covalent bonds will be formed (Jazayeri et al., 2016) (Figure 20). 
Figure 20 EDC/NHS carbodiimide crosslinker coupling chemistry, in order to activate 
carboxylic protein acids or Ab carboxyl groups for effective linking with 
primary amines in order to create strong amide bonds (Kokkinis et al., 
2013). 
Studies by Stuchinskaya et al. (2011) reported effective and targeted PDT of breast 
cancer cells using Ab-phthalocyanine-gold nanoparticle conjugates, whereby an 
active targeting Ab was successfully conjugated onto a functionalized AuNPs 
surface using EDC/NHS chemistry. Moreover, studies by Jazayeri et al. (2016) 
noted that an Abs c’ terminus carboxyl group can react with primary amines on 
functionalized AuNPs by means of a condensation reaction to yield amide bonds, 
when applying EDC/NHS chemistry. Thus, it was decided to use EDC/NHS 
chemistry within this study in order to activate and facilitate covalent bonding 
between the Anti-GCC Ab and the already conjugated ZnPcS4 - AuNP-PEG5000-
SH-NH2, in order to actively enhance the ZnPcS4 PSs drug absorption in targeted 
CRC cells for more efficient PDT. However, only the Anti-GCC  Ab was activated 
EDC/NHS chemistry, as to ensure the correct orientation of the Ab attachment (i.e. 
using c’ terminus bound to AuNP and n’ terminus free for active site targeting), to 
the PS nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2) in order to produce a 
bio-active Ab targeting NPs for active PS delivery. 
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4.2 Molecular Characterization Results Analysis of the Final Actively 
Targeted PS Nanoconjugate 
To ensure efficient binding of the Ab and PS to the surface of the functionalized 
AuNPs, as well as stability, the following molecular characterization assays were 
performed on the final actively targeted PS nanoconjugate. 
4.2.1 UV-Visible Spectroscopy 
In order to ensure efficient binding of the Anti-GCC Ab and ZnPcS4 PS to the 
surface of the AuNP-PEG5000-SH-NH2, as well as PS photostability and ROS 
generation, the final actively targeted PS nanoconjugate was subjected to UV−Vis 
spectra analysis.  
The UV-Visible absorption and fluorescent spectra of the final actively targeted PS 
nanoconjugate and various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti-GCC 
Ab, ZnPcS4 - AuNP-PEG5000-SH-NH2) were recorded using a Jenway Genova 
Nano Plus Life Science Spectrophotometer. The absorption and fluorescent 
spectra were read using the spectrum/purity scan mode within the 198 to 800 nm 
spectral region and 220 nm protein direct UV option. Moreover, the protein and 
ZnPcS4 PS concentration, as well as number of bound AuNP of the final actively 
targeted PS nanoconjugate was confirmed by comparing original spectra of 
unbound chemical components (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti- GCC Ab) 
at known concentrations with final spectra obtained from the final actively targeted 
PS nanoconjugate (Tan et al., 2015).  
4.2.1.1 Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis within the 400 
to 800 nm Spectral Region 
With reference to Figure 21, 000125 M or 125 µM of ZnPcS4 in 0.001 M PBS (w/v) 
predictably elicited two major Q bands of emission at 634 and 674 nm within the 
far-red spectral range (Brozek-Pluska et al., 2016). In addition, AuNPEG5000-SH-
NH2 as anticipated demonstrated an absorption spectrum of 520 nm, with an OD 
of 50 which equated to 2.85 X 1015 particles/ml.  
When comparing various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, Anti-GCC 
Ab, ZnPcS4 - AuNP-PEG5000-SH-NH2) to the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 – Anti-GCC Ab), it retained its 
respective absorption peaks, however with some reduction in absorption, signifying 
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that both ZnPcS4 and AuNPEG5000-SH-NH2 had successfully bound together, 
however lowered in concentration.  
 
Figure 21 UV-Visible absorption spectra of the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) and 
various controls (ZnPcS4, AuNP-PEG5000-SH-NH2, ZnPcS4 - AuNP-
PEG5000-SH-NH2) within the 400 to 800 nm spectral region.  
 
Table 11 Absorbance fold fall comparison to determine concentration of bound 
ZnPcS4 and AuNP-PEG5000-SH-NH2 within the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab). 
Sample UV Absorbance 
at 673 nm 
Fold Fall Concentration 
ZnPcS4 0.2321  0.000125 M / 125 µM 
ZnPcS4 – AuNP 0.1033 2.25 0.0000555 M or 56 µM 
ZnPcS4 - AuNP - Anti-GCC Ab 0.0655 3.54 0.0000353 M or 35 µM 
Sample UV Absorbance 
at 520 nm 
Fold Fall Concentration 
AuNP 1.0531  2.85 X 1015 particles/ml 
ZnPcS4 – AuNP 0.4337 2.43 1.17 X 1015 particles/ml 
ZnPcS4 - AuNP - Anti-GCC Ab 0.3522 2.99 0.95 X 1015 particles/ml 
Therefore, by comparing the absorbance fold falls of 125 µM ZnPcS4 in 0.001 M 
PBS (w/v) at 673 nm and AuNPEG5000-SH-NH2 (2.85 X 1015 particles/ml) at 520 
nm, to the absorbance peak values exhibited by the final actively targeted PS 
nanoconjugate within these ranges, the amount of ZnPcS4 loaded onto 
AuNPEG5000-SH-NH could be quantified, as well as the final number of AuNP 
present (Table 11). In relation to Table 11, the final actively targeted PS 
nanoconjugate (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC  Ab) consisted of 
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0.95 X 1015 particles/ml AuNPEG5000-SH-NH bound to 0.0000353 M or 35 µM of 
ZnPcS4 in 0.001 M PBS (w/v). 
As observed in Figure 21, the final actively targeted PS nanoconjugate presented 
a distinct absorption spectrum at 673 nm, which is closely related to the absorption 
peak of ZnPcS4. This indicates that the photochemical properties of ZnPcS4 
remained intact even after conjugation and so was undoubtedly still capable of 
generating ROS and singlet oxygen in PDT experiments (Brozek-Pluska et al., 
2016). Furthermore, the final actively targeted PS nanoconjugate also 
demonstrated a noticeable absorption spectrum of 520 nm, suggesting that 
AuNPEG5000-SH-NH2 still retained its desirable theranostic and photodynamic 
properties (Yao et al., 2016). 
Furthermore, looking at Figure 21, the absorption peaks obtained at 520 and 673 
nm by the final actively targeted PS nanoconjugate in comparison with ZnPcS4 and 
AuNPEG5000-SH-NH2 control peaks, did not broaden much and remained sharp 
and smooth, indicating that an ideal size distribution with negligible aggregation 
was achieved (Naidoo et al., 2019). However, with the absorption peaks of the final 
actively targeted PS nanoconjugate a slightly broadening could be noticed, this is 
indicative of a definitive bonding between all the chemical components, due to the 
increase in the molecular size (Crous and Abrahamse, 2020). Lastly, the final 
actively targeted PS nanoconjugate noted a slight shift in the resonance peak 
position of AuNP at 520 nm, suggesting that ZnPcS4 and Anti-GCC Ab had been 
successfully conjugated to its surface (Decker and Oldenberg, 2017). 
4.2.1.2 UV-Visible Protein Direct Absorption Spectra Analysis within the 
200 to 310 nm Spectral Region 
Most proteins such as Abs typically exhibit a UV absorption peak around 280 nm. 
This absorption is attributed to constituent aromatic amino acids such as tyrosine, 
tryptophan, and phenylalanine (Prasad et al., 2017). Thus, their presence can be 
demonstrated by a definitive UV-Vis absorption spectra peak seen within the 280 
nm spectral region (Prasad et al., 2017). 
As shown in Figure 22, it is evident that the 200 µg/ml Anti-GCC Ab control 
obtained a significant UV-Vis absorption spectra peak within the 280 nm spectral 
range. However, there was a notable decline in the spectral features of the final 
actively targeted PS nanoconjugate versus the absorption spectra peak of the 
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original 200 µg/ml Anti-GCC Ab control within this same range. These results 
clearly suggested that only a certain amount of the original 200 µg/ml Anti-GCC 
has been successfully conjugated to the surface of the final actively targeted PS 
nanoconjugate.  
Figure 22 UV-Visible protein direct absorption spectra of the final actively targeted 
PS nanoconjugate and various controls (Anti-GCC Ab, AuNPEG5000-SH-
NH2, ZnPcS4-AuNP- AuNPEG5000-SH-NH2) within the 200 to 310 nm 
spectral region for protein presence observation, as well as amide and di-
sulphide bond confirmation.  
Therefore, by comparing the absorbance fold falls of the final actively targeted PS 
nanoconjugate to the original 200 µg/ml Anti-GCC Ab at 280 nm and removing any 
possible protein impurities from AuNPEG5000-SH-NH2 and ZnPcS4, within the 280 
nm absorbance peak range, the total concentration of Anti-GCC Ab conjugated to 
the surface of the final actively targeted PS nanoconjugate could be calculated 
(Table 12). In relation to Table 12, 30.91 µg/ml of Anti-GCC  Ab was successfully 
bound to the final actively targeted PS nanoconjugate, which as previously 
confirmed consisted of 1.17 X 1015 AuNPEG5000-SH-NH2 particles/ml and 




Table 12 Absorbance fold fall comparison to determine the final bound Anti-GCC Ab 
protein concentration within the final actively targeted PS nanoconjugate 
(ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab).   





Anti-GCC Ab 1.8255  200 µg/ml 
AuNP 0.0666   
ZnPcS4 0.2219   
ZnPcS4 - AuNP - Anti-GCC Ab 0.5705   
ZnPcS4 - AuNP - Anti-GCC Ab, 
calculation eliminating any protein 
presence from ZnPcS4 and AuNP 
0.5705 - 0.2219 - 0.0666 
= 0.282 
6.47 30.91 µg/ml 
Standard literature highlights that amine functional groups (NH2) strongly absorb 
at a wavelength spectra of 195 nm, whereas a significant absorption peak at a 
wavelength spectra of 220 nm is indicative of amide peptide bond (CO-NH) 
formation following the condensation of an amine with a carboxylic acid (Naidoo et 
al., 2019). In relation to Figure 22, AuNPEG5000-SH-NH2 control revealed a 
significant amine functional group (NH2) absorption peak at a wavelength spectrum 
of 195 nm, which is anticipated since it was amine functionalized. Moreover, Anti-
GCC Ab control also revealed a strong prominent amine functional group (NH2) 
absorption peak at a wavelength spectrum of 195 nm, which is attributed to the 
amine groups on its n’ terminal. However, the final actively targeted PS 
nanoconjugate demonstrated a decayed amine functional group (NH2) absorption 
peak at a wavelength spectra of 195 nm, when compared to that of the 
AuNPEG5000-SH-NH2 control, indicating that amine functional group on the AuNP 
had condensed with the activated carboxylic group on the c’ terminus of the Abs to 
produce the amide bond (CO-NH). The final amide bond (CO-NH) was also 
additionally confirmed within Figure 22, by assessing the 220 nm high absorption 
peak within the final actively targeted PS nanoconjugate wavelengths spectra. This 
result can corroborate that several carboxylic groups on the activated c’ terminus 
of the Anti-GCC Abs had certainly bound with functionalized amine groups (NH2) 
on the AuNPs to establish a rigid peptide bond. 
Furthermore, when comparing amine functional group (NH2) absorption peak at 
195 nm of the Anti-GCC Ab control to that of the final actively targeted PS 
nanoconjugate (Figure 22), it can be observed that there is an absorbance fold fall, 
however amine functional groups can still be detected in the final actively targeted 
PS nanoconjugate. This absorbance fold fall implies that not all of the initial 200 
µg/ml Anti-GCC Ab bound to final actively targeted PS nanoconjugate. 
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Nonetheless, since the final actively targeted PS nanoconjugate still elicited an 
amine functional groups at the 195 nm absorption peak, this was conclusive that 
the n’ terminus active targeting sites of the Anti-GCC Ab within the final actively 
targeted PS nanoconjugate was well-preserved, perfectly orientated (i.e. bound to 
the AuNPEG5000-SH-NH at c’ terminus) and so was actively functional for PS 
delivery. 
Lastly, standard literature also mentions that the occurrence of di-sulphide bonds 
yields distinctive UV-Vis spectral absorption properties, typically within the 250 to 
280 nm range (Li et al., 2002). With reference to Figure 22, it can be noted that the 
final actively targeted PS nanoconjugate exhibited a stronger and more prominent 
UV-Vis spectral absorption within the 250 to 280 nm range when compared to both 
AuNPEG5000-SH-NH2 and ZnPCS4 controls. This result indicates that the 
sulphonated ZnPCS4 PS and AuNPEG5000-SH could have possibly underwent 
ligand absorption in order to form di-sulphide bond between them within the final 
actively targeted PS nanoconjugate (Stuchinskaya et al., 2011). 
4.2.2 Fourier Transform Infrared (FTIR) Spectroscopic Analysis  
Fourier Transform Infrared (FTIR) spectroscopy has various applications in 
structural identification, and can be used for quantitative, as well as qualitative 
analysis of molecular bond formations (Ekka and Roy, 2014).  
Thus, the final actively targeted PS nanoconjugate was subjected to FTIR analysis 
for confirmatory ligand exchange and absorption bond analysis, by noting and 
identifying the formation of strong Au-S and weak disulphide bonds, when 
compared to the FTIR spectra of AuNP-PEG5000-SH-NH2 alone (Figure 23). 
Moreover, the final actively targeted PS nanoconjugate was also subjected to FTIR 
analysis for confirmatory amide bond analysis, by noting and identifying the 
formation of amide bonds when compared to the FTIR spectra of AuNP-PEG5000-
SH-NH2 alone (Figure 24). 
With referral to studies conducted by Nguyen et al. (2012) and Mecozzi and 
Sturchio, (2017), FTIR spectrum in Figure 23 reported characteristic peaks closely 
related to the occurrence of Au-S ligand exchange bonding, since the FTIR spectra 
of AuNPEG5000-SH-NH2 + ZnPcS4, revealed a C-S (1050-1200 cm-1) stretch shift, 
indicating that AuNPEG5000-SH-NH2 had lost their C-S groups to bond with 
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ZnPcS4. Additionally, the existence of Au-S ligand exchange bonding was 
confirmed since the FTIR spectra (Figure 23) of AuNPEG5000-SH-NH2 + ZnPcS4 
noted a loss of a C-S (1200 cm-1) sharp band when compared to ZnPcS4 alone, 
suggesting ZnPcS4 lost its C-S groups to bond with AuNPEG5000-SH-NH2. Finally, 
the FTIR spectra of AuNPEG5000-SH-NH2 + ZnPcS4 exhibited a sharp S-S (500-
540 cm-1) band indicating that ligand absorption between the sulphonated ZnPcS4 




Figure 23 FTIR spectra analysis for confirmatory ligand exchange (Au-S) and 
absorption (S-S) bond confirmation between AuNP-PEG5000-SH-NH2 
and ZnPcS4 within the final actively targeted PS nanoconjugate. 
 
Furthermore, the final actively targeted PS nanoconjugate underwent FTIR 
analysis for confirmatory amide bond analysis, by examining and identifying the 
formation of amide bonds when compared to the FTIR spectra of AuNPEG5000-
SH-NH alone (Figure 24). With referral to studies conducted by Mecozzi and 
Sturchio (2017), with reference to FTIR characterization in Figure 24 the presence 
of the C=O band within the final actively targeted PS nanoconjugate confirms 
amide bond formation alone but the N=H band is not clearly evident, when 
compared to the AuNPEG5000-SH-NH2 alone, signifying that strong primary and 
secondary amide bonds (CO-NH) had formed between the amine (NH) 





Figure 24 FTIR spectra analysis for confirmatory amide (CO-NH) bond confirmation 
between AuNP-PEG5000-SH-NH2 and the activated carboxylic group on 
the c’ terminus of the Anti-GCC Ab within the final actively targeted PS 
nanoconjugate. 
4.2.3 Dynamic Light Scattering (DLS) and Zeta potential (ZP) Analysis 
For the adequate characterization of NPs and drug delivery systems within initial 
stages of drug development studies in relation to particle size, shape, surface 
charge, dispersity, purity and functionalization for active targeting, as well as to 
ensure biomolecular conjugation dynamic light scattering (DLS) and Zeta potential 
(ZP) assays are often performed (Bhattscharjee et al., 2016). Furthermore, DLS 
technique is often applied to investigate and measure the hydrodynamic size of a 
NP drug delivery system in order to determine if the final nanomaterial is small 
enough for cellular uptake (Bhattscharjee et al., 2016).  
According to Yu et al. (2016) in relation to the design of NP-based carriers for 
targeted drug delivery, the average particle size distribution should not be any 
larger than 100 - 150 nm, in order to ensure successful cellular uptake and 
absorption. The final actively targeted PS nanoconjugate was noted to have a 
mean Z-average diameter of 57.18 ± 3.04 nm (Table 13), suggesting that it was 
indeed small enough to be considered as an active nanodrug carrying system, with 
the definitive possibility of cellular uptake and absorption. 
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Table 13 DLS and ZP results for characterization of final NP PS drug delivery 
system. 
DLS also allows for the homogeneity or purity of a sample to be determined in NP 
drug delivery studies, whereby the hydrodynamic radius distribution graph should 
produce one single peak that is identical from multiple measurements (Stetefeld et 
al., 2016; Lim et al., 2013). If a sample produces multiple peaks, it suggests that 
the sample is a heterogeneous mixture of various particle sizes and so is not pure 
(Stetefeld et al., 2016; Lim et al., 2013). If a sample produces one major definitive 
peak, with smaller minor follow on peaks, this suggests that the sample could be 
homogenous, however have unwanted aggregates, which is sometimes 
problematic in active drug targeting delivery studies, as it could be an indicator of 
particulate clumping and so hinder the active targeting abilities of Abs (Stetefeld et 
al., 2016; Jans et al., 2009). Additionally, reports by Bhattscharjee et al. (2016) and 
Jans et al. (2009), noted that in terms of DLS data interpretation for NP purity 
characterization the hydrodynamic radius distribution graph should produce one 
single major compact peak, that is very narrow in width, for a particle to considered 
spherical in shape, with no aggregation. With reference to Figure 25 below, it can 
be observed that the DLS hydrodynamic radius distribution graph of the final 
actively targeted PS nanoconjugate produced one single major peak (repeated in 
triplicate) with a narrow width and no additional smaller side peaks, suggesting that 
it was homogenously pure, remained spherical in shape and reported no 
aggregation. 
Sample Mean Z-Average 
Diameter Measured 






AuNP 11.78 ± 0.966 0.351 
(Monodisperse) 
 
ZnPcS4 18.15 ± 1.44 0.107(Monodisperse)  
Expected average ZnPcS4 - 
AuNP  
48.08 ± 1.20   
Result average ZnPcS4 - 
AuNP  
44.57 ± 0.564 0.250 
(Monodisperse) 
 
Anti-GCC Ab 5.21 ± 0.51 0.400 
(Monodisperse) 
 
    
Expected average ZnPcS4 - 
AuNP - Anti-GCC Ab 
54.99 ± 0.537   
    
Result average ZnPcS4 - 
AuNP - Anti-GCC Ab (final 
actively targeted PS 
nanoconjugate) 
57.18 ± 3.04 0.353 
(Monodisperse) 













Figure 25 DLS hydrodynamic radius distribution graph of final actively targeted PS 
nanoconjugate consisting of ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-
GCC Ab, repeated in triplicate. 
Furthermore, DLS measurements can be used to monitor successful biomolecule 
conjugation in nanoconjugate carriers (Jans et al., 2009). This is due to the fact 
that when a complete layer of bound biomolecules is successfully absorbed onto 
a NPs outer core, a soft external surface coat is formed around the NPs hard core, 
which also scatters light (James and Driskell, 2013). This biomolecule outer 
coating causes the diameter of a NPs surface to increase by at least two times the 
diameter of the originally measured protein / Ab or drug molecule that was bound 
to it (Jans et al., 2009; James and Driskell, 2013). The increase in the final size of 
the nanocarrier platform can be  compared to the original size of the NP alone, 
protein / Ab or drug molecule alone controls and so allows one to determine if 
biomolecule conjugation and surface functionalized of the nanocarrier platform was 
successful (Figure 26) (Jans et al., 2009; James and Driskell, 2013). If a NP alone 
has a diameter of a least 3 nm, the absorption and formation of a stable monolayer 
of a protein for example on an NPs surface is readily detectable using DLS and so 




Figure 26 Two fold increase in diameter of a NPs surface by addition of biomolecule 
external coat.  
 
With reference to Table 13, the mean z-average DLS diameters of Anti-GCC Ab is 
5.21 ± 0.51nm and ZnPcS4 is 18.15 ± 1.44 nm. The original size of the AuNP was 
(11.78 ± 0.966 nm) (Table 13).  If both the Anti-GCC Ab and ZnPcS4 bound to the 
AuNP, this would have doubled the size diameter of the original AuNP pre-
determined diameter, equating to a final actively targeted PS nanoconjugate 
expectancy average size of 54.99 ± 0.537 nm (Table 13). The mean z-average 
DLS diameter of the final actively targeted PS nanoconjugate was found to be 
57.18 ± 3.04 nm, which is very similar to the expected average calculated result of 
54.99 ± 0.537nm, taking the standard deviation into account and so this result pre-
confirmed the biomolecule effective conjugation of the Anti-GCC Ab and ZnPcS4  
to the AuNPs (Table 13). However, since it was questionable if the DLS laser light 
scattering at 633 nm could have slightly interfered with the molecular integrity of 
ZnPcS4, as it’s a fluorochrome which is excitable at 634 nm, the successful 
conjugation of ZnPcS4 and Anti-GCC Ab to AuNPs, was additionally and further 
confirmed using the above discussed UV-Vis and FTIR spectra techniques 
(Geißler et al., 2015; Bhattscharjee et al., 2016). 
Moreover, DLS can calculate the Polydispersity Index (PDI) of a sample by 
measuring the intensity of light scatter and so determine the purity of a sample 
(Bhattscharjee et al., 2016). Monodisperse samples are considered to be pure, 
singular samples of the same size and generally have a PDI value range between 
0.1 to 0.4, due to a compact light scatter, whereas polydisperse samples have a 
PDI ≥ 0.4 and so are considered to be a mixture of various particle sizes 
(Bhattscharjee et al., 2016). With reference to Table 13, it can be observed that 
the final actively targeted PS nanoconjugate noted a PDI value of 0.353, signifying 
it was monodispersed in nature and consisted mostly of singular sized particles. 
Moreover, these results imply that the three individual constituents (ZnPcS4, AuNP-
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PEG5000-SH-NH2 and Anti-GCC Ab) were successfully bonded together to form 
one single final actively targeted PS nanoconjugate molecule. 
Zeta potential is a scientific term for electro kinetic potential in a colloidal system 
(Honary et al., 2013). Within the ZP technique the net surface potential charge of 
a NP drug delivery system can be determined (Honary et al., 2013). According to 
studies by Bhattscharjee et al. (2016), these surface net charge ZP values can be 
directly correlated to the colloid steadiness of NP-dispersions and so determine 
the overall stability of a NP drug delivery system. The standard classification 
guidelines for NP-drug delivery dispersion stability classification are as follows: ±0-
10 mV - highly unstable; ±10-20 mV - relatively stable; ±20-30 mV - moderately 
stable; and ±30 mV - highly stable (Patel et al., 2011; Bhattscharjee et al., 2016). 
Moreover, since ZP is a potential charge that exists on the outer parts of a 
molecular compound, it is often used an indicator of electrophoretic mobility of the 
compound (Bhattscharjee et al., 2016). Within an in vivo system a very high 
positive or negative ZP surface net charge can affect a NP drug delivery systems 
distribution and subcellular localization, due to the electrostatic repulsive forces 
that naturally occur on all biomolecules  in vivo surfaces, such as proteins, lipids, 
cell membranes etc. (Bhattscharjee et al., 2016). Moreover, cancer cell surfaces 
are usually more negatively charged than average normal cell surfaces, due to the 
constant translocation of negatively charged constituents from the inner layer of 
the cell membrane (e.g., phosphatidylserine, anionic phospholipids, glycoproteins 
and proteoglycans) to the outer cancer cells surface (Honary et al., 2013). Hence, 
when considering final NP delivery systems for successful drug subcellular 
localization, a ZP result of near neutral to slightly positive is considered favorable, 
taking into consideration that generally cancer cellular membranes exhibit higher 
negative charges than normal cells (Yu et al., 2016). Studies by Honary et al. 
(2013), have noted that NPs with an overall positive charge are more preferentially 
taken up by the tumours and retained for a longer time span, compared to 
negatively charged or neutral particles. 
Favourably as can be observed in Table 13, the ZP value of the final actively 
targeted PS nanoconjugate was found to be 36.5 ± 2.6 mV, proposing that it is 
highly stable with a slightly positively charge, hinting at the fact that it should remain 
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stable within an in vivo environment, as well as be retained within cancer tumour 
cells more selectively for a longer period of time. 
4.2.4  Presumptive ROS Generation  
Since the final actively targeted PS nanoconjugate contained ZnPcS4 PS which 
absorbs at 350 nm (Soret Band) and emits at 583, 634 and 674 nm range (Q band) 
in PBS (Abramczyk et al., 2014; Brozek-Pluska et al., 2016), it should possess the 
ability to generate ROS. However, the ability of a molecular drug conjugate to 
generate ROS can sometimes be affected, due to it becoming quenched with side 
chain conjugates (Brozek-Pluska et al., 2016).  
Thus, in order to presumptively confirm if the final actively targeted PS 
nanoconjugate was capable of ROS generation before conducting PDT 
experiments (in order to observe the cytotoxic ROS effects in cell culture), its UV-
Visible absorption and fluorescent spectra were recorded using the Jenway 
Genova Nano Plus Life Science Spectrophotometer pre- and post-laser irradiation 
exposure within the 198 to 800 nm spectral region. 
The presumptive production of ROS from the final actively targeted PS 
nanoconjugate was determined by comparing the decay in absorbance intensity of 
the UV-Vis Q band in the known 634 and 674 nm range of ZnPcS4, pre- and post-
laser irradiation with that of a previously run control sample of ZnPcS4 alone.  
As can be observed in Figure 27, two strong UV-Vis absorption Q bands in the 634 
and 673 nm range can be observed pre-laser irradiation suggesting that the final 
actively targeted PS nanoconjugate with ZnPcS4 had photolytic activity within these 
far-red regions of the visible spectrum (Brozek-Pluska et al., 2016). Post laser 
irradiation it can be observed that these two strong absorption bands decayed in 
intensity, suggesting that upon laser light exposure at 673 nm the final actively 
targeted PS nanoconjugate became excited, transferring its energy to surrounding 
oxygen molecules, presumptively generating ROS and so became photobleached 
(Stuchinskaya et al., 2011). These results presumptively confirmed the photolytic 
activity of the final actively targeted PS nanoconjugate, however only additional 
PDT cell culture assays, performed later on in this study could definitively confirm 
if this potential ROS generation was cytotoxic enough to destroy CRC cells. Lastly, 
it must be noted that when comparing the final actively targeted PS nanoconjugate 
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UV-Vis absorption Q bands at 520 nm, pre- and post- laser irradiation, a significant 
decay in intensity was also noted. Since the UV-visible absorption spectrum peaks 
at 520 nm demarcate the presence of AuNPs, within the final actively targeted PS 
nanoconjugate, it could be suggested that upon laser light exposure at 673 nm, the 
final actively targeted PS nanoconjugate AuNPs produces photothermal energy 
and so presumptively could enhance PDT treatment outcomes, due to its 
theranostic properties.  
Figure 27 UV-Visible absorption spectra of the final actively targeted PS 
nanoconjugate (ZnPcS4 - AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) pre- 
and post- laser irradiation at 673 nm, recorded within the 400 to 800 nm 
spectral region. 
4.2.5 Photostability Analysis 
The photostability parameter of any potential PS should be monitored over time as 
to ensure it remains stable in the dark and its absorbance doesn’t decay overtime, 
rendering it ineffective (Rojkiewicz et al., 2013). Only upon light exposure it should 
go into an excited state and so transfer its energy to neighbouring molecules (for 
example oxygen) and then return to a ground state (Rojkiewicz et al., 2013). 
Sometimes PS nano conjugates can degrade overtime and so lose their absorption 
and excitation properties, due to many external properties, such as the solvent they 
suspended in, additional substituents being present or because the compound 
might have started to aggregate (Rojkiewicz et al., 2013). When the final actively 
targeted PS nanoconjugate or its controls were not being utilized in laser irradiation 




Figure 28 UV-Visible absorption photostability spectra of the final actively targeted 
PS nanoconjugate (ZnPcS4 -AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) 
recorded within the 300 to 800 nm spectral region over an 8-week period. 
In order to determine the photostability of the final actively targeted PS 
nanoconjugate its Soret and Q bands values were measured prior to laser light 
irradiation experiments over the duration of experimental assays (8 weeks) with a 
UV-Vis spectrophotometer (Genova Nano Plus Life Science Spectrophotometer - 
Jenway), using the spectrum/purity scan mode within the 198 to 800 nm spectral 
region. The UV spectra results were captured and reported over an 8-week period, 
to note any photostability absorption changes that could have occurred within the 
final actively targeted PS nanoconjugate. With reference to Figure 28, no 
significant or obvious changes within the UV spectra, were noted suggesting that 
the final actively targeted PS nanoconjugate remained stable and free of 
aggregation. Furthermore, there were no significant shift changes within the high 
absorption (350 nm - Soret Band) and absorption (583, 634 and 674 nm - Q band) 
peaks indicating that the ZnPcS4 PS within the final PS nanoconjugate retained to 
photochemical properties and did not quench (Figure 28). 
4.3 Sub-Cellular Localization Confirmation of Final Actively Targeted PS 
Nanoconjugate 
The success of targeted PDT hinges on different dynamics, namely on the efficacy 
of the PS nanocarriers cancer targeting abilities in normal versus cancer tumour 
cells (Mesquita et al., 2018). Immunofluorescent microscopy staining subcellular 
localization studies were performed in order to determine the intracellular 
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concentration of ZnPcS4 PS within in vitro cultured CRC cells (CaCo-2) and the 
degree of cellular uptake, when administered alone, versus within a specifically 
active PS nanocarrier system (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-GCC Ab). 
Additionally, these immunofluorescent stained images were compared to in vitro 
cultured normal human fibroblasts (WS1), which also received the PS alone and 
final actively targeted PS nanoconjugate, in order to assess if the final actively 
targeted PS nanoconjugate demonstrated any improved targeted specify or affinity 
for CRC cells only or indicated any uptake in normal human cells. Images were 
captured at 400x magnification. 
Table 14 Subcellular localization comparison of ZnPcS4 PS uptake in CaCo-2 cells, 
treated with ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 and the 
final actively targeted PS nanoconjugate. DAPI-stained nuclei (Blue), 
cellular membrane proteins (Green) and ZnPcS4 localization (RED). 
 
With reference to Table 14, CRC cells note a slight passive subcellular uptake of 
the ZnPcS4 PS when it was administered alone. These results coincided with the 
findings reported by Roguin et al. (2019), highlighting that ZnPc is a stable 
compound, which exhibits selective passive accumulation in tumour tissues. In an 
effort to further augment the passive subcellular localization of the ZnPcS4 PS in 
CRC cells, it was integrated with a gold nanocarrier. Since studies by Hong et al. 
(2016) stated that nanoparticles significantly enhance the solubility of PSs and so 
Description ICAM Green Cellular 
Membrane Protein 
DAPI Blue Nucleus ZNPCS4 Red CY5 for 
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increases their selective passive localization. When looking at Table 14, CRC cells 
which received the same concentration of ZnPcS4 PS, however conjugated to 
AuNPs (ZnPcS4-AuNPEG5000-SH-NH2) noted an improved PS drug passive 
uptake indicated by a slightly increased intensity of the PS staining colour in cells. 
Several lines of evidence emphasize that when targeting moieties, which correlate 
with overexpressed cancer cell receptors are correctly attached to PS nanocarrier 
platforms, the PS absorption is selective and can be directly up via cell membrane 
endocytosis into target tumours in higher concentrations (Hodgkinson et al., 2017).  
With reference to Table 14, the experimental group of CRC cells treated with the 
final actively targeted PS nanoconjugate (AuNPEG5000-SH-NH2 + ZnPcS4 + Anti-
GCC Ab) noted enhanced affinity and active accumulation of the PS, which is 
indicated by a greater intensity of the PS staining colour in cells . These findings 
indicate that the final targeted PS nanoconjugate facilitated enhanced ZnPcS4 PS 
retention in CRC cells (CaCo-2), via the specific PS nanoconjugates Anti-GCC Ab 
selective and active targeting abilities.   
Table 15 Subcellular localization comparison of ZnPcS4 PS uptake in WS1 cells, treated 
with ZnPcS4 PS alone, AuNPEG5000-SH-NH2 - ZnPcS4 and the final actively targeted PS 
nanoconjugate. DAPI-stained nuclei (Blue), cellular membrane proteins (Green) and 
ZnPcS4 localization (RED). 
Description ICAM Green Cellular 
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DAPI Blue Nucleus ZNPCS4 Red CY5 for 
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With reference to Table 15, normal human fibroblasts WS1 cells treated with 
ZnPcS4 alone noted some absorption of the PS, suggesting that within these 
applied conditions, normal human cells would be affected within CRC localized 
PDT treatments and so unwanted side effects could be observed. Whereas, 
normal human fibroblasts WS1 cells treated with AuNPEG5000-SH-NH2 - ZnPcS4 
control conjugate, noted still only slight absorption of the PS at the same 
administered concentration, which is indicated by a slightly increased intensity of 
the PS stainig colour in cells, suggesting that the AuNPs promoted the PS for a 
more passive uptake within cancer tissues and so CRC PDT treatment outcomes 
would have lessened side effects of normal surrounding tissues (Table 15). 
However, experimental normal human fibroblasts WS1 cells treated with the final 
actively targeted PS nanoconjugate, noted no detectable subcellular localization of 
the PS. These findings indicated that the final PS nanoconjugate, has no actively 
specific affinity for healthy cells (such as fibroblasts), suggesting that if it was to be 
applied within actively targeted PDT treatment for CRC, the treatment would 
remain localized to CRC only, with no unwanted side effects being induced in 
healthy surrounding tissues.  
4.4 Dose Response Studies  
4.4.1 CaCo-2 ZnPcS4 PS PDT Dose Response Analysis 
In order to determine the lowest possible concentration of ZnPcS4 PS which could 
be administered to CRC cells to yield 50 % cell viability, as well as induce a 
significant amount of cytotoxicity, and to establish cell death induction potential, 
but still be able to determine cellular responses, varying concentrations of ZnPcS4 
PS was administered to cultured cells within PDT dose response assays (0.0312, 
0.0625, 0.125 and 0.25 µM). Furthermore, these PDT dose response assays were 
performed in order to determine the ideal ICD50 concentrations at which the ZnPcS4 
PS contained within the final actively targeted PS nanoconjugate, should also be 
administered so that results could be compared in relation to PS PDT treatment 
alone versus PS nanoconjugate actively targeted PDT at the same concentration.  
4.4.1.1  Cellular Morphological Assessment by Light Microscopy 
The effect of ZnPcS4 PS PDT treatment alone on the various control and 
experimental groups was analysed by viewing the captured inverted microscope 
digital images and comparing them. All images were captured at a 40x 
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magnification. The cellular structures of the CRC cells were evaluated based on 
changes in cell shape, size and non-viable cells (Noguchi et al., 2015). Change in 
the microscopic structure of cells and their cellular components is an indication of 
cell damage occurring or having occurred (Noguchi et al., 2015). 
Table 16 Morphological comparison of various control and experimental groups of 
CaCo-2 CRC cells treated within ZnPcS4 PDT dose response assays. 




Cells + Irradiation (10 J/cm2) 
 
Cells + 0.0312 µM ZnPcS4 
 
Cells + 0.0625 µM ZnPcS4 
 
Cells + 0. 125 µM ZnPcS4 
  
Cells + 0. 25 µM ZnPcS4 
PDT Treated Experimental Groups 
 
Cells + 0.0312 µM ZnPcS4 + PDT 
 
Cells + 0.0625 µM ZnPcS4 + PDT 
 
Cells + 0.125 µM ZnPcS4 + PDT 
 
Cells + 0.25 µM ZnPcS4 + PDT 
 
With reference to Table 16 it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
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appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
CRC cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on CRC cells (Table 16). All control groups of CRC cells, which 
received the varying concentrations of PS alone (0.0312, 0.0625, 0.125 and 0.25 
µM) without laser irradiation, noted no significant morphological changes or effects 
when compared to the cells only control. According to Kruger et al. (2018), ideally 
a PS should have no dark toxicity and should only affect cells when activated by 
laser light. These findings indicated that the ZnPcS4 PS at these various 
concentrations, remained inactive within dark conditions and so exerted no dark 
cytotoxicity on CRC cells.  
However, experimental group CRC cells, which received varying concentrations of 
the PS (0.0312, 0.0625, 0.125 and 0.25 µM) and PDT laser irradiation at 673nm 
with a fluency of 10 J/cm2, demonstrated changes in cellular morphology in a dose-
dependent manner. In a dose dependent manner ZnPcS4 PS PDT induced cellular 
damage in CRC cells when compared to the CRC control of cells only. Cells started 
changing their distinctive appearance, in terms of rounding up and detaching from 
cell culture plates. The most significant damage noted in ZnPcS4 PS PDT treated 
CRC cells, were those which received 0.25 µM ZnPcS4, as most cells appeared as 
free-floating structures and the cells which remained attached had irregular nuclear 
fragmentation, as well as reduced nuclear genetic material, suggesting this 
particular dose was lethal. Whereas, ZnPcS4 PS PDT treated CRC cells, which 
received 0.125 µM ZnPcS4, noted a significant amount of morphological damage 
and debris, however at least 50% of the cells appeared functional, suggesting that 
this is the likely ICD50 dose required.   
4.4.1.2  Cellular Viability Assessment  
The Trypan blue exclusion test was performed to assess the effect ZnPcS4 PS 
PDT dose responses had on the survival of CRC treated cells, since it indicates 
the percentage of viable cells, due to its staining ability to distinguish between 
viable and non-viable cells. Figure 29 showed that the control group of CRC cells 
only had 100% viable cells, indicating that the cells were both normal and healthy. 
This control group of CRC cells only, was utilized for statistically significant 
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comparisons of findings against other various control and experimental groups for 
overall result analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
 
Figure 29 Trypan blue exclusion cell viability assay. Response of CaCo-2 cells 
treated with varying concentrations of ZnPcS4 PS following PDT, 
demonstrating a decrease in cell viability in a dose dependent manner. 
It is clearly shown that the control group of CRC cells which received laser 
irradiation at 673 nm and a fluency of 10 J/cm2 noted an insignificant decrease in 
cell viability when compared to the reference control group of cells only (Figure 
29). This is consistent with literature, as it suggests that laser irradiation at 673 nm 
with a fluency 10 J/cm2, without any addition of a PS, does cause damage to CRC 
cells (Manoto et al., 2012).  
Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a dose dependent decrease in cell viability noted for these control 
groups treated which received the various concentrations of ZnPcS4 only, however 
it was insignificant (Figure 29). This suggests that the ZnPcS4 PS in its inactivated 
form when administered alone, at these varying concentrations, lacks cytotoxicity 
and so does not damage CRC cells, without laser irradiation being applied.  
The PDT experimental groups which consisted of CRC cells treated with varying 
concentrations of the PS and exposed to 673 nm laser irradiation at 10 J/cm2, noted 
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a significant decrease in cellular viability in a dose-dependent manner (Figure 29). 
The most significant decrease in cell viability was 44%*** and this was noted in 
PDT treated experimental groups which received 0.25 µM ZnPcS4 PS, signifying 
that at this particular concentration CRC PDT treatment could obliterate cells 
beyond cellular responses detection, due to severe cell death induction. Within the 
PDT treated experimental groups whereby CRC cells received 0.125 µM ZnPcS4 
PS, significant cellular damage had occurred, however 54%** of the cells were 
found to be viable and so from this assay the recommended ICD50 concentration 
of the ZnPcS4 PS would be 0.125 µM. Overall these results indicate that ZnPcS4 
is an excellent PS for the use in this type of CRC PDT treatment, since it is capable 
of substantial cell death induction.  
4.4.1.3  Cellular Proliferation Assessment 
The CellTiter-Glo® luminescent assay (AnaTech: Promega, PRG7571) was used 
to measure cellular proliferation by evaluating the amount of ATP produced from 
metabolically active cells. 
 
Figure 30 ATP luminescence cell proliferation assay. Response of CaCo-2 cells 
treated with varying concentrations of ZnPcS4 PS following PDT, 
demonstrating a decrease in cellular proliferation in a dose dependent 
manner. 
Figure 30 showed that the control group of CRC cells only had 100% viable cells 
capable of proliferation, indicating that the cells were both normal and healthy. This 
control group of CRC cells only, was utilized for statistically significant comparisons 
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of findings against other various control and experimental groups for overall result 
analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2, noted no significant decreases in cellular viability when 
compared to the reference control group of cells only (Figure 30). These results 
are consistent with studies performed by Manoto et al. (2012) which noted that 
laser irradiation at 673 nm, with a fluency 10 J/cm2, without any addition of a ZnPc 
PS does not cause damage to CRC cells. 
Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a slight dose dependent cellular proliferation decrease noted for these 
control groups, which were treated with the various concentrations of ZnPcS4 only, 
however it was insignificant (Figure 30). This suggests that the ZnPcS4 PS in its 
inactivated form when administered alone (without laser irradiation), within these 
particular concertation ranges, lacks cytotoxicity and so does not damage cellular 
proliferation mechanisms within CRC cells.  
The PDT experimental groups which consisted of CRC cells treated with varying 
concentrations of the PS and exposed to 673nm laser irradiation at 10 J/cm2, noted 
a significant decrease in cellular proliferation in a dose-dependent manner (Figure 
30). The most significant decrease in cellular viability was noted in PDT treated 
experimental groups which received 0.25 µM ZnPcS4 PS, signifying that at this 
particular concentration CRC PDT treatment could obliterate cells beyond cellular 
responses detection, due to the severe cellular proliferation damage it induced. 
Within the PDT treated experimental groups, whereby CRC cells received 0.125 
µM ZnPcS4 PS, significant cellular proliferation damage had occurred, however in 
comparison to the CRC cells only control, 4.E+05*** cells were found to be 
metabolically active and capable of cellular proliferation and this concentration 
approximately 50% of the CRC were viable. Hence, these results were suggestive 
that the recommended ICD50 concentration of the ZnPcS4 PS would be 0.125 µM. 
Overall these results indicate that ZnPcS4 is an excellent PS for the use in this type 




4.4.1.4  Cellular Cytotoxicity Assessment  
The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Anatech: Promega, 
PRG1780), was used to quantitatively measure the amount of LDH released into 
the culture media of the various experimental and control cells to evaluate the 
degree of cytoxicity the ZnPcS4 PS was able to induce in CRC cells.  
With reference to Figure 31, the LDH positive control signifies 100% cellular 
cytotoxicity in CRC cells (CaCo-2), due to complete cellular lysis and so was used 
as a standard reference to calculate percentage cytotoxicity in all other control and 
experimental groups. The control group of cells only, was used as a standard 
reference for viable CRC cells, which reflects no cellular cytotoxicity, for statistical 
significance comparisons in all other control and experimental groups (P˂0.05*) 
(P˂0.01**) (P˂0.001***). 
 
Figure 31 Cytotoxicity of control and experimental groups of ZnPcS4 PS drug at 
different concentrations with and without 673 nm laser irradiation at 10 
J/cm2, using Lactate Dehydrogenase membrane integrity assay. 
The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2, noted no significant increases in cellular cytotoxicity when 
compared to the LDH positive control group of cells only (Figure 31). As previously, 
discussed these results are consistent with studies performed by Manoto et al. 
(2012) which noted that laser irradiation at 673 nm, with a fluency 10 J/cm2, without 
any addition of a ZnPc PS does not induce any cytotoxicity in CRC cells. 
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Control culture CRC cells, which received various concentrations of ZnPcS4, with 
no laser irradiation applied to them, were used as comparative controls groups. 
There was a slight dose dependent cellular cytotoxicity increase noted for these 
control groups, which were treated with the various concentrations of ZnPcS4 only, 
however it was insignificant (Figure 31). This suggests that the ZnPcS4 PS in its 
inactivated form when administered alone (without laser irradiation), within these 
particular concertation ranges, lacks cytotoxicity and so does not induce cellular 
damage within CRC cells.  
The PDT experimental groups which consisted of CRC cells treated varying 
concentrations of the PS and exposed to 673nm laser irradiation at 10 J/cm2, noted 
a significant increase in cellular cytoxicity in a dose-dependent manner (Figure 31). 
The most significant increase in cellular cytotoxicity was 67%*** and this was noted 
in PDT treated experimental groups which received 0.25 µM ZnPcS4 PS, signifying 
that at this particular concentration CRC PDT treatment could obliterate cells 
beyond cellular responses detection, due to severe cytotoxicity it induced. Within 
the PDT treated experimental groups, whereby CRC cells received 0.125 µM 
ZnPcS4 PS, significant cytotoxicity had occurred, however it was only 45%** and 
so from this assay the recommended ICD50 concentration of the ZnPcS4 PS would 
be 0.125 µM. Overall these results indicate that ZnPcS4 is an excellent PS for the 
use in this type of CRC PDT treatment, since it is capable of substantial cellular 
cytoxicity induction. 
4.4.1.5  Summation of ZnPcS4 PS PDT Dose Response Assays 
Analysis in Relation to Final Actively Targeted PS 
Nanoconjugate Correction Factor 
The optimal IDC50 dose response concentration of ZnPcS4 PS after PDT treatment 
that induced approximately 50 % cytotoxicity was found to be 0.125 µM, after 
assessing the above morphological, cellular viability, proliferation and cytotoxicity 
results. 
Therefore, once the above had been established then further final actively targeted 
PS nanoconjugate PDT experiments within in vitro cultured CaCo-2 could be 
conducted utilizing the synthesized ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC 
Ab at the recommended and adjust ICD50 ZnPcS4 PS concentration of 0.125 µM. 
This was done for comparative result reporting, in order to compare if the ZnPcS4 
120 
 
PS PDT induced cytotoxicity alone, induced more or less cytotoxicity versus the 
final actively PDT targeted PS nanoconjugate.  
Since the molecular characterization results in Table 11 and 12 noted that the final 
actively targeted PS nanoconjugate consisted of 30.91 µg/ml of Anti-GCC  Ab, 
which was successfully bound to 0.95 X 1015 AuNP-PEG5000-SH-NH2 particles/ml 
and on average 0.000035 M / 35 uM of ZnPcS4 in 0.001 M PBS (w/v), it meant it 
required a dilution correction factor. Thus to bring the ZnPcS4 PS concentration 
down to recommended ICD50 concentration of 0.125 µM, when being added to the 
various control and experimental culture plates, it was diluted. The calculations 
showing this dilution factor correction have been shown in Appendix E7. 
After diluting the experimental synthesized final actively targeted PS 
nanoconjugate, using a 280-fold dilution factor to contain 0.125 µM ZnPcS4 PS, it 
must be noted that this also affected the final concentration of the AuNP-PEG5000-
SH-NH2 and Anti-GCC Ab. Therefore, within the final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab) PDT 
response assays, within in vitro cultured CRC and WS1, culture plates received 
0.11 µg/ml Anti-GCC  Ab, which was successfully bound to 3.39 X 1012 AuNP-
PEG5000-SH-NH2 particles/ml conjugated to a 0.125 µM of ZnPcS4 in 0.001 M 
PBS (w/v). Thus, the required 0.125 µM ZnPcS4 PS concentration, corrected 
volumes of final actively targeted PS nanoconjugate that was required to be 
administered to the various control and experimental control groups cell culture 
media within the final PDT PS nanoconjugate assays was indicated in Table 8 
(Section 3.11).  
4.4.2  CaCo-2 CBD Dose Response Assays  
In order to determine the lowest possible concentration of CBD which could be 
administered to CRC cells to yield 50 % cell viability, as well as induce a significant 
amount of cytotoxicity, in order to establish cell death induction potential (ICD50), 
but still be able to determine cellular responses, varying concentrations of CBD 
(0.5; 1; 1.5 and 2 µM) were administered to cultured cells, with and without laser 
irradiation. Furthermore, these CBD dose response assays were performed in 
order to determine the ideal ICD50 concentrations, at which it could be administered 




4.4.2.1  Cellular Morphological Assessment by Light Microscopy 
The effect of CBD alone and in combination with laser treatment on the various 
control and experimental groups was analysed by viewing the captured inverted 
microscope digital images and comparing them. All images were captured at a 40x 
magnification. The cellular structures of the CRC cells were evaluated based on 
changes in cell shape, size and non-viable cells (Noguchi et al., 2015). Change in 
the microscopic structure of cells and their cellular components is an indication of 
cell damage occurring or having occurred (Noguchi et al., 2015). 
Table 17 Morphological comparison of various control and experimental groups of 





Cells + Irradiation (10 J/cm2) 
 
Cells + Ethanol 
 
Cells + 0.5 µM CBD 
 
Cells + 1 µM CBD 
 
 
Cells + 1.5 µM CBD 
  
Cells + 2 µM CBD 
 
Laser Treated Experimental Groups 
 
Cells + 0.5 µM CBD + Laser 
 
Cells + 1 µM CBD + Laser  
 
 
Cells + 1.5 µM CBD + Laser 
 





With reference to Table 17 it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal” 
when assessing the other various control and experimental groups. Control group 
CRC cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone, has no effect on CRC cells (Table 17). The control group of CRC cells 
treated with ethanol only, noted no visible changes in morphology, suggesting that 
the ethanol concentration, in which the CBD was solubilized had no significant 
cytotoxic effects on CRC cells (Table 17).  
Control groups of CRC cells, which received 0.5 and 1 µM CBD without laser 
irradiation, noted no obvious changes in morphology, signifying that CBD at these 
particular concentrations, have no visible effects on cells (Table 17).  However, 
control groups of CRC cells, which received 1.5 and 2 µM CBD without laser 
irradiation, noted some obvious changes in morphology in comparison to the 
control group of CRC cells only (Table 17). The cells appeared rounding up and 
detached from cell culture plates, signifying that CBD, at these particular 
concentrations, does have a significant cytotoxic effect on CRC cells. Studies 
performed by Aviello et al. (2012) support these findings, since they reported 
similar results within in vitro cultured CRC, when applying similar concentrations 
and noted that CBD reduced cell proliferation, though apoptotic cell death 
mechanisms, while generating anti-tumour immune responses after treatment. 
Experimental groups of CRC cells, which received varying concentrations of CBD 
(0.5, 0.1, 1.5 and 2 µM) and laser irradiation at 673nm, with a fluency of 10 J/cm2, 
demonstrated changes in cellular morphology in a dose-dependent manner (Table 
17). In a dose dependent manner CBD plus laser irradiation induced cellular 
damage in CRC cells, when compared to the CRC cells only control. These 
experimental groups lost their distinctive appearance and started to round up in 
shape and detach from culture dishes. The most significant damage noted in CBD 
laser treated CRC cells, were those which received 2 µM CBD, as most cells 
appeared as free-floating structures and the cells which remained attached had 
irregular nuclear fragmentation, as well as reduced nuclear genetic material, 
suggesting this particular dose was lethal. Whereas, CBD laser treated CRC cells, 
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which received 1 µM CBD, noted a significant amount of morphological damage 
and debris, however at least 50% of the cells appeared functional, suggestive that 
this could perhaps be the ICD50 dose required to be utilized in final actively targeted 
PS PDT nanoconjugate assays. Furthermore, these findings suggest that the 
combination of CBD and laser irradiation, possibly does visually affect CRC 
morphologically more than CBD treatment alone and so required further 
cytotoxicity analysis.  
4.4.2.2  Cellular Viability Assessment 
The Trypan blue exclusion test was performed to assess the effect CBD dose 
responses had on the survival of CRC treated cells, since it indicates the 
percentage of viable cells, due to its staining ability to distinguish between viable 
and non-viable cells. Figure 32 showed that the control group of CRC cells only 
had 100% viable cells, indicating that the cells were both normal and healthy. This 
control group of CRC cells only, was utilized for statistically significant comparisons 
of findings against other various control and experimental groups for overall result 
analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
 
Figure 32 Trypan blue exclusion cell viability assay. Response of CaCo-2 cells 
treated with varying concentrations of CBD alone and laser irradiation, 
demonstrating a decrease in cell viability in a dose dependent manner. 
It is clearly shown that the control group of CRC cells which received laser 
irradiation at 673 nm and a fluency of 10 J/cm2 noted an insignificant decrease in 
cell viability, when compared to the reference control group of cells only (Figure 
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32). This is consistent with literature, as it suggests that laser irradiation at 673 nm 
with a fluency 10 J/cm2, without any addition of therapeutic drugs, does not cause 
damage to CRC cells (Manoto et al., 2012). The control group of CRC cells treated 
with ethanol only, noted no significant change in viability, suggesting that the 
ethanol concentration, in which the CBD was solubilized had no significant 
cytotoxic effects on CRC cells (Figure 32). 
Control culture CRC cells, which received various concentrations of CBD, with no 
laser irradiation applied to them, noted a significant dose dependent decrease in 
cell viability, especially CRC cells which received 2 µM CBD (37%**) (Figure 32). 
These findings suggest that the administration of CBD alone to CRC cells within 
the dosing range of 0.5 to 2 µM, does have a cytotoxic effect on them in a dose 
dependent manner. These findings are supported by a study performed by Aviello 
et al. (2012), whereby in vitro cultured CRC cells treated with similar concentration 
of CBD, noted a significant decrease in cellular viability due to apoptotic cell death. 
The experimental groups, which consisted of CRC cells treated with varying 
concentrations of the CBD and exposed to 673 nm laser irradiation at 10 J/cm2, 
noted a highly significant decrease in cellular viability in a dose-dependent manner 
(Figure 32). The most significant decrease in cell viability was found in CRC cells 
which received 1.5 µM and 2 µM CBD and laser irradiation, whereby cellular 
viability was found to be 35%*** and 29%*** respectively. This is suggestive that 
CBD plus laser irradiation can induce an appreciable cell death in CRC cells and 
this treatment could obliterate cells beyond cellular responses detection, due to 
severe cell death induction. However, if one had to compare these results to the 
control CRC cells which received 2 µM CBD (37%**) and no laser irradiation, it can 
be seen that laser irradiation with CBD only slightly promotes cellular viability 
decreases. This suggests that laser irradiation had a negligible effect on CBD 
cellular viability result outcomes and so it could be utilized in combination with 
irradiation or without to induce cytotoxic effects on CRC cells, without any 
influential outcomes. Within the laser irradiated experimental groups, whereby 
CRC cells received 1 µM CBD, significant cellular damage had occurred, however 
44%** of the cells were found to be viable and so from this assay the recommended 
ICD50 concentration of CBD plus irradiation would be 1 µM.  
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Overall, these results indicate that CBD is an excellent chemo preventative agent 
for the treatment of CRC, since it is capable of substantial cell death, whether 
administered alone or in combination with laser irradiation.  
4.4.2.3  Cellular Proliferation Assessment 
The CellTiter-Glo® luminescent assay (AnaTech: Promega, PRG7571) was used 
to measure cellular proliferation by evaluating the amount of ATP produced from 
metabolically active cells. Figure 33 showed that the control group of CRC cells 
only, had 100% viable cells capable of proliferation, indicating that the cells were 
both normal and healthy. This control group of CRC cells only, was utilized for 
statistically significant comparisons of findings against other various control and 
experimental groups for overall result analysis (P˂0.05*) (P˂0.01**) (P˂0.001***). 
 
Figure 33 ATP luminescence cell proliferation assay. Response of CaCo-2 cells 
treated with varying concentrations of CBD alone and laser irradiation, 
demonstrating a decrease in cellular proliferation in a dose dependent 
manner. 
The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2 noted an insignificant decrease in cellular proliferation, when 
compared to the reference control group of cells only (Figure 33). Similar findings 
were reported by Manoto et al., (2012), whereby CRC in vitro cultured cells treated 
with laser irradiation alone at 673 nm with a fluency 10 J/cm2, noted no hinderance 
in cellular proliferation (Manoto et al., 2012). The control group of CRC cells treated 
with ethanol only, also noted no significant change in cellular viability, suggesting 
that the ethanol concentration, in which the CBD was solubilized, had no significant 
anti-proliferative effects on CRC cells (Figure 33). 
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Control culture CRC cells, which received various concentrations of CBD, with no 
laser irradiation applied to them, noted a significant dose dependent decrease in 
cellular proliferation, especially CRC cells which received 2 µM CBD (1,E+06**) 
(Figure 33). These findings suggest that the administration of CBD alone to CRC 
cells within the dosing range of 0.5 to 2 µM, does have a significant anti-
proliferative on them, in a dose dependent manner. Studies by Aviello et al. (2012), 
noted similar anti-proliferative effects within in vitro cultured CRC, which received 
similar concentrations of CBD, due to an apoptotic form of cell death being induced.  
The experimental groups, which consisted of CRC cells treated with varying 
concentrations of the CBD and exposed to 673 nm laser irradiation at 10 J/cm2, 
noted a highly significant decrease in cellular viability in a dose-dependent manner 
(Figure 33). The most significant decrease in cellular viability was found in CRC 
cells, which received 1.5 µM and 2 µM CBD and laser irradiation, whereby their 
cellular proliferation was found to be 7,E+05*** and 6,E+05*** respectively. These 
findings suggest that CBD plus laser irradiation at these particular concentrations 
can significantly deteriorate cellular proliferation mechanisms in cells, causing 
severe destruction. Furthermore, if one had to compare these results to the control 
CRC cells which received 2 µM CBD (1,E+06**) and no laser irradiation, it can be 
seen that laser irradiation with CBD, most definitely did cause more significant anti-
proliferative effects in CRC cells, in comparison to CBD administration alone. 
These findings suggest that laser irradiation, supported CBD anti-proliferation 
induction effects in CRC cells and so when administered in combination, post-PDT 
is far more effective. Studies by Shams et al. (2015) have shown that stimulation 
of a host immune system with CBD can elicit anti-tumour immune responses 
capable of halting metastatic tumour growth and so have anti-proliferative effects. 
Furthermore, studies by Kenyon et al. (2018) have noted that CBD has the 
potential to induce cell death directly, it can disrupt intracellular signaling pathways, 
such as P13K/AKT/mTOR and ERK, making certain cancer cells respond to 
additional combinative treatments. So perhaps this is the reason as to why CBD 
plus laser irradiation treatment noted improved anti-proliferative effects in 
experimental CRC cells when compared to control cells which received CBD 
treatment alone. Within the laser irradiated experimental groups, whereby CRC 
cells received 1 µM CBD, a significant decrease in cellular proliferation had 
occurred (9,E+05***), however in comparison to the CRC cells only control it can 
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be seen that approximately 50% of the cells remained functional and so from this 
assay the recommended ICD50 concentration of CBD plus irradiation would likely 
be 1 µM.  
Overall, these results indicate that CBD is an excellent chemo preventative agent 
for the treatment of CRC, since it is capable of substantial anti-proliferative effects, 
especially when administered in combination with laser irradiation. 
4.4.2.4  Cellular Cytotoxicity Assessment 
The CytoTox 96® Non-Radioactive Cytotoxicity Assay (Anatech: Promega, 
PRG1780), was used to quantitatively measure the amount of LDH released into 
the culture media of the various experimental and control cells to evaluate the 
degree of cytoxicity CBD with and without laser irradiation was able to induce in 
CRC cells.  
 
Figure 34 Lactate Dehydrogenase membrane integrity cytotoxicity assay. Response 
of CaCo-2 cells treated with varying concentrations of CBD alone and laser 
irradiation, demonstrating a decrease in cytotoxicity in a dose dependent 
manner. 
With reference to Figure 34, the LDH positive control signifies 100% cellular 
cytotoxicity in CRC cells (CaCo-2), due to complete cellular lysis and so was used 
as a standard reference to calculate percentage cytotoxicity in all other control and 
experimental groups. The control group of cells only, was used as a standard 
reference for viable CRC cells, which reflects no cellular cytotoxicity, for statistical 




The control group of CRC cells which received laser irradiation at 673 nm and a 
fluency of 10 J/cm2 noted an insignificant decrease in cellular proliferation, when 
compared to the reference control group of cells only (Figure 34). Similar findings 
were reported by Manoto et al. (2012), whereby CRC in vitro cultured cells treated 
with laser irradiation alone at 673 nm with a fluency 10 J/cm2, noted no induced 
cytotoxicity. The control group of CRC cells treated with ethanol only, reported no 
significant cytotoxicity, suggesting that the ethanol concentration, in which the CBD 
was solubilized, had no cytotoxic effects on CRC cells (Figure 34). 
Control culture CRC cells, which received various concentrations of CBD, with no 
laser irradiation applied to them, noted a significant dose dependent increases in 
cellular cytotoxicity, especially CRC cells which received 2 µM CBD (66%**) 
(Figure 34). These findings suggest that the administration of CBD alone to CRC 
cells within the dosing range of 0.5 to 2 µM, does have significant cytotoxic effect 
on them, in a dose dependent manner. Studies by Aviello et al. (2012), noted 
similar cytotoxic effects within in vitro cultured CRC, which received similar 
concentrations of CBD, due to apoptosis cell death induction.  
The experimental groups, which consisted of CRC cells treated with varying 
concentrations of the CBD and exposed to 673 nm laser irradiation at 10 J/cm2, 
noted a highly significant increase in cellular cytotoxicity in a dose-dependent 
manner (Figure 34). The most significant increase in cellular cytotoxicity was found 
in CRC cells which received 1.5 µM and 2 µM CBD and laser irradiation, whereby 
cellular cytotoxicity was found to be 67%*** and 69%*** respectively. This is 
suggestive that CBD plus laser irradiation can induce a significant amount of 
cytotoxicity and cell death in CRC cells, when administered under these conditions. 
However, if one had to compare these results to the control CRC cells which 
received 2 µM CBD (66%**) and no laser irradiation, it can be seen that laser 
irradiation with CBD only slightly promotes cellular cytotoxicity. This suggests that 
laser irradiation had a negligible effect on CBD cellular cytotoxicity result outcomes 
and so it could be utilized in combination with irradiation or without to induce 
cytotoxic effects on CRC cells, without any influential outcomes. Within the laser 
irradiated experimental groups, whereby CRC cells received 1 µM CBD, significant 
cellular cytotoxicity had occurred, however in only 53%** of the cells and so from 
this assay the recommended ICD50 concentration of CBD plus irradiation would be 
1 µM.  
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Overall, these results indicate that CBD is an excellent chemo preventative agent 
for the treatment of CRC, since it is capable of substantial cytotoxicity, whether 
administered alone or in combination with laser irradiation.  
4.4.2.5  Summation of CBD Dose Response Assays Analysis in 
Relation to Final Actively Targeted PS Nanoconjugate PDT 
Response with and without CBD Treatment  
The optimal IDC50 dose response concentration of CBD that induced 
approximately 50 % cytotoxicity in combination with laser irradiation was found to 
be 1 µM, after assessing the above morphological, cellular viability, proliferation 
and cytotoxicity results. 
Therefore, once the above had been established then further final actively targeted 
PS nanoconjugate PDT experiments within in vitro cultured CaCo-2 could be 
conducted utilizing the synthesized ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC  
Ab at the recommended and adjust ICD50 ZnPcS4 PS concentration of 0.125 µM 
and CBD recommended adjusted concentration of 1 µM. This was done for 
comparative result reporting, in order to compare if CBD administration alone or in 
combination with the final actively targeted PS nanoconjugate PDT assays, could 
induce more or less damage in CRC cells.  
The calculations showing the dilution factor correction factor of CBD to 1 µM have 
been shown in Appendix E1. Thus, the required 1 µM CBD concentration, 
corrected volumes that was required to be administered to the various control and 
experimental control groups cell culture media within the final actively targeted PS 
nanoconjugate PDT response assays with and without CBD Treatment was 
indicated in Table 8 (Section 3.11). 
4.5 Final Actively Targeted PS Nanoconjugate PDT Response Assays with 
and without CBD Treatment in CaCo-2 CRC Cells 
4.5.1 Cellular Morphology by Light Microscopy Assessment in CRC Cells  
The effect of the final actively targeted PS nanoconjugate PDT response assays 
with and without CBD Treatment on within the various CRC control and 
experimental groups were analysed by viewing the captured inverted microscope 
digital images and comparing them. All images were captured at a 40x 
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magnification. The cellular structures of the CRC cells were evaluated based on 
changes in cell shape, size and non-viable cells (Noguchi et al., 2015). Change in 
the microscopic structure of cells and their cellular components is an indication of 
cell damage occurring or having occurred (Noguchi et al., 2015). 
4.5.1.1 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
without CBD Treatment in CaCo-2 CRC Cells 
With reference to Table 18, it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of CRC cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on CRC cells (Table 18).  
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight in significant morphological 
changes of rounding up in comparison to the cells only control, however still 
appeared attached to the cell culture dishes with distinctive viability (Table 18). 
These findings suggest that the ZnPcS4 PS alone, in conjugation with AuNPs or 
when finally bound to the active nanoconjugate exhibited no dark cytotoxicity and 
remained inactive without PDT activation. 
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted significant morphological changes of 
rounding up, nuclear destruction and detachment from cell culture plates in 











Table 18 CaCo-2 CRC Cells morphological comparison of various control and 
experimental groups of final actively targeted PS Nanoconjugate PDT 
response assays with and without CBD treatment. 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays without and without CBD Treatment in CaCo-2 
CRC Cells 
General Control Groups 
Cells only 
 
Cells + Irradiation (10 J/cm2) 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays without CBD Treatment in CaCo-2 CRC Cells 
Control Groups 
 
Cells plus 0.125 µM ZnPcS4 
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC Ab 
PDT Treated Experimental Groups 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + Irradiation  
Final Actively Targeted PS Nanoconjugate PDT Response Assays with CBD Treatment in CaCo-2 CRC Cells 
Control Groups 
 
Cells + 1uM CBD  
 
Cells + 1uM CBD + Irradiation   Cells + Ethanol 
 
Cells plus 0.125 µM ZnPcS4 + 
1uM CBD 
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + 1uM CBD 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + 1uM CBD 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
1uM CBD + Irradiation 
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + 1uM CBD + 
Irradiation 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + 1uM CBD + Irradiation 
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However, PDT irradiated experimental groups of CRC cells, which received 0.125 
µM ZnPcS4, did not exhibit as much significant morphological damage, when 
compared to the same groups which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, and furthermore when comparing these two groups to the 
experimental group which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, and irradiation, which showed the most significant morphological 
damage (Table 18). These outcomes can be attributed to the following; second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, drastically hindering their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018). However, when PSs are combined with AuNPs, their passive 
uptake in tumour cells is improved via the EPR effect and so when activated with 
laser irradiation PDT outcomes are improved (Hong et al., 2016). Additionally, 
AuNPs enhance the overall PDT cytotoxic cellular destruction by contributing 
photothermal destruction (Kruger and Abrahamse, 2018). Nevertheless, the most 
cytotoxic form of PDT tumour cell destruction can be found when bound AuNP-
PSs are conjugated to targeting ligands such as mAbs, since their specific and 
active uptake is localized, with additional photothermal contributions and so this 
form of targeted PDT is often the most effective (Kruger and Abrahamse, 2019). 
Overall, these findings suggest that the final actively targeted PS nanoconjugate 
was the most effective PDT treatment for CRC morphological destruction, due to 
its enhanced passive, as well as actively specific targeted AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab bound constituents for improved ZnPcS4 PS subcellular 
localization.  
4.5.1.2 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with CBD Treatment in CaCo-2 CRC Cells 
With reference to Table 18, it can be observed that the control group of CRC cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of CRC cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on CRC cells (Table 18). Additionally, the control group of CRC 
cells treated with ethanol only, noted no visible changes in morphology, suggesting 
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that the ethanol concentration, in which the CBD was solubilized had no significant 
cytotoxic effects on CRC cells (Table 18). 
Control groups of CRC cells treated with 1 µM CBD with and without laser 
irradiation noted significant similar morphological changes in relation to rounding 
up and slightly appearing detached from cell culture plates (Table 18). Studies 
performed by Aviello et al. (2012) noted similar findings within CRC in vitro treated 
cells treated with similar concentrations of CBD alone and stated that CBD reduced 
cell proliferation, though apoptotic cell death mechanisms, while generating anti-
tumour immune responses after treatment. Furthermore, these findings suggest 
that CBD when administered alone at 1 µM, with or without laser irradiation can 
morphologically affect CRC cells in a similar manner and so it can be stated that 
laser irradiation has a negligible effect on 1 µM CBD cellular cytotoxicity result 
outcomes in relation to CRC treatment applications. 
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, did note slightly more 
significant morphological changes of rounding up, in comparison to the same 
control groups without CBD treatment, however still appeared attached to the cell 
culture dishes with distinctive viability (Table 18). These findings suggest that the 
ZnPcS4 PS alone, in conjugation with AuNPs or when finally bound to the active 
nanoconjugate exhibited no dark cytotoxicity and remained inactive without PDT 
activation and that these slight morphological effects were probably attributed to 
the 1 µM CBD administration.  
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD noted severely significant 
morphological changes of rounding up, nuclear destruction and detachment from 
cell culture plates, in comparison to the same control groups without CBD 
treatment (Table 18). These findings suggest that CBD most definitely promoted 
cellular morphological destruction within PDT irradiated experimental groups of 
CRC cells, which received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, suggesting 
that CBD when utilized in combination with PDT can promote its treatment 
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outcomes. However, considering that the experimental group which received 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, plus 1 µM CBD and 
irradiation, showed the most significant morphological damage, these findings 
suggest that the final actively targeted PS nanoconjugate was the most effective 
PDT treatment for CRC morphological destruction, due to its enhanced passive, 
as well as actively specific targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab 
bound constituents for improved ZnPcS4 PS subcellular localization and that this 
actively targeted treatments outcomes can be improved upon, when utilized in 
combination with CBD.   
 
4.5.2 Flow Cytometry Annexin V-FITC/PI Cell Death Pathway Detection 
Analysis in CRC Cells 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
from necrosis cells, or cells remaining viable within experimental samples 24 hours 
post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate plus cannabidiol (ZnPcS4 
– AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab + CBD), was able to enhance PDT 
treatment, as well as limit secondary CRC more than ZnPcS4 PS drug 
administration alone, CBD treatment alone, or final actively targeted PS 
nanoconjugate treatment alone. The CRC cells only control was used to gate and 
statistically compare results of viable cells, whereas the necrosis and apoptosis 
(early and late) controls were used to gate and statistically compare cells 
undergoing these particular modes of cell death (P˂0.05*) (P˂0.01**) (P˂0.001***). 
4.5.2.1 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
without CBD Treatment in CaCo-2 CRC Cells 
With reference to Figure 35, it can be observed that the control group of CRC cells 
only, were found to be 98% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
90% necrosis and the apoptosis positive control group noted 43% early apoptosis 




Figure 35 Percentage of different stages of cell death after flow cytometry analysis 
using Annexin V-FITC/PI staining method on various control and 
experimental groups of CRC cells, within final actively targeted PS 
nanoconjugate PDT response assays (without CBD). 
Control group of CRC cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
irradiation alone had no effect on CRC cells (Figure 35). 
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight increases in apoptotic forms of cell 
death, with decreases in cellular viability, however these changes were 
insignificant (Figure 35). These findings suggest that the 0.125 µM ZnPcS4 PS 
alone, in conjugation with AuNPs or when finally bound to the active 
nanoconjugate, exhibited no dark cytotoxicity and remained in active without PDT 
irradiation. 
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted significant forms of apoptotic cell death, 
with decreases in cellular viability (Figure 35).  However, PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4, did not exhibit 
as much significant late apoptotic cell death (15%*), as when compared to the 
same groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
(21%**). Furthermore, when comparing these two groups to the experimental 
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group, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC 
Ab, and irradiation, the most significant late apoptotic cell death of 34%*** was 
noted, with a significant increase of 16%* of necrotic cell death.  
Accruing evidence has shown that cells undergoing early apoptosis are often 
autophagic and so have the potential to rejuvenate, thus early phases of apoptotic 
cell death is not ideal in PDT cancer treatments, as cells can recover leading to 
tumour re-occurrence. (Noguchi et al., 2015). Thus, the most favourable forms of 
cell death in relation to successful PDT treatment outcomes, is either late apoptotic 
or necrotic cell death modes, whereby cancer cells are destroyed beyond recovery 
(Van Straten et al., 2017; Chilakamarthi and Giribabu, 2017). Since second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, this drastically hinders their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018), affecting their overall treatment outcomes and so this could 
explain why the 0.125 µM ZnPcS4 PDT treatment did not exhibit as much 
significant late apoptotic cell death (15%*), as when compared to the same groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (21%**) (Figure 35). 
Furthermore, since studies by Hong et al., (2016) have also stated that when PSs 
are combined with AuNPs, their passive uptake and solubility in tumour cells is 
improved via the EPR effect and so when activated with laser irradiation, PDT 
outcomes generally produce more favourable late apoptotic forms of cell death. 
Additionally, AuNPs tend to enhance overall PDT cellular destruction outcomes by 
contributing photothermal destruction (Kruger and Abrahamse, 2018) and so all of 
this could have also attributed to the higher late apoptotic cell death of 21%** being 
noted in the PDT irradiated experimental groups of CRC cells, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (Figure 35). 
Nevertheless, the most favorable and cytotoxic form of PDT tumour cell death was 
found within the PDT experimental groups, which received 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and irradiation, whereby the most 
significant decrease in cellular viability was found, with the most favorable 
significantly late apoptotic cell death of 34%*** and an increase of 16%* of necrosis 
(Figure 35). These favorably enhanced forms of induced PDT cell death was 
probably due to the fact that the PS nanoconjugate had an actively selective 
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targeting mAb attached to it, which promoted PS localization in CRC cells and so 
improved overall treatment outcomes, with significant cell death induction. This 
statement can be supported by studies conducted by Kruger and Abrahamse, 
(2019), whereby the most significant PDT apoptotic and necrotic cellular 
destruction can be found when bound AuNP-PSs are conjugated to targeting 
ligands such as mAbs, since their specific and active uptake is localized, with 
additional photothermal contributions and so this form of targeted PDT is often the 
most effective in cancer cell obliteration.  
4.5.2.2 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with CBD Treatment in CaCo-2 CRC Cells 
With reference to Figure 36, it can be observed that the control group of CRC cells 
only, were found to be 98% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
90% necrosis and the apoptosis positive control group noted 43% early apoptosis 
and 39% late apoptosis and so was utilized for control and experimental groups 
result comparability. 
 
Figure 36 Percentage of different stages of cell death after flow cytometry analysis 
using Annexin V-FITC/PI staining method on various control and 
experimental groups of CRC cells, within final actively targeted PS 
nanoconjugate PDT response assays with CBD. 
Control group of CRC cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
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irradiation alone had no effect on CRC cells (Figure 36). Additionally, the control 
group of CRC cells treated with ethanol only, noted no visible changes in 
morphology, suggesting that the ethanol concentration, in which the CBD was 
solubilized had no significant cytotoxic effects on CRC cells (Figure 36). 
Control groups of CRC cells treated with 1 µM CBD with and without laser 
irradiation noted significant decreases in cellular viability, with increases in early (± 
28%**), as well as late forms of apoptosis (± 21%**) (Figure 36). Studies performed 
by Aviello et al. (2012) noted similar findings within CRC in vitro treated cells 
treated with similar concentrations of CBD alone and stated that CBD reduced cell 
proliferation, though apoptotic cell death mechanisms, while generating anti-
tumour immune responses after treatment. These findings suggest that CBD when 
administered alone at 1 µM, with or without laser irradiation can affect CRC cells 
in a similar manner and so it can be stated that laser irradiation has a negligible 
effect on 1 µM CBD cellular cytotoxicity result outcomes, in relation to CRC 
treatment applications. Furthermore, it can be stated that 1 µM of CBD can most 
definitely be utilized as a singular treatment to induce favorable cytotoxic apoptotic 
forms of cell death in CRC cells. 
Non-irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, plus with 1 µM CBD, did note significant 
decreases in cellular viability, with increases in early (± 12%*), as well as late forms 
of apoptosis (± 9%*) (Figure 36). These findings suggest that the ZnPcS4 PS alone, 
in conjugation with AuNPs or when finally bound to the active nanoconjugate 
exhibited no dark cytotoxicity and remained in active, without PDT activation and 
that the significant apoptotic cell death effects were probably attributed to the 1 µM 
CBD administration. This conclusion was drawn especially when assessing these 
same controls in Figure 35 without CBD treatment and Figure 36 which noted 
highly significant 1 µM CBD cell death in the cells only control. The reasoning for 
perhaps less apoptotic forms of cell death in the non-irradiated control groups of 
CRC cells, which received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, plus with 1 
µM CBD, in comparison to control groups of CRC cells treated with 1 µM CBD with 
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and without laser irradiation, is probably attributed to the fact that the additional PS 
and conjugate dosing could have diluted the CBD potency.  
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, noted severely significant 
appreciable forms of cell death (Figure 36),  in comparison to the same control 
groups without CBD treatment (Figure 35). PDT irradiated experimental groups of 
CRC cells, which received 0.125 µM ZnPcS4, plus 1 µM CBD reported a significant 
39%*** early apoptosis and 21%** late apoptosis, whereas, PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, plus 1 µM CBD reported a significant 19%* early apoptosis, 
48%*** late apoptosis and 11%* necrosis (Figure 36). This significantly improved 
late apoptotic and necrotic cellular destruction in PDT irradiated experimental 
groups of CRC cells, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 
plus CBD could be attributed to the improved passive uptake and solubilization of 
the PS, due to the AuNP conjugated carrier, as well as the photothermal 
contributions it made to the overall treatment (Hong et al., 2016). Additionally, the 
CBD itself most definitely improved upon the PDT induced cellular death 
mechanisms, especially when the above results from Figure 36, were compared to 
the same PDT irradiated experimental groups of CRC cells, which did not receive 
CBD (Figure 35).  
However, the most favourably significant results were the PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, plus 1 µM CBD, whereby 16%* early apoptosis, 
52%*** late apoptosis and 26%** necrosis was found (Figure 36). Considering that 
the PDT experimental group which received 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC Ab, plus 1 µM CBD and irradiation, showed more significant 
and favourable forms of heightened favourable cell death (52%*** late apoptosis 
and 26%** necrosis – Figure 36) in comparison to the PDT experimental groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab and 
no CBD (34%** late apoptosis and 16%* of necrosis – Figure 35), these findings 
indicate that PDT treatment with the final actively targeted PS nanoconjugate  
combined with CBD can successfully kill off CRC cells. These favourably 
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significant enhanced forms of induced PDT cell death (i.e. late apoptosis and 
necrosis), was probably due to the fact that the PS nanoconjugate had an actively 
selective targeting mAb attached to it, which promoted PS localization in CRC cells 
and so improved overall treatment outcomes, with significant cell death induction. 
This statement can be supported by studies conducted by Kruger and Abrahamse, 
(2019), whereby the most significant PDT apoptotic and necrotic cellular 
destruction can be found when bound AuNP-PSs are conjugated to targeting 
ligands such as mAbs, since their specific and active uptake is localized, with 
additional photothermal contributions and so this form of targeted PDT is often the 
most effective in cancer cell obliteration. Furthermore, the combination of CBD 
enhanced this nano conjugate targeted form of CRC PDT treatment and this 
statement can be supported by Kenyon et al. (2018) whereby it was noted that 
when CBD is administered in combination with other cancer treatment therapies, it 
promotes disruption intracellular signaling pathways, such as P13K/AKT/mTOR 
and ERK, and so enhances combinative treatment cell death outcomes. 
4.6 Final Actively Targeted PS Nanoconjugate PDT Response Assays with 
and without CBD Treatment in WS1 Normal Human Fibroblast Cells 
The comparisons of the final actively targeted PS Nanoconjugate PDT response 
assays with and without CBD treatment was evaluated within in vitro cultured 
normal human WS1 fibroblast cells, since it was desirable to evaluate the safety, 
tolerability and effective targeting abilities profiles of these combinative treatments, 
as to ensure they had negligible effects on surrounding healthy tissues. 
4.6.1 Cellular Morphology by Light Microscopy Assessment in WS1 Cells 
The effect of the final actively targeted PS nanoconjugate PDT response assays 
with and without CBD treatment within the various WS1 control and experimental 
groups were analysed by viewing the captured inverted microscope digital images 
and comparing them. All images were captured at a 40x magnification. The cellular 
structures of the WS1 cells were evaluated based on changes in cell shape, size 
and non-viable cells (Noguchi et al., 2015). Change in the microscopic structure of 
cells and their cellular components is an indication of cell damage occurring or 




4.6.1.1 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
without CBD Treatment in WS1 Normal Human Fibroblast Cells 
With reference to Table 19, it can be observed that the control group of WS1 cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of WS1 cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on WS1 cells (Table 19).  
Non-irradiated control groups of WS1 cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, no significant morphological changes were 
observed (Table 19). These findings showed that the ZnPcS4 PS alone, in 
conjugation with AuNPs or when finally bound to the active nanoconjugate 
exhibited no dark cytotoxicity and remained in active without PDT activation. 
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 alone, did note significant morphological changes of rounding up, nuclear 
destruction and detachment from cell culture plates in comparison to the cells only 
control (Table 19). Whereas, PDT irradiated experimental groups of WS1 cells 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
reported no significant morphological changes (Table 19).  
These findings suggest that the administration of 0.125 µM ZnPcS4 alone with laser 
irradiation does cytotoxically affect normal human cells, whereas when 
administered with either a AuNP carrier and / or active targeting mAb, it does not. 
These results are probably attributed to the fact that conventional administrations 
of PS alone, without any further functionalization for enhanced passive or active 
targeting, are generally inadequately absorbed by tumour cells and so the PS can 
accumulate within these surrounding healthy tissues, inducing unwanted effects 
within them when laser irradiation is applied (Hong et al., 2016). Furthermore, 
these results coincided with studies conducted by Nombona et al., (2012) which 
reported that ZnPcS linked to AuNPs or bound to liposomes, exerted a significant 
PDT phototoxic effect on cancer cells, due to improved PS passive absorption and 
so negligible phototoxicity on normal human fibroblast cells was found.  
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Table 19 WS1 normal human cells morphological comparison of various control and 
experimental groups of final actively targeted PS Nanoconjugate PDT 
response assays with and without CBD treatment. 
Final Actively Targeted PS Nanoconjugate PDT Response Assays without and without CBD Treatment in WS1 
Human Fibroblast Cells 




Cells + Irradiation (10 J/cm2) 
 




Cells plus 0.125 µM ZnPcS4 
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2 – Anti-GCC Ab 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + Irradiation  




Cells + 1uM CBD  
 
Cells + 1uM CBD + Irradiation  
 
Cells + Ethanol 
 
Cells plus 0.125 µM ZnPcS4 + 
1uM CBD 
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + 1uM CBD 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + 1uM CBD 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
1uM CBD + Irradiation 
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + 1uM CBD + 
Irradiation 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH- NH2 – Anti-GCC Ab + 1uM CBD + Irradiation 
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Additionally, studies by Kruger and Abrahamse (2019), reported that non-targeted 
standard PS delivery systems yield relatively poor PDT clinical outcomes, since 
only negligible amounts of the PS are taken up by cancer cells and the remainder 
of the PS induces unwanted PDT phototoxic damage in normal cells. This study 
went on further to state that the only way to overcome PS dispersion in normal 
cells, was to enhance their concentrated and localized uptake in tumour cells only, 
through further functionalizion delivery mechanisms, such as nanoconjugate 
platforms or active targeting with biomarkers.  
Overall, these findings suggest that the final actively targeted PS nanoconjugate 
was probably the most effective PDT treatment for CRC, as it indicated no photo 
toxic side effects on normal human cells, due to its enhanced passive, as well as 
actively specific targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab bound 
constituents for improved ZnPcS4 PS subcellular localization in tumor tissues only.   
 
4.6.1.2 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with CBD Treatment in WS1 Normal Human Fibroblast Cells 
With reference to Table 19, it can be observed that the control group of WS1 cells 
only, demonstrated no changes in morphology and retained their distinctive 
appearance and so this was utilized as a comparative reference of being “normal”, 
when assessing the other various control and experimental groups. Control group 
of WS1 cells treated with 673nm laser irradiation at a fluency of 10 J/cm2 alone, 
presented no detectable morphological changes, suggesting that laser irradiation 
alone has no effect on WS1 cells (Table 19). Additionally, the control group of WS1 
cells treated with ethanol only, noted no visible changes in morphology, suggesting 
that the ethanol concentration, in which the CBD was solubilized had no significant 
cytotoxic effects on WS1 cells (Table 19). 
Control groups of WS1 cells treated with 1 µM CBD with and without laser 
irradiation noted no significant morphological changes in comparison to control 
cells only (Table 19). Furthermore, non-irradiated control groups of WS1 cells, 
which received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, 
also did not note any significant morphological changes (Table 19). These findings 
suggest that CBD when administered alone or in combination with the final actively 
targeted PS nanoconjugate (or individual constituents), without laser irradiation, 
144 
 
has no significant morphological effect on normal cells.  These outcomes propose 
that the ZnPcS4 PS alone, in conjugation with AuNPs or when finally bound to the 
active nanoconjugate exhibited no dark cytotoxicity and remained in active without 
PDT activation. Furthermore, it can be stated that CBD does not have a destructive 
affinity for normal human cells, only cancer cells, this is due to the fact that it only 
simulates anti-tumour immune system response capable of controlling metastatic 
tumour growth and so normal tissues remain unharmed (Shams et al., 2015) 
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab, both with 1 µM CBD noted no significant morphological 
changes in comparison to the cells only control group (Table 19). However, PDT 
irradiated experimental groups of WS1 cells, which received 0.125 µM ZnPcS4, 
plus 1 µM CBD, noted severely significant morphological changes of rounding up, 
nuclear destruction and detachment from cell culture plates (Table 19). When 
comparing this group to the same PDT irradiated experimental groups of WS1 
cells, which received 0.125 µM ZnPcS4, without 1 µM CBD, similar morphological 
damages were found. Furthermore, since control groups of WS1 cells treated with 
1 µM CBD with and without laser irradiation, noted no significant morphological 
changes in comparison to control cells only, these findings suggest that the only 
destructive component within this treatment was the 0.125 µM ZnPcS4 PDT. As 
discussed previously the reasoning for the 0.125 µM ZnPcS4 PDT morphological 
destruction within WS1 cells, was probably due to its lack of enhanced passive or 
actively concentrated uptake in targeted cancer cells.  
Overall, these findings suggest that 1 µM CBD is non-toxic to normal human cells 
and that when administered in combination with the final actively targeted PS 
nanoconjugate, it is the most effective PDT treatment for CRC, as this form of 
treatment has no targeting affinity for normal cells and so localized treatment with 
unwanted side effects.  
4.6.2 Flow Cytometry Annexin V-FITC/PI Cell Death Pathway Detection 
Analysis in WS1 Cells 
Annexin V-FITC/PI cell death detection kit (BD Scientific: BD/556570), was used 
for detection and quantitation of cells undergoing early or late apoptosis, cells dying 
from necrosis cells, or cells remaining viable within experimental samples 24 hours 
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post laser irradiation, using flow cytometry. This assay was performed in order to 
determine if the final actively targeted PS nanoconjugate plus cannabidiol (ZnPcS4 
– AuNP-PEG5000-SH-NH2 – Anti-GCC Ab + CBD), induced any unwanted side- 
effects on normal human WS1 cells. The WS1 cells only control was used to gate 
and statistically compare results of viable cells, whereas the necrosis and 
apoptosis (early and late) controls were used to gate and statistically compare cells 
undergoing these particular modes of cell death (P˂0.05*) (P˂0.01**) (P˂0.001***). 
4.6.2.1 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
without CBD Treatment in WS1 Normal Human Fibroblast Cells 
With reference to Figure 37, it can be observed that the control group of WS1 cells 
only, were found to be 93% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
89% necrosis and the apoptosis positive control group noted 49% early apoptosis 
and 37% late apoptosis and so was utilized for control and experimental groups 
result comparability. 
 
Figure 37 Percentage of different stages of cell death after flow cytometry analysis 
using Annexin V-FITC/PI staining method on various control and 
experimental groups of WS1 cells, within final actively targeted PS 
nanoconjugate PDT response assays (without CBD). 
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Control group of WS1 cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
irradiation alone had no effect on WS1 cells (Figure 37). 
Non-irradiated control groups of WS1 cells, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, noted slight increases in early apoptotic forms 
of cell death, however these changes were insignificant (Figure 37). These findings 
suggest that the 0.125 µM ZnPcS4 PS alone, in conjugation with AuNPs or when 
finally bound to the active nanoconjugate, exhibited no dark cytotoxicity and 
remained in active without PDT irradiation within normal cells.  
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab, also only noted slight increases in early apoptotic forms of cell 
death, however these changes were insignificant (Figure 37). However, PDT 
irradiated experimental groups of WS1 cells, which received 0.125 µM ZnPcS4, 
noted a significant decrease in cellular viability (73%**) and significant increases 
in early apoptosis (12%*) and late apoptosis (10%*).  
These findings suggest that the administration of 0.125 µM ZnPcS4 with laser 
irradiation, does cytotoxically affect normal human cells, whereas when 
administered with either a AuNP carrier and / or active targeting mAb, it does not. 
Since studies by Nombona et al. (2012) have reported that ZnPcS when 
administered alone, does exert PDT cytotoxic effect on normal fibroblast cells, due 
to its lack of functionalization for enhanced passive or active targeting, these 
results were probable. Thus, it can be stated that the administration of 0.125 µM 
ZnPcS4 alone within PDT studies for CRC cancer, unwanted normal healthy cell 
damage would be observed.  
Therefore, these findings suggest that the final actively targeted PS nanoconjugate 
was probably the most effective PDT treatment for CRC, as it indicated no photo 
toxic side effects on normal human cells, due to its enhanced passive, as well as 
actively specific targeted AuNP-PEG5000-SH-NH2 – Anti-GCC Ab bound 




4.6.2.2 Final Actively Targeted PS Nanoconjugate PDT Response Assays 
with CBD Treatment in WS1 Normal Human Fibroblast Cells 
With reference to Figure 38, it can be observed that the control group of WS1 cells 
only, were found to be 93% viable and so this was utilized as a comparative 
reference of being “normal”, when assessing the other various control and 
experimental groups. Furthermore, the positive control group for necrosis noted 
89% necrosis and the apoptosis positive control group noted 49% early apoptosis 
and 37% late apoptosis and so was utilized for control and experimental groups 
result comparability. 
 
Figure 38 Percentage of different stages of cell death after flow cytometry analysis 
using Annexin V-FITC/PI staining method on various control and 
experimental groups of WS1 cells, within final actively targeted PS 
nanoconjugate PDT response assays with CBD. 
Control group of WS1 cells treated with 673nm laser irradiation at a fluency of 10 
J/cm2 alone, presented no significant cell death changes, suggesting that laser 
irradiation alone had no effect on WS1 cells (Figure 38). Additionally, the control 
group of WS1 cells treated with ethanol only, noted no visible changes in 
morphology, suggesting that the ethanol concentration, in which the CBD was 
solubilized had no significant cytotoxic effects on WS1 cells (Figure 38). 
Control groups of WS1 cells treated with 1 µM CBD with and without laser 
irradiation noted no significant cell death changes in comparison to control cells 
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only (Figure 38). Furthermore, non-irradiated control groups of WS1 cells, which 
received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, also 
did not note any significant cell death changes (Figure 38). These findings suggest 
that CBD when administered alone or in combination with the final actively targeted 
PS nanoconjugate (or individual constituents), without laser irradiation, has no 
significant cellular damaging effects on normal cells. These outcomes propose that 
the ZnPcS4 PS alone, in conjugation with AuNPs or when finally bound to the active 
nanoconjugate exhibited no dark cytotoxicity and remained inactive without PDT 
activation. Furthermore, it can be stated that CBD does not have a destructive 
affinity for normal human cells, only cancer cells, this is due to the fact that it only 
simulates anti-tumour immune system response capable of controlling metastatic 
tumour growth and so normal tissues remain unharmed (Shams et al., 2015). 
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-
NH2 – Anti-GCC Ab, both with 1 µM CBD, noted a slight increase in early apoptosis, 
however it was insignificant. However, PDT irradiated experimental groups of WS1 
cells, which received 0.125 µM ZnPcS4, plus 1 µM CBD, noted significant 
decreases in cellular viability (71%**), with increases in early (16%**), as well as 
late forms of apoptosis (11%*) (Figure 38). When comparing this group to the same 
PDT irradiated experimental groups of WS1 cells, which received 0.125 µM 
ZnPcS4, without 1 µM CBD, similar cellular death patterns were found - a significant 
decrease in cellular viability (73%**) and significant increases in early apoptosis 
(12%*) and late apoptosis (10%*) (Figure 37). Furthermore, since control groups 
of WS1 cells treated with 1 µM CBD with and without laser irradiation, noted no 
significant morphological changes in comparison to control cells only, these 
findings suggest that the only destructive component within this treatment was the 
0.125 µM ZnPcS4 PDT. As discussed previously the reasoning for the 0.125 µM 
ZnPcS4 PDT cellular destruction within WS1 cells, was probably due to its lack of 
enhanced passive or actively concentrated uptake in targeted cancer cells.  
Overall, these findings suggest that 1 µM CBD is non-toxic to normal human cells 
and that when administered in combination with the final actively targeted PS 
nanoconjugate, it is probably the most effective PDT treatment for CRC, as this 
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form of treatment has no targeting affinity for normal cells and so localized 
treatment with unwanted side effects is possible.  
4.7 Nuclear DNA Damage Examination by Hoechst 33258 Analysis in Final 
Actively Targeted PS Nanoconjugate PDT Response Assays with and 
without CBD Treatment in CRC Cells 
Hoechst 33258 bisbenzimide derivate fluorescent stain is a nuclear DNA staining 
method which is used for the detection and assessment of cellular nuclear DNA 
damage. It can seek out and place itself within the minor grooves of the double-
stranded DNA with binding affinity within the A-T rich regions of the DNA, allowing 
for the detection of nuclei cell damage (Chen et al., 2016). Hoechst 33258 is a blue 
fluorescent dye that is excited by ultraviolet light at a wavelength of 352 nm and 
has maximum fluorescence at 461 nm in the violet-blue region. Hoechst 33258 is 
a cell permeable nucleic acid stain and according to Chen et al. (2016) it can 
differentiate between live, necrotic and apoptotic cell stages, due to the degree of 
nuclear damage that is caused by DNA conformation and chromatin state of the 
cell and the stains sensitivity.  
Thus, in order to confirm if the final actively targeted PS nanoconjugate 
combinative treatment with CBD was able to induce more notable PDT induced 
cellular DNA nuclear damage in CRC CaCo-2 cells, than when compared to the 
administration of CBD alone, ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-
NH2 alone or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab alone, Hoechst 
33258 bisbenzimide derivate fluorescent stain was performed and images were 
captured at 400x magnification.  
With reference to Table 20, the Hoechst blue stained nuclei noted no cellular 
damage in control groups of CRC cells only or those that just received laser 
irradiation at 673 nm with a fluence of 10 J/cm2. The cellular nuclei appeared 
prominent and round in shape and so these images were used as reference 
comparisons against the PDT experimental groups. 
Within experimental PDT groups, which received 0.125 µM ZnPcS4 alone and 
irradiation, most of the cellular nuclei appeared prominent and round in shape, with 
very slight fragmentation in comparison to the CRC group of cells only (Table 20). 
These findings suggested that 0.125 µM ZnPcS4 PDT treatment alone, does not 
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induce significant DNA damage, as most of the cellular nuclei remained intact and 
appeared viable. These outcomes, can be attributed to the following; second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, drastically hindering their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells and so 
minimal cellular destruction is often observed (Kruger and Abrahamse, 2018). 
Within experimental PDT groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, and laser irradiation, it can be observed that the CRC nuclei 
began changing shape, as some were irregularly swollen and fragmented in shape 
(Table 20). Studies by Manoto et al. (2012) linked morphological shrinkage and 
swelling of the Hoechst stained nuclei in CRC cells treated with 10 µM PDT 
photoactivated ZnPcSmix to signify apoptotic cell death. The DNA damage findings 
within this experimental group can also be linked to apoptotic cell death, since the 
flow cytometry cell death results for this same experimental group noted a 
significant 21%** of late apoptotic cell death (Figure 35). This improved DNA 
damage in comparison to 0.125 µM ZnPcS4 PDT treatment alone, can be attributed 
to the fact that in this experimental group the PS was combined with an AuNP, 
which promoted its solubilization and passive uptake in CRC cells and so the PDT 
cytotoxic cellular destruction was improved upon (Kruger and Abrahamse, 2018). 
Additionally, AuNPs enhance the overall PDT cytotoxic cellular destruction by 
contributing photothermal destruction (Kruger and Abrahamse, 2018). 
In comparison to the above two discussed groups, the experimental PDT groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, and 
irradiation, the nuclei displayed prominent shrinkage and fragmentation. Studies 
by Balusamy et al. (2018) have reported that when Hoechst stained nuclei present 
shrinkage with fragmentation the DNA chromatin state of the cell is becoming 
disrupted and it is usually indicative of late apoptotic forms of cell death, whereby 
cells are unable to recover. The DNA damage findings within this experimental 
group can also be linked to late forms of apoptotic cell death, since the flow 
cytometry cell death results for this same experimental group noted a significant 
34%** of late apoptotic cell death, with a significant increase of 16%* of necrotic 
cell death (Figure 35). This improved DNA damage in comparison to 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2 PDT treatment alone, can be attributed to the 
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fact that in this experimental group the PS was bound to AuNP which was 
conjugated to targeting mAb biomarker and so its cellular uptake was far more 
concentrated and actively localized in CRC, with additional photothermal 
contributions and so this form of targeted PDT is often more lethal (Kruger and 
Abrahamse, 2018). Overall, these results suggested that the final actively targeted 
PS nanoconjugate had indeed enhanced the primary PDT treatment of CRC cells 
in vitro, by selectively and actively targeting tumour cells in comparison to ZnPcS4 
PDT treatment alone. 
Table 20 Hoechst 33258 CRC cells nuclear DNA damage examination in final 
actively targeted PS nanoconjugate PDT response assays with and without CBD treatment. 
Final Actively Targeted PS Nanoconjugate PDT Response Assays with and without CBD Treatment in CaCo-2 CRC 
Cells 




Cells + Irradiation (10 J/cm2) 
 
 
Final Actively Targeted PS Nanoconjugate PDT Response Assays without CBD Treatment in CaCo-2 CRC Cells 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 
Irradiation  
 
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + Irradiation  
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 – Anti-GCC Ab + Irradiation  
Final Actively Targeted PS Nanoconjugate PDT Response Assays with CBD Treatment in CaCo-2 CRC Cells 
Control Groups 
 
Cells + 1uM CBD + Irradiation  
 
Cells + Ethanol 
 
 
PDT Treated Experimental Groups 
 
Cells plus 0.125 µM ZnPcS4 + 1uM 
CBD + Irradiation 
   
Cells plus 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH- NH2 + 1uM CBD + 
Irradiation 
  
Cells plus 0.125 µM ZnPcS4 – AuNP-




The control group of CRC cells treated with ethanol only, noted no visible changes 
in morphology, suggesting that the ethanol concentration, in which the CBD was 
solubilized had no significant cytotoxic effects on CRC cells (Table 20). 
The control group of CRC cells treated with 1 µM CBD with laser irradiation it can 
be observed that the CRC nuclei began changing shape, as some were irregularly 
condensed and fragmented in shape (Table 20). Studies by Balusamy et al. (2018) 
have reported that when Hoechst stained nuclei present morphological 
condensation and fragmentation the DNA chromatin state of the cell is usually 
becoming disrupted and it is usually indicative of some form of apoptotic cell death. 
If these findings are linked to the flow cytometry cell death results for the same 
control group it was noted that significant decreases in cellular viability, with 
increases in early (28%**), as well as late forms of apoptosis (21%**) was observed 
(Figure 36). Studies by Aviello et al. (2012) support these findings as they noted 
within in vitro CRC cells treated with similar concentrations of CBD, reduced 
cellular proliferation, though apoptotic forms of cell death mechanisms, while 
generating anti-tumour immune responses after treatment. These findings suggest 
that 1 µM of CBD can most definitely be utilized as a singular treatment to induce 
favourable cytotoxic apoptotic forms of cell death in CRC cells. 
PDT irradiated experimental groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, noted severely significant 
appreciable forms of cellular DNA damage, in comparison to the same control 
groups without CBD treatment (Table 20). Their nuclei displayed complete 
shrinkage with loss of cohesion between the cells with very prominent 
fragmentation (Table 20). Studies by Balusamy et al., (2018) have reported that 
when Hoechst stained nuclei present complete shrinkage with fragmentation, the 
DNA conformation and chromatin state of the cell has become completely 
disrupted, it is usually indicative of late apoptotic or necrotic forms of cell death, 
whereby cells are unable to recover and so are considered completely destroyed. 
If these findings are linked to the flow cytometry results of PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4, plus 1 µM 
CBD they reported a significant 39%*** early apoptosis and 21%** late apoptosis, 
whereas, PDT irradiated experimental groups of CRC cells, which received 0.125 
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µM ZnPcS4 – AuNP-PEG5000-SH-NH2, plus 1 µM CBD reported a significant 19%* 
early apoptosis, 48%*** late apoptosis and 11%* necrosis (Figure 36). This 
significantly improved late apoptotic and necrotic cellular destruction in PDT 
irradiated experimental groups of CRC cells, which received 0.125 µM ZnPcS4 – 
AuNP-PEG5000-SH-NH2, plus CBD could be attributed to the improved passive 
uptake and solubilization of the PS, due to the AuNP conjugated carrier, as well as 
the photothermal contributions it made to the overall treatment (Hong et al., 2016). 
Additionally, the CBD itself most definitely improved upon the PDT induced cellular 
death mechanisms, especially when the above results Table 20, were compared 
to the same PDT irradiated experimental groups of CRC cells, which did not 
receive CBD.  
However, the most favourable results of complete nuclei and DNA destruction were 
observed in the PDT irradiated experimental groups of CRC cells, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, plus 1 µM CBD. If 
these findings are linked to the same experimental groups flow cytometry results, 
whereby the most significant forms of cell death (52%*** late apoptosis and 26%** 
necrosis – Figure 36) were noted throughout all the experimental groups, it can be 
safely stated that this combinative form of CRC treatment was the most effective. 
Especially, when comparing these results to the PDT experimental groups, which 
received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab and no CBD 
(34%** late apoptosis and 16%* of necrosis – Figure 35 and Table 20), which noted 
less cellular death and DNA damage when targeted PDT was applied in its form 
singular form without CBD. These favourably significant enhanced forms of 
induced PDT cell death (i.e. late apoptosis and necrosis), was probably due to the 
fact that the PS nanoconjugate had an actively selective targeting mAb attached 
to it, which promoted PS localization in CRC cells and so improved overall 
treatment outcomes, with significant cell death induction. Furthermore, the 
combination of CBD enhanced this nano conjugate targeted form of CRC PDT 
treatment and this statement can be supported by Kenyon et al. (2018) whereby it 
was noted that when CBD is administered in combination with other cancer 
treatment therapies, it promotes disruption intracellular signaling pathways, such 




In conclusion, these results are suggestive that irradiated experimental groups, 
which received the combined PDT therapy of final actively targeted PS 
nanoconjugate (0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab) and 
CBD were unlikely to recover post-PDT, due to their severe nuclear damage and 
so this implies that this active PS drug targeting form of PDT combined with CBD 
was the most efficient treatment option for concurrent primary and secondary 
treatment of in vitro cultured CRC cells. Lastly, these results indicated that the final 
actively targeted PS nanoconjugate significantly enhanced the primary PDT 
treatment of CRC cells in vitro by specifically and actively targeting cancer cells, 
and its combinative treatment with CBD eradicated PDT-resistant cells, thus 























CONCLUSION AND FUTURE DIRECTIVES 
5.1 Conclusion 
Effective CRC treatment remains an arduous task in human healthcare, due to its 
rampant tumour resistance and metastasis (Nkune et al., 2020). Currently, 
conventional treatments for CRC include surgical excision, radiation therapy, 
chemotherapy and, more recently immunotherapy, along with a combinative 
approach of these modalities (Nkune et al., 2020). However, these treatments have 
undesirable side effects and significant efforts have been made to investigate safer 
treatments with increased potency, such as PDT (Kruger and Abrahamse, 2018).   
PDT is a clinically approved non-conventional modality which incorporates three 
fundamentals: a PS administered to target tissues, oxygen, and light (Kwiatkowski 
et al., 2018).  Following PS activation using a specific wavelength of light, an 
energy transfer cascade occurs, that ultimately generates cytotoxic species, which 
in turn induce cell death (Nkune et al., 2020). According to Kwiatkowski et al. 
(2018), cancer cells significantly take up greater volumes of PSs than normal 
tissues do, due to the increased affinity demonstrated by PS drugs to low-density 
lipoproteins (LDL) which are highly expressed by cancer cells during cell division, 
as well as the EPR effect. Thus, the advantages of PDT over conventional 
therapies are: higher tumour specificity, lack of cross-resistance, wide range of 
total light and drug dose that is localized, as well as very good cosmetic effect with 
small or no scarring, allowing for collagen preservation and colon mechanical 
strength preservation (Sun et al. 2016). 
Pcs are widely used second generation PSs in PDT treatments (Yalazan et al., 
2019). According to Brozek-Pluska et al., (2020), Pcs are endowed with unique 
chemical and physical properties, such as their resemblance to biomolecule 
structures (haemoglobin, chlorophyll), long near-infrared absorption, high 
extinction coefficients and a diverse chemical structure (central atoms), which 
allow for chemical modification enhancements. Brozek-Pluska and colleagues also 
noted that metallated Pcs demonstrate more improved chemical and 
photochemical stability, which elicit high triplet quantum yields and long triplet 
lifetimes. A study conducted by Mfouo-Tynga and Abrahamse, (2015) reported that 
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a mixed sulfonated metallophthalocyanine (ZnPcSmix) containing zinc as the 
central atoms, effectively enters cancer cells and accumulates in pivotal 
organelles, like the mitochondria, lysosomes and Golgi apparatus, which in turn 
trigger apoptotic cell death. Studies by Sekhejane et al. (2014) reported notable 
zinc phthalocyanine sulfonated mix (ZnPcSmix) PS PDT induced apoptotic cell 
death (40%) within in vitro treated CRC cell lines (DLD-1 and CaCo-2). However, 
studies by Broekgaarden et al. (2016) suggested that this PS should be further 
modified within its sulphide groups for improved solubilisation, as well as be 
considered for targeted cellular uptake and absorption to enhance PDT treatment. 
Such enhancements could include its conjugation to NPs, which could further 
augment solubility and cellular uptake (Hodgkinson et al., 2017). Studies by 
Chiarante et al. (2017) have shown the successful PDT treatment of 2D and 3D 
CRC cell cultures, when ZnPcS PSs were encapsulated into poloxamine polymeric 
micelles. Thus, ZnPcS is an ideal PS for chemical modification into an active 
targeting nano drug delivery system for CRC PDT treatment. 
In an effort to circumvent the non-specificity of PSs and enhance their ROS yield, 
considerable efforts have been devoted towards the synthesis and characterization 
of bio-conjugate markers, which can increase host PS accumulation specificity, in 
targeted cancer tumours (Hong et al., 2016). Studies by Calavia et al. (2018) 
reported the improved PDT treatment of in vitro cultured CRC cells, when a 
combination of ZnPcS PS conjugated to AuNPs was administered, due to 
improved PSs passive uptake. Additionally, studies by Danaee et al. (2017) noted 
that CRC tumour receptors tend to specifically overexpress the GUCY2C protein 
gene and stated that Anti-GCC mAbs could be bound to NP-PS molecules, in order 
to enhance the selective active targeting of CRC cells for improved PDT treatment.  
However, studies by Wei et al. (2014) reported that CRC stem-like cells (CSCs) 
tend to exhibit a high resistance to PDT, leading to its possible recurrence after 
treatment. Thus, advanced types of CRC often require treatment of both primary 
tumours and secondary systemic disease.  
Cannabinoids are a family of naturally occurring compounds highly abundant in the 
Cannabis sativa plant (Śledziński et al., 2018). These compounds possess 
pharmacological properties, which have the ability to inhibit cell growth and 
proliferation (Sharma et al., 2014). One such compound CBD has been found to 
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be effective against a variety of cancers (Sharma et al., 2014). A review by Lukhele 
and Motadi (2016) noted that CBD has extensive potential as an anticancer drug, 
since its anti-proliferative and its pro-apoptotic effects are known to interfere with 
tumour neovascularization, cancer cell migration, adhesion, invasion and 
metastasis, and so can possibly inhibit secondary systematic spread of cancer. 
Studies by Shams et al. (2015) have shown that stimulation of the host immune 
system can elicit anti-tumour immune responses capable of controlling metastatic 
tumour growth. Studies by Jeong et al. (2019) investigated the chemo preventive 
in vitro effect of CBD in mice CRC induced models and noted that it reduced cell 
proliferation through apoptotic cell death mechanisms, while generating anti-
tumour immune responses after treatment, and so aided within the control of CRC 
metastatic tumour proliferation and secondary spread. 
Thus, the aim of this study was to combine a ZnPcS4 PS, with CRC specific 
targeting antibodies – Anti-Guanylate Cyclase mAb (Anti-GCC) on the surface of 
heterobifunctional PEG amine stabilized AuNPs, in order to enhance PS passive / 
active drug delivery and specificity in CRC cells, so primary CRC can be effectively 
treated. However, to possibly enhance this treatment outcome and try and hinder 
its secondary reoccurrence, this final actively targeted PS nanoconjugate was 
administered to in vitro cultured CRC in combination with CBD. This current study 
investigated the combined effect of CBD and ZnPcS4 final actively targeted PS 
nanoconjugate post-PDT, to explore the prospect of implementing this combinative 
treatment in treating primary CRC tumours, as well as inhibiting the secondary 
malignant spread of CRC, with negligible effect on healthy tissues, since it has not 
been accomplished to date. 
To further improve the ZnPcS4 PSs drug passive uptake, as well as promote 
solubility and stability, it was conjugated to purchased AuNPs which were 
pegylated. Furthermore, these purchased AuNPs were amine functionalized to 
facilitate the conjugation of the CRC active targeting mAbs (Anti-GCC Ab) on their 
surface, in order to promote receptor-mediated endocytosis for actively specific 
and enhanced PS cellular uptake. After this final actively targeted PS 
nanoconjugate was successfully constructed a number of characterization assays 
were employed to validate the efficient binding and conjugation of the mAbs and 
PS to the surface of these functionalized AuNPs. These molecular characterization 
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studies were also used to identify the final actively targeted PS nanoconjugate UV 
absorption band, as well as confirm its structure, size and stability. 
Optical characterization UV spectra and FTIR assays confirmed that ZnPcS4 PS 
was successfully conjugated onto the AuNPPEG5000 surface, via ligand 
absorption and exchange methods with strong Au-S and weak di-sulphide bonds. 
Furthermore, these assays confirmed that the Anti-GCC mAbs were successfully 
conjugated on the amine functionalized AuNP-PEG5000-SH-NH2 via amide 
bonding. ZP results noted that the final actively targeted PS nanoconjugate had a 
mean Z-average diameter of 57.18 ± 3.04 nm, indicating that it was small enough 
to be considered as an active nano drug carrying system, with the definitive 
possibility of cellular uptake and absorption (Yu et al., 2016). Additionally, The ZP 
value of the final actively targeted PS nanoconjugate was found to be 36.5 ± 2.6 
mV, proposing that it is highly stable with a slightly positively charge, hinting at the 
fact that it should remain stable within an in vivo environment, as well as be 
retained within tumour cells more selectively (Bhattscharjee et al., 2016; Honary et 
al., 2013). DLS measurements noted that the final actively targeted PS 
nanoconjugate was homogenously pure, remained spherical in shape, reported no 
aggregation, with a PDI value of 0.353, signifying it was monodispersed in nature 
and consisted mostly of singular sized particles (Bhattscharjee et al., 2016). 
Moreover, these results suggested that the three individual constituents (ZnPcS4, 
AuNP-PEG5000-SH-NH2 and Anti-GCC Ab) were successfully bonded together to 
form one single molecule (Bhattscharjee et al., 2016). Lastly, within UV spectra 
assays the final actively targeted PS nanoconjugate confirmed UV-Vis absorption 
Q bands within the 520, 634 and 674 nm wavelength regions, showing it retained 
its photodynamic and photothermal properties and remained photostable. 
Furthermore, these results showed the final actively targeted PS nanoconjugate 
did not undergo much aggregation, and so presumptively had the ability to 
generate ROS. 
In order to determine the optimal dosing of both CBD and the ZnPcS4 PS within 
the final actively targeted PS nanoconjugate PDT mediated assays, individual dose 
response studies were performed. Various control and experimental groups of 
CRC cells were treated with varying concentrations of ZnPcS4 PS (0.0312, 0.0625, 
0.125 and 0.25 µM) and CBD (0.5, 1, 1.5, and 2 µM) for 20 hrs, after which some 
were irradiated at 673nm with a fluency of 10 J/cm2 and incubated for another 24 
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hrs. Cellular biological responses were used to determine the lowest possible 
concentration of ZnPcS4 PS or CBD which could be administered to in vitro 
cultured CaCo-2 to yield 50% cell viability, as well as induce a significant amount 
of cytotoxicity, in order to establish cell death induction potential (ICD50), but still 
allow cellular biological responses post-PDT treatment to be determined. The 
optimal ICD50 dose response concentrations of ZnPcS4 and CBD post-PDT 
treatment that induced approximately 50 % cytotoxicity was found to be 0.125 µM 
ZnPcS4 and 1 µM CBD, after observing morphological changes, cellular viability, 
cellular proliferation and cellular cytotoxicity damage. Furthermore, the CRC 
control groups from these assays noted no significant cellular cytoxicity in relation 
to laser irradiation alone or the ethanol in which the CBD was solubilized within, 
suggesting that laser irradiation at 673 nm with a fluence of 10 J/cm2 or ethanol 
administration alone, had no contributing external factors to CRC cells destruction. 
Lastly, CRC control groups which received CBD with or without laser irradiation, 
indicated no significant differences in CRC cellular cytotoxicity, suggesting that 
laser irradiation did not influence any destructive properties the CBD had on CRC 
cells and so it could be applied in combination within the final actively targeted PS 
nanoconjugate PDT experiments 
Once the above had been achieved, final actively targeted PS nanoconjugate PDT 
experiments were performed within in vitro cultured CRC and WS1 cells, by 
adjusting the ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC Ab concentrations 
that were administered to the recommended ICD50 of 0.125 µM for the ZnPcS4 PS, 
with some experimental and control groups additionally receiving the additional 
recommended ICD50 of 1 µM CBD. Therefore, within the final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC  Ab) PDT 
response assays, cell culture plates received 0.11 µg/ml Anti-GCC  Ab, which was 
successfully bound to 3.39 X 1012 AuNP-PEG5000-SH-NH2 particles/ml 
conjugated to a 0.125 µM of ZnPcS4 in 0.001 M PBS (w/v).  
This was performed in order to compare the PDT phototoxicity of ZnPcS4 PS alone 
versus the final actively targeted PS nanoconjugate, in order to observe if the final 
PS nanoconjugate was able to improve the PDT primary treatment outcomes of 
CRC. Furthermore, these adjustments allowed for the comparison of CBD 
treatment alone versus its combinative administration with the final actively 
160 
 
targeted PS nanoconjugate PDT assays, in order to evaluate its ability in 
enhancing CRC treatment outcomes, as well as limiting its secondary spread.  
Within subcellular localization studies, equal concentrations of final actively 
targeted PS nanoconjugate were administered to in vitro cultured human CRC cells 
(CaCo-2) and fibroblasts (WS1) cells. CRC control groups which received ZnPcS4 
alone noted a poor cellular uptake of the PS, whereas CRC control groups which 
received ZnPcS4 – AuNP-PEG5000-SH-NH2 noted an improved passive 
absorption of the PS. However, the most improved subcellular localization was 
found in CRC experimental groups which received the final actively targeted PS 
nanoconjugate. These findings confirmed that the final actively targeted PS 
nanoconjugate was able to actively and specifically localize within in vitro cultured 
human CRC cells. In relation to WS1 control groups which received ZnPcS4, minor 
amounts of the PS were found within the cells, suggesting that when this PS is 
administered alone it can be absorbed by surrounding healthy tissues and so when 
activated with PDT can induce unwanted side-effects. WS1 control groups which 
received ZnPcS4 – AuNP-PEG5000-SH-NH2 noted only slight increments of the 
PS within the cells. Whereas, WS1 experimental groups which received the final 
actively targeted PS nanoconjugate, noted no subcellular localization whatsoever 
of the PS. These findings confirmed that the final actively targeted PS 
nanoconjugate demonstrate no affinity for in vitro cultured WS1 cells, suggesting 
that its selective targeting affinity was specifically directed at CRC cells only and 
so when administered with PDT the treatment should remain localized to CRC cells 
only, leaving healthy tissues unharmed. These findings coincided with studies 
conducted by Gao et al. (2017) which reported that PSs when encapsulated into 
an active targeting moiety are more effectively taken up by CRC cells, which in turn 
exerted appreciable anti-proliferative effects within in vivo tumour models, with 
negligible effects on normal tissues. Overall, these results indicated that the final 
actively targeted PS nanoconjugate demonstrated enhanced retention and specific 
localization of the ZnPcS4 PS within cellular membrane proteins and cytoplasm of 
the CRC cells, which is indicative of efficient subcellular organelle absorption for 
enhanced ROS production, with no effects on healthy tissues. Thus, the final 
actively targeted PS nanoconjugate should be considered as a more efficient PS 
delivery system in relation to the administration of ZnPcS4 PS drug alone for 
improved PDT treatment outcomes.  
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Flow cytometric cellular death analysis was performed on WS1 cells in order to 
determine if the final actively targeted PS nanoconjugate plus cannabidiol (ZnPcS4 
– AuNP-PEG5000-SH-NH2 – Anti-GCC Ab + CBD), induced any unwanted side- 
effects on normal human tissues.  
Within assays investigating just the PDT effects of the final actively targeted PS 
nanoconjugate and its individual control components in WS1 cells, it was found 
that the 0.125 µM ZnPcS4 PS alone, in conjugation with AuNPs or when finally 
bound to the active nanoconjugate, exhibited no dark cytotoxicity and remained in 
active without PDT irradiation. PDT irradiated experimental groups, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, also only noted slight increases in early 
apoptotic forms of cell death, however these changes were insignificant. Whereas, 
PDT irradiated experimental groups, which received 0.125 µM ZnPcS4, noted a 
significant decrease in cellular viability (73%**) and significant increases in early 
apoptosis (12%*) and late apoptosis (10%*). These findings suggested that the 
administration of 0.125 µM ZnPcS4 with laser irradiation, does cytotoxically affect 
normal human cells, whereas when administered with either a AuNP carrier and / 
or active targeting mAb, it does not. Since studies by  Nombona et al., (2012) have 
reported that ZnPcS when administered alone, does exert PDT cytotoxic effect on 
normal fibroblast cells, due to its lack of functionalization for enhanced passive or 
active targeting, these results were probable. Thus, it can be stated that the 
administration of 0.125 µM ZnPcS4 alone within PDT studies for CRC cancer, 
unwanted normal healthy cell damage would be observed. Thus, results indicated 
that the final actively targeted PS nanoconjugate was probably the most effective 
PDT treatment for CRC, as it indicated no photo toxic side effects on normal human 
cells, due to its enhanced passive, as well as actively specific targeted AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab bound constituents for improved ZnPcS4 PS 
subcellular localization in tumor tissues only.   
Within assays investigating the PDT effects of the final actively targeted PS 
nanoconjugate and CBD within WS1 cells, control groups treated with 1 µM CBD 
with and without laser irradiation, noted no significant cell death changes in 
comparison to control cells only. Furthermore, non-irradiated control groups which 
received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, also 
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did not note any significant cell death changes. These findings suggest that CBD 
when administered alone or in combination with the final actively targeted PS 
nanoconjugate (or individual constituents), without laser irradiation, has no 
significant cellular damaging effects on normal cells. These outcomes propose that 
CBD does not have a destructive affinity for normal human cells, only cancer cells 
and that this is probably due to the fact that it only simulates anti-tumour immune 
system response capable of controlling metastatic tumour growth and so normal 
tissues remain unharmed (Shams et al., 2015). PDT irradiated experimental 
groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 and 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, both with 1 µM CBD, noted 
a slight increase in early apoptosis, however it was insignificant. However, PDT 
irradiated experimental groups, which received 0.125 µM ZnPcS4, plus 1 µM CBD, 
noted significant decreases in cellular viability (71%**), with increases in early 
(16%**), as well as late forms of apoptosis (11%*). When comparing this group to 
the same PDT irradiated experimental groups of WS1 cells, which received 0.125 
µM ZnPcS4, without 1 µM CBD, similar cellular death patterns were found. 
Furthermore, since control groups of WS1 cells treated with 1 µM CBD with and 
without laser irradiation, noted no significant morphological changes in comparison 
to control cells only, these findings suggest that the only destructive component 
within this treatment was the 0.125 µM ZnPcS4 PDT. The reasoning for the 0.125 
µM ZnPcS4 PDT cellular destruction within WS1 cells, was probably due to its lack 
of enhanced passive or actively concentrated uptake in targeted cancer cells. 
Thus, these findings suggested that 1 µM CBD is non-toxic to normal human cells 
and that when administered in combination with the final actively targeted PS 
nanoconjugate, it is probably the most effective PDT treatment for CRC, as this 
form of treatment has no targeting affinity for normal cells and so localized 
treatment with unwanted side effects is possible. 
Then flow cytometric cellular death analysis was performed on CRC cells in order 
to determine if the final actively targeted PS nanoconjugate plus cannabidiol, was 
able to enhance PDT treatment, as well as limit secondary CRC more than ZnPcS4 
PS drug administration alone, CBD treatment alone, or final actively targeted PS 
nanoconjugate treatment alone. 
Within assays investigating just the PDT effects of the final actively targeted PS 
nanoconjugate and its individual control components in CRC cells, it was found 
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that non-irradiated control groups, which received 0.125 µM ZnPcS4, 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, noted slight increases in apoptotic forms of cell death, with 
decreases in cellular viability, however these changes were insignificant. These 
findings suggested that the 0.125 µM ZnPcS4 PS alone, in conjugation with AuNPs 
or when finally bound to the active nanoconjugate, exhibited no dark cytotoxicity 
and remained in active without PDT irradiation. PDT irradiated experimental 
groups, which received 0.125 µM ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-
SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, noted 
significant forms of apoptotic cell death, with decreases in cellular viability.  
However, PDT irradiated experimental groups, which received 0.125 µM ZnPcS4, 
did not exhibit as much significant late apoptotic cell death (15%*), as when 
compared to the same groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 (21%**). Furthermore, when comparing these two groups to the 
experimental group, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, and irradiation, the most significant late apoptotic cell death of 
34%*** was noted, with a significant increase of 16%* of necrotic cell death. 
Accruing evidence has shown that cells undergoing early apoptosis are often 
autophagic and so have the potential to rejuvenate, thus early phases of apoptotic 
cell death is not ideal in PDT cancer treatments, as cells can recover leading to 
tumour re-occurrence. (Noguchi et al., 2015). Thus, the most favourable forms of 
cell death in relation to successful PDT treatment outcomes, is either late apoptotic 
or necrotic cell death modes, whereby cancer cells are destroyed beyond recovery 
(Van Straten et al., 2017; Chilakamarthi and Giribabu, 2017). Since second-
generation PSs (such as ZnPcS4) when administered alone are hydrophobic and 
tend to aggregate under physiological conditions, this drastically hinders their PDT 
cytotoxic species formation, due to their limited uptake in tumour cells (Kruger and 
Abrahamse, 2018), affecting their overall treatment outcomes and so this could 
explain why the 0.125 µM ZnPcS4 PDT treatment did not exhibit as much 
significant late apoptotic cell death (15%*), as when compared to the same groups, 
which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 (21%**). 
Furthermore, since studies by Hong et al., (2016) have also stated that when PSs 
are combined with AuNPs, their passive uptake and solubility in tumour cells is 
improved via the EPR effect and so when activated with laser irradiation, PDT 
outcomes generally produce more favourable late apoptotic forms of cell death. 
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Additionally, AuNPs tend to enhance overall PDT cellular destruction outcomes by 
contributing photothermal destruction (Kruger and Abrahamse, 2018) and so all of 
this could have also attributed to the higher late apoptotic cell death of 21%** being 
noted in the PDT irradiated experimental groups of CRC cells, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2. Nevertheless, the most favourable 
and cytotoxic form of PDT tumour cell death was found within the PDT 
experimental groups, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, and irradiation, whereby the most significant decrease in cellular 
viability was found, with the most favourable significantly late apoptotic cell death 
of 34%*** and an increase of 16%* of necrosis. These favourable enhanced forms 
of induced PDT cell death were probably due to the fact that the PS nanoconjugate 
had an actively selective targeting mAb attached to it, which promoted PS 
localization in CRC cells and so improved overall treatment outcomes, with 
significant cell death induction. This statement can be supported by studies 
conducted by Kruger and Abrahamse, (2019), whereby the most significant PDT 
apoptotic and necrotic cellular destruction can be found when bound AuNP-PSs 
are conjugated to targeting ligands such as mAbs, since their specific and active 
uptake is localized, with additional photothermal contributions and so this form of 
targeted PDT is often the most effective in cancer cell obliteration.  
Within assays investigating the PDT effects of the final actively targeted PS 
nanoconjugate and CBD within CRC cells, control groups of CRC cells treated with 
1 µM CBD with and without laser irradiation noted significant decreases in cellular 
viability, with increases in early (± 28%**), as well as late forms of apoptosis (± 
21%**). Studies performed by Aviello et al. (2012) noted similar findings within 
CRC in vitro treated cells treated with similar concentrations of CBD alone and 
stated that CBD reduced cell proliferation, though apoptotic cell death 
mechanisms, while generating anti-tumour immune responses after treatment. 
Furthermore, these findings concurred with the studies by Kim et al. (2019) which 
reported that CBD significantly altered cell morphology and decreased colony-
forming ability of in vitro cultured colon cancer cells. In general, these findings 
suggest that CBD when administered alone at 1 µM, with or without laser irradiation 
can affect CRC cells in a similar manner and so it can be stated that laser irradiation 
has a negligible effect on 1 µM CBD cellular cytotoxicity result outcomes. 
Furthermore, it can be stated that 1 µM of CBD can most definitely utilized as a 
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singular treatment to induce favourable cytotoxic apoptotic forms of cell death in 
CRC cells. Non-irradiated control groups of CRC cells, which received 0.125 µM 
ZnPcS4, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, plus 1 µM CBD, did show significant decreases 
in cellular viability, with increases in early (± 12%*), as well as late forms of 
apoptosis (± 9%*). These findings suggested that the ZnPcS4 PS alone, in 
conjugation with AuNPs or when finally bound to the active nanoconjugate 
exhibited no dark cytotoxicity and remained inactive, without PDT activation and 
that the significant apoptotic cell death effects were probably attributed to the 1 µM 
CBD administration. This conclusion was drawn especially when assessing these 
same controls without CBD treatment, which noted highly significant 1 µM CBD 
cell death. The reasoning for perhaps less apoptotic forms of cell death in the non-
irradiated control groups of CRC cells, which received 0.125 µM ZnPcS4, 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, plus with 1 µM CBD, in comparison to control groups of CRC cells 
treated with 1 µM CBD with and without laser irradiation, is probably attributed to 
the fact that the additional PS and conjugate dosing could have diluted the CBD 
potency. PDT irradiated experimental group, which received 0.125 µM ZnPcS4, 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, all with 1 µM CBD, noted severely significant 
appreciable forms of cell death,  in comparison to the same control groups without 
CBD treatment. PDT irradiated experimental groups of CRC cells, which received 
0.125 µM ZnPcS4, plus 1 µM CBD reported a significant 39%*** early apoptosis 
and 21%** late apoptosis, whereas PDT irradiated experimental groups of CRC 
cells, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, plus 1 µM CBD 
reported a significant 19%* early apoptosis, 48%*** late apoptosis and 11%* 
necrosis. This significantly improved late apoptotic and necrotic cellular destruction 
in PDT irradiated experimental groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, plus CBD could be attributed to the improved passive uptake 
and solubilization of the PS, due to the AuNP conjugated carrier, as well as the 
photothermal contributions it made to the overall treatment (Hong et al., 2016). 
Additionally, the CBD itself most definitely improved upon the PDT induced cellular 
death mechanisms, especially when the above results were compared to the same 
PDT irradiated experimental groups of CRC cells, which did not receive CBD. 
However, the most favourable significant results were the PDT irradiated 
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experimental groups of CRC cells, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, plus 1 µM CBD, whereby 16%* early apoptosis, 
52%*** late apoptosis and 26%** necrosis was found. Considering that the PDT 
experimental group which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-GCC Ab, plus 1 µM CBD and irradiation, showed more significant and 
favourable forms of heightened favourable cell death (52%*** late apoptosis and 
26%** necrosis) in comparison to the PDT experimental groups, which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab and no CBD (34%** 
late apoptosis and 16%* of necrosis), these findings indicate that PDT treatment 
with the final actively targeted PS nanoconjugate  combined with CBD can 
successfully kill off CRC cells. These favourably significant enhanced forms of 
induced PDT cell death (i.e. late apoptosis and necrosis), was probably due to the 
fact that the PS nanoconjugate had an actively selective targeting mAb attached 
to it, which promoted PS localization in CRC cells and so improved overall 
treatment outcomes, with significant cell death induction. This statement can be 
supported by studies conducted by Kruger and Abrahamse, (2019), whereby the 
most significant PDT apoptotic and necrotic cellular destruction can be found when 
bound AuNP-PSs are conjugated to targeting ligands such as mAbs, since their 
specific and active uptake is localized, with additional photothermal contributions 
and so this form of targeted PDT is often the most effective in cancer cell 
obliteration. Furthermore, the combination of CBD enhanced this nanoconjugate 
targeted form of CRC PDT treatment and this statement can be supported by 
Kenyon et al. (2018) whereby it was noted that when CBD is administered in 
combination with other cancer treatment therapies, it promotes disruption 
intracellular signaling pathways, such as P13K/AKT/mTOR and ERK, and so 
enhances combinative treatment cell death outcomes. 
Finally, in order to confirm if the final actively targeted PS nanoconjugate 
combinative treatment with CBD was able to induce more notable PDT induced 
cellular DNA nuclear damage in CRC CaCo-2 cells, than when compared to the 
administration of CBD alone, ZnPcS4 PS alone, ZnPcS4 – AuNP-PEG5000-SH-
NH2 alone or ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab alone, Hoechst 
33258 bisbenzimide derivate fluorescent stain was performed. Within experimental 
PDT groups, which received 0.125 µM ZnPcS4 alone and irradiation, most of the 
cellular nuclei appeared prominent and round in shape, with very slight 
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fragmentation in comparison to the CRC group of cells only. These findings 
suggested that 0.125 µM ZnPcS4 PDT treatment alone, did not induce significant 
DNA damage. Since second-generation PSs (such as ZnPcS4) when administered 
alone are hydrophobic and tend to aggregate under physiological conditions, 
drastically hindering their PDT cytotoxic species formation, due to their limited 
uptake in tumour cells, often minimal cellular destruction is often observed (Kruger 
and Abrahamse, 2018). Within experimental PDT groups, which received 0.125 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2, and laser irradiation, CRC nuclei began 
changing shape, as some were irregularly swollen and fragmented. Studies by 
Manoto et al., (2012) linked morphological shrinkage and swelling of the Hoechst 
stained nuclei in CRC cells treated with 10 µM PDT photoactivated ZnPcSmix to 
signify apoptotic cell death. This improved DNA damage in comparison to 0.125 
µM ZnPcS4 PDT treatment alone, was attributed to the fact that in this experimental 
group the PS was combined with an AuNP, which promoted its solubilization and 
passive uptake in CRC cells and so the PDT cytotoxic cellular destruction was 
improved upon (Kruger and Abrahamse, 2018). Additionally, AuNPs enhance the 
overall PDT cytotoxic cellular destruction by contributing photothermal destruction 
(Kruger and Abrahamse, 2018).In comparison to the above two discussed groups, 
the experimental PDT groups, which received 0.125 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-GCC Ab, and irradiation, the nuclei displayed prominent 
shrinkage and fragmentation. Studies by Balusamy et al., (2018) have reported 
that when Hoechst stained nuclei present shrinkage with fragmentation the DNA 
chromatin state of the cell is becoming disrupted and it is usually indicative of late 
apoptotic forms of cell death, whereby cells are unable to recover. This improved 
DNA damage in comparison to 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 PDT 
treatment alone, was attributed to the fact that in this experimental group the PS 
was bound to AuNP which was conjugated to targeting mAb biomarker and so its 
cellular uptake was far more concentrated and actively localized in CRC, with 
additional photothermal contributions and so this form of targeted PDT is often 
more lethal (Kruger and Abrahamse, 2018). Overall, these results suggested that 
the final actively targeted PS nanoconjugate had indeed enhanced the primary 
PDT treatment of CRC cells in vitro, by selectively and actively targeting tumour 
cells in comparison to ZnPcS4 PDT treatment alone. Whereas, PDT irradiated 
experimental groups of CRC cells, which received 0.125 µM ZnPcS4, 0.125 µM 
ZnPcS4 – AuNP-PEG5000-SH-NH2, 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 
168 
 
– Anti-GCC Ab, all with 1 µM CBD, noted severely significant appreciable forms of 
cellular DNA damage, in comparison to the same control groups without CBD 
treatment. Their nuclei displayed complete shrinkage with loss of cohesion 
between the cells with very prominent fragmentation. Studies by Balusamy et al. 
(2018) have reported that when Hoechst stained nuclei present complete 
shrinkage with fragmentation, the DNA conformation and chromatin state of the 
cell has become completely disrupted, it is usually indicative late apoptotic or 
necrotic forms of cell death, whereby cells are unable to recover and so are 
considered completely destroyed. This significantly improved late apoptotic and 
necrotic cellular destruction in PDT irradiated experimental groups which received 
0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, plus CBD could be attributed to the 
improved passive uptake and solubilization of the PS, due to the AuNP conjugated 
carrier, as well as the photothermal contributions it made to the overall treatment 
(Hong et al., 2016). Additionally, the CBD itself most definitely improved upon the 
PDT induced cellular death mechanisms, especially when the above results, were 
compared to the same PDT irradiated experimental groups of CRC cells, which did 
not receive CBD.  However, the most favourable results of complete nuclei and 
DNA destruction were observed in the PDT irradiated experimental groups of CRC 
cells, which received 0.125 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-GCC Ab, 
plus 1 µM CBD. These favourably significant enhanced forms of induced PDT cell 
death (i.e. late apoptosis and necrosis), was probably due to the fact that the PS 
nanoconjugate had an actively selective targeting mAb attached to it, which 
promoted PS localization in CRC cells and so improved overall treatment 
outcomes, with significant cell death induction. Furthermore, the combination of 
CBD enhanced this nano conjugate targeted form of CRC PDT treatment and this 
statement can be supported by Kenyon et al, (2018) whereby it was noted that 
when CBD is administered in combination with other cancer treatment therapies, it 
promotes disruption intracellular signaling pathways, such as P13K/AKT/mTOR 
and ERK, and so enhances combinative treatment cell death outcomes. 
Conclusively, these results are suggestive that irradiated experimental groups, 
which received the combined PDT therapy of final actively targeted PS 
nanoconjugate and CBD were unlikely to recover post-PDT, due to their severe 
nuclear damage and so this implies that this active PS drug targeting form of PDT 
combined with CBD was the most efficacious treatment option for concurrent 
primary and secondary treatment of in vitro cultured CRC cells. Lastly, these 
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results indicated that the final actively targeted PS nanoconjugate significantly 
enhanced the primary PDT treatment of CRC cells in vitro by specifically and 
actively targeting cancer cells, and its combinative treatment with CBD eradicated 
PDT-resistant cells, thus limiting secondary CRC spread.       
Overall, these findings coincided with the studies conducted by Kruger and 
Abrahamse, (2019) which emphasize that incorporating NP-PS drug carrier 
systems with specific targeting moieties, complementary to receptors 
overexpressed on cancer cells, allows for more efficient and active accumulation 
of PSs in cancer cells due to their targeting abilities and so improves the overall 
efficacy of PDT with negligible damage to healthy tissues. Furthermore, these 
results put further emphasis on studies conducted by Ramano et al. (2014), which 
highlighted that CBD could exert a considerable anti-proliferative effect on CRC 
cells. Thus, these results suggest that the Anti-GCC Ab, which was linked to the 
ZnPcS4 – AuNP-PEG5000-SH-NH2 actively enhanced PS uptake in CRC cells and 
that when this PDT treatment was coupled with CBD, it drastically amplified overall 
treatment outcomes. Lastly, these results imply that the PDT treatment of CRC cell 
with the final actively targeted PS nanoconjugate was superior at inducing cell 
death (due to its enhance targeted specificity) and so would undoubtedly eradicate 
primary in vitro tumours. However, when this treatment was coupled with CBD 
(which is known to yield anti-tumour immune responses capable of controlling 
metastatic tumour growth - Shams et al., 2015), this studies results suggest this 
combinative treatment form could be capable of destroying both primary tumour 
growths of CRC, as well as eradicating its secondary spread.  
5.2 Future Directives 
In relation to molecular conjugate characterization for effective immobilization of 
mAb to the nano-PS drug surface, additional techniques could be employed to 
validate the binding affinity of Anti-GGC to ZnPcS4 – AuNP-PEG5000-SH-NH2 
(Zaltariov et al. 2014). A well-established technique for simultaneous analysis of 
particle size and concentration number still needs to be explored, as studies by 
Tarik et al., (2017) observed that inductively coupled plasma mass spectrometry 
(ICPMS) is a method of choice for determining the concentration number of each 
individual element within a molecular component, as it has the ability to detect and 
quantify more than one volatile compound simultaneously. This single particle 
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ICPMS could also be coupled with dynamic light scattering (DLS) to further 
functionalize and characterize the bonding concentration number of each 
component on the nano bioconjugate (Stuchinskaya et al. 2011). Additionally, 
nanoparticle tracking analysis (NTA), which is a highly precise and reproducible 
technique for determining nanoparticle size could be utilized in the future study to 
address challenges faced by DLS (Hoover et al. 2020). Furthermore, due to the 
complexity and inherent heterogeneity of mAb and antibody-related products, an 
ELISA assay would be highly recommended for further quantification and 
characterization of the nano bioconjugates targeting abilities, in order to determine 
the antigenic functionality and activity of the bound Abs (Zhang et al. 2020). 
According to Hong and Rao, (2019) AuNPs have exceptional stability, high 
scattering energy, high surface area, biocompatibility, strong absorption within the 
NIR region, and easy surface functionalization. Therefore, for the physical 
characterization of the final actively targeted PS nanoconjugate, thermal 
gravimetric analysis (TGA) coupled with Transmission electron microscopy (TEM) 
assay could be used to further corroborate the properties of multicomponent 
nanoparticle based system in relation to the AuNPs’ thermal stability and structural 
configuration respectively (Crouse and Abrahamse, 2020). Several lines of 
evidence indicate that ROS is closely connected to numerous biological processes 
and defence mechanisms, cells rely on it for survival; such as immune defence, 
antimicrobial activity, cell cycle and signal transduction mechanisms (He et al. 
2017). However, at high concentrations ROS can induce autophagy, apoptosis and 
necrosis (He et al., 2017). These molecules are activated by various mechanisms 
including PDT and can be assessed using various spectrophotometry techniques, 
such electron spin resonance (ESR/EPR), chemiluminescence and fluorescence 
(Zhang et al. 2018).  
Furthermore, this study warrants further investigation into the therapeutic efficacy 
of this final actively targeted PS nanoconjugate, as well as its combinative 
treatment with CBD using reliable models that resemble in vivo conditions of CRC 
cells. Virtually all in vitro PDT experiments are performed on monolayer cultures 
and the cellular environments of these models do not emulate that of in vivo 
models. Therefore, tumour spheroids will serve as excellent models in cancer 
research for the assessment of the therapeutic mediations since they precisely 
mimic different features of solid tumours (Costa et al. 2016). Additionally, one could 
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recommend co-culturing CaCo-2 and WS1 cells together in vitro with regards to 
subcellular localization experiments, in order to more effectively explore 
comparative subcellular localization assays. 
Lastly, the combination of CBD with the final actively targeted PS nanoconjugate 
and laser irradiation within this study exerted a remarkable cytotoxicity and cell 
death in CRC. Therefore, this merits further investigation in relation to the particular 
signalling pathways this combinative therapy either activates or inactivates, in 
order to fully understand cellular death mechanisms involved in CRC tumour 
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Appendix A: Characterization of Final Targeted PS Nanoconjugate 








































Appendix C: List of Consumables 
Product Catalogue no. Company/Supplier 
0.1 mM nonessential amino acids  M7145 Sigma Aldrich 
1.0 mM sodium pyruvate  S8636 Sigma Aldrich 
35mm x 10mm Style Treated Polystyrene 
Cell Culture Dish 
430165 Corning Incorporated 
5 ml Disposable pipette BD357543 Beckson Dickinson 
10 ml Disposable pipette BD357551 Beckson Dickinson 
4 % Paraformaldehyde P6148 Sigma Aldrich 
4’6-diamidine-2-phenylindole (DAPI) D9564 Sigma Aldrich 
50% w/v hydroxylamine 438227 Sigma- Aldrich 
672.3 nm Laser  National Laser Centre 
CaCo-2 Cell line  SS1402 CCAC-FL; 
CCAC-C 
Cellonex 
Amphotericin B A2942 Sigma Aldrich 
Azide S8032 Sigma Aldrich 
Anti-GCC  antibody  122404 Abcam 
Anti-ICAM1 antibody  [MEM-111] AB2213 AC Abcam 
Annexin V/PI apoptosis detection kit 556570 BD Pharmigen 
Biofreezing medium 25 Ml F2270 Biochrom AG 
BSA A2153 Sigma Aldrich 
Cannabidiol  90899-1ML Sigma Aldrich 
CellTitreGlo ATP kit G7573 Promega 
Centrifuge tube, 50 mL, PP flat top, sterile, 
bulk 
CR430489 Corning Incorporated 
Coverslips CG88 Lasec 
CytoTox 96® Non-Radioactive Cytotoxicity 
Assay 
G1780 Promega 
Dulbecco’s Modified Eagle Medium D5796 Sigma Aldrich 
EDC N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride ≥99.0%  
03449 Sigma Aldrich 
Eppendorf®, Microtubes Z666521 Sigma Aldrich 
Eppendorf®, Microtubes Z666505 Sigma Aldrich 
Eppendorf®, Microtubes Z666515 Sigma Aldrich 
Ethanol absolute 99.99% 32221 Sigma Aldrich 
Falcon (5ml) Polystyrene round bottom tube BD352054 Beckson Dickinson 
Fluoromount™ Aqueous Mounting Medium  F4680 Sigma Aldrich 
Foetal Bovine Serum 10499-044 Thermo Fisher Scientific 
Formaldehyde Solution  F8775 Sigma Aldrich 
Goat Anti-Mouse IgG H&L (FITC) AB6785 AC Abcam 
Gold nanoparticles AUNPPEG5000-SH-NH MKCB6206 Sigma Aldrich 
Hanks Balances Salt Solution (HBSS) 55021C Sigma Aldrich 
Heavy tin foil 5m x 45 cm 6009652290191 Pick n’ Pay 
Hoechst 33258 Pentahydrate (bis-
benzimide) 10mg 
H211491 Thermo Fisher Scientific 
Latex Gloves large powder free EV/55620 Thermo Fisher Scientific 
L-Glutamine G7513 Sigma Aldrich 
Minimum Essential Medium Eagle with 
Earle’s Salts and sodium bicarbonate, 
without L-glutamine, liquid, sterile filtered, 
suitable for cell culture 
RNBG8606 Sigma Aldrich 
Microplate, 96 well, F-Bottom clear, sterile 
2pcs/bag 
655161 Sigma Aldrich 
Microplate, 96 well, F-Bottom (Chimney 
well), white, lumitrac, high binding, sterile 
10pcs/bag 
665074 Sigma Aldrich 
Microscope slides, frosted one end size 25 
mm x 75 mm 
S8400 Sigma Aldrich 
Mounting medium 10 Ml M1289 Sigma Aldrich 
Sulfo-NHS,  56485 Sigma- Aldrich 
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Paraformaldehyde (4%) P6148 Sigma Aldrich 
PBS P4417 Sigma Aldrich 
Penicillin/Streptomycin P4333 Sigma Aldrich 
Phosphate buffered saline P5493 Sigma Aldrich 
Tissue culture flask 25 cm2, angled neck, 
vent, sterile 
CR/423052 Corning Incorporated 
Tissue culture flask 75 cm2, angled neck, 
vent, sterile 
CR/430641U Corning Incorporated 
Tissue culture flask 175 cm2, angled neck, 
vent, sterile 
CR/431080 Corning Incorporated 
Triton X-100 T9284 Sigma Aldrich 
TrypLETM Select (500 mL) 12563-029 Gibco Invitrogen 
Trypan Blue stain 0.4% T10282 Invitrogen 
Universal fit pipette tips,100-1000 µl,Bulk CR4868 Corning 
WS-1 Cell line Normal Human 
Fibroblasts (WS1 ATCC 
CRL-1502) 
ATCC 
Zinc sulfo tertra phthalocyanine (ZnPcS4) 
powder 
Purchased from Santa Cruz® Biotechnology (sc-





















Appendix D: List of Chemicals, Solutions and Media 
Chemicals, Solutions and Media 
D1 70% (v/v) Ethanol (100 ml) Absolute Ethanol  70 ml 
Distilled Water  30 ml 
D2 200 µg/mL Anti-GCC  (working solution) Anti-GCC  457.7ug/ml  300ul 
0.001 M PBS D3 0.69ml 
D3 0.001 M PBS (1 L) 10 x 0.1 M PBS  1 ml 
Sterilized Distilled water  99 ml 
D4 Suspension Stock 0.0005 M ZnPcS4 
• Weigh off 0.0006g of ZnPcS4 
powder (or 0.0012g) 
• Add 1.25ml of 0.001M PBS and mix 
well (or 2.5ml) 
• Store at room temp. and wrap in tin 
foil due to light sensitivity = ZnPcS4 
Stock of 0.0005M (E6) 
ZnPcS4 powder 
molar mass: 898.15 g/mol 
 0.0006 g 
0.001 M PBS  D3 1.25 ml 
D5 Working Stock 0.000125 M or 125 µM 
ZnPcS4 
• Take 1ml of ZnPcS4 Stock of 
0.0005M and add 4ml 0.001M PBS 
and mix well to make 0.000125 M 
or 125 µM 
• The following calculation was done: 
C1V1 = C2V2 
(X) (4ml) = (0.0005 M of ZnPcS4) (1 ml) 
X = 0.000125 M = 125 µM (E6) 
Suspension Stock 0.0005 
M ZnPcS4 
 1ml 
0.001 M PBS  D3 4ml 
D6 50% (w/v) Hydroxylamine Quencher Hydroxylamine  5 µg 
0.001 M PBS D3 10 µl 
D7 Complete CaCo-2 Cell Growth Medium 
(500 ml) 
DMEM - Dulbecco’s 
Modified Eagle Medium 
 500 ml 
15% Foetal Bovine Serum  75 ml 
0.1% Penicillin-
Streptomysin 
 500 µl 
0.1% Amphotericin β  500 µl 
D8 Complete WS1 Cell Growth Medium 
(500 ml) 
MEM- Minimum Essential 
Media   
 500 ml 
10% Foetal Bovine Serum  50 ml 
1% Penicillin-Streptomysin  5 ml 
1% Amphotericin β  5 ml 
2% L-glutamate  10 ml 
1% Sodium pyruvate  5 ml 
1% Non-essential amino 
acids 
 5 ml 
D9 0.01 M PBS (100 ml) 10 x 0.1 M concentrate 
PBS 
 10 ml 
Sterilized Distilled water  90 ml 
D10 3.7% Formaldehyde Solution  Formalin  3.7 ml 
Sterilized Distilled water  96.3 ml 
D11 PBS BSA Sodium Azide Buffer (100 ml) 0.01 M PBS D9 100 ml 
Bovine Serum Albumin 
(BSA) 
 1 g 
Sodium Azide  0.01 g 
Note: filter sterilize   
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D12 2 µg/ml ICAM -1 Mouse Monoclonal 
IgG1 Antibody (working solution of 
1:500 dilution)   
 
1000 µg/ml ICAM -1 
Mouse Monoclonal IgG1 
Antibody (ab2213) 
 1 µl 
PBS BSA Sodium Azide 
Buffer 
D9 499 µl 
D13 5 µg/ml Goat Anti-Mouse IgG Antibody 
(working solution of 1:400 dilution) 
2000 µg/ml Goat Anti-
Mouse IgG Antibody 
(ab6785) 
 1 µl 
PBS BSA Sodium Azide 
Buffer 
D9 399 µl 
D14 Stock Solution: 1.0 mg/ml 40-6-




 0.001 g 
Sterilized Distilled water  1 ml 
Note: light sensitive   
D15 Working solution: 1 µg/ml 40-6-
Diamidino-2-phenylindole (DAPI) 
1.0 mg/ml 40-6-Diamidino-
2-phenylindole (DAPI) or 
1000 µg/ml 
D14 1 µl 
Sterilized Distilled water  1 ml 
Note: light sensitive   
D16 20% Fluoromount® Aqueous Mounting 
Medium (10 ml) 
Fluoromount® Aqueous 
Mounting Medium 
 2 ml 
Distilled water  8 ml 
D17 ATP CellTiter-Glo® Luminescent 
Solution 
CellTiter-Glo® Buffer  10 ml 
CellTiter-Glo® Substrate  0.07 g 
Note: this is enough 
solution to run 200 assays 
  
D18 LDH CytoTox 96® Non-Radioactivity 
Solution 
CytoTox 96® Substrate mix  0.012 g 
CytoTox 96® Assay buffer  1.2 ml 
Note: this is enough 
solution to run 20 assays 
  
D19 1x (v/v) Binding Buffer (18.7 ml) 10 x concentrated Binding 
Buffer 
 1.7 ml 
Sterilized Distilled water  17 ml 
D20 Reconstituted Propidium Iodide Staining 
Solution (1 ml) 
Powdered Propidium 
Iodide  
 250 µg 
1 x (v/v) Binding buffer D19 1 ml 





 0.001 g 











Appendix E: Calculations 
E.1 Preparation & Calculation of CBD Concentration and Volume 
• Preparation of Stock CBD 0.5 mg/ml in 99.8% ethanol:  
o Cannabidiol solution, 10 mg/ml in 1 ml ethanol with molecular mass of 314.46 
g/mol (Sigma-Aldrich: 90899-1ml) was purchased and stored the fridge. Upon 
receipt it was diluted by adding 19 ml more 99.8% ethanol to the concentrated 
solution to make a CBD stock concentration of 0.5 mg/ml in 20 ml 99.8% 
ethanol, it was stored in the fridge and covered with tin foil due to its light 
sensitivity.  
• Calculation of Stock CBD Concentration:  
o Stock CBD 0.5 mg/ml in 20ml 99.8% ethanol, convert 0.5 mg/ml to grams 0.0005 
g/ml  
o Molar Mass = 314.46 g/mol 
o n = m/M = 0.0005 g/ml / 314.46 g/mol = 0.0000015mol 
o C = n/V = 0.0000015 mol / 0.02 L (20ml ethanol) 
o = 0.000075 M (molar stock conc of CBD 0.5 mg/ml in 20 ml 99.8% ethanol) 
o Convert 0.000075 M to 75 µM (stock) 
o Calculation of Working CBD Concentration:  
o Required CBD working concentrations: 0.5, 1, 1.5 and 2 µM 
o Thus, if you wanted to add a working concentration of 1 µM of CBD which is 
equivalent to 0.000001 M of CBD to a culture plate with a 3ml final volume (growth 
medium) and the stock concentration of 75 µM CBD would have to be diluted. 
o The following calculation was done: 
o C1V1 = C2V2 
o (0.000001 M) (3ml) = (0.000075 M) (X) 
o X = 0.04 ml x 1000 = 40ul 
o Therefore, 40ul of the stock solution of 0.5 mg/ml 0.000075 M CBD was added 
to the culture plate which contained 2960 ul of relevant complete growth culture 
medium in order to acquire a working concentration of 1 µM of CBD. 
Conc (M) Conc (uM) *Vol 75 µM CBD to 3 ml culture media 
0.000 0005M 0.5 µM 20 µl of CBD to 2980 µl culture media 
0.000 001M 1 µM 40 µl of CBD to 2960 µl culture media 
0.000 0015M 1.5 µM 60 µl of CBD to 2940 µl culture media 
0.000 002M 2 µM 80 µl of CBD to 2920 µl culture media 
E.2 Calculation of Inoculum for Cell Culture Flasks  
• For instance if the Countess II FL Automated Cell Counter (E9) identified a total of 5.0 
x 105 viable cells/ml from the cell pellet resuspended in 10 ml of complete cell culture 
media, and perhaps the recommended inoculum for CaCo-2 cells is 1x105 viable 
cells/ml in a 75 cm2 cell culture, the following calculation would be performed: 
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• Viable cells (cells/ml) x re-suspension volume = Total viable cells 
• Seeding Ratio ÷ Total viable cells = cellular re-suspension  
• Cellular re-suspension x flask size = total cellular re-suspension  
• 500000cells/ml x 10 ml = 5000000 cells / 10ml 
• 1x 105 cells/ml ÷ 50000000 cells / 10ml = 0.02 ml 
• 0.02 ml x 75 cm2 = 1.5 ml 
• Therefore, you would remove 1.5 ml from the 10 ml of cellular re-suspension, and 
inoculate it into the 75 cm2 cell culture flask that contains freshly prepared cell culture 
media to cover the surface area of the base of the flask, to attain a 1x 105 cells/ml 
seeding ratio. 
E.3 Calculation for Seeding of Cell Culture Plates   
The seeding density of cells in a cell culture plate prior to PDT experimentations differs with 
cell lines. An optimum seeding density is always calculated as to ensure specific number 
of cells was available for biochemical assays after irradiation. The amount used to seed 
colon cancer (CaCo-2) cells was 6 x 105 cells/ ml in a 3.4 cm diameter cell culture dish, 
which contained 3ml culture media. 
The calculation is illustrated below: 
o Total viable cells (E9) 5 x 107/ 6x 105 = 83 
o Cell suspension of 10 ml/ 83 = 0.120 ml 
Therefore 0.120 ml of the cells were removed and inoculated into a culture plate and 
enriched with 2.88 ml of complete media (D6), to make the total volume of complete culture 
media 3 ml.  
E.4  Calculation of Cell Seeding for Cryopreservation  
• For instance If the Countess II FL Automated Cell Counter (E9) reported that the total 
viable cells was 5.2 x 106 cells/ml, after re-suspending the cell pellet in 2 ml of complete 
cell culture media and you wanted to cryopreserve cells with a seeding ratio of 2 x 106 
cells per 2 ml, the following calculation would be performed: 
o Viable cells (cells/ml) x re-suspension volume = Total viable cells 
o Total viable cells ÷ Seeding Ratio = amount of cryovials that can be made  
o Re-suspension ÷ amount of cryovials = cellular re-suspension per vial 
o 5200000 cells/ml x 2ml = 10400000 cells / 2 ml 
o 10400000 cells / 2 ml ÷ 2x 106 cells/ 2 ml = 5.2 cryovials 
o 2 ml ÷ 5.2 = 0.385 ml of re-suspension per vial 
Therefore, from the cellular re-suspension, you would remove 0.385 ml and pipette it 
into a cryovial that contains 1.615 ml of cell freezing medium to obtain a 2 x 106 cells 
per 2 ml seeding ratio. 
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E.5  Laser Irradiation Duration of Exposure Calculation for Diode Laser 
• The laser parameters of the 673 nm diode laser are listed below: 
Name and Type Semiconductor (Diode) 
Wavelength 673 nm 
Spectrum Red (Visible) 
Pulsed or Continuous Continuous wave (CW) 
Average Output 75 mW 
Spot Area 36.31681001 cm2 
Spot Radius 3.39999995 cm2 
Energy Density 10 J/cm2 
Number of exposures 1 exposure 24 hours after seeding plates 
Duration of exposure 16 minutes and 8 seconds 
 
• The average output power of the 673 nm diode laser was measured using a power 
meter. 
• The output power of the 673 nm diode laser ranged from 70 mW to 80 mW, thus the 
average output power was determined to be 70 mW 
• The following formula was used to calculate laser irradiation time:  
 
• Therefore, to determine the laser irradiation time for the 673 nm diode laser the 
fluence that was used was 10 J/cm2 and the output power of the laser on the day of 
irradiation was 75 mW, this output was then multiplied by 1.25 as this is specific to 
the laser, the following example was used. 
(93.75 mW x 4) ÷ 36.31681 = 10.3257968 mW/cm2 
10.3257968 mW/cm2 ÷ 1000 = 0.0103257968 W/cm2 
10 J/cm2 ÷ 0.0103257968 W/cm2 = 968.448 seconds 
968.448 seconds ÷ 60 = 16 minutes 
16 minutes x 60 = 960 seconds 
968.4 – 960 = 8 seconds   
Therefore, the average laser time was 16 minutes and 8 seconds. 
E.6  Preparation & Calculation of Photosensitizer Volume ZnPcS4 
Preparation  
• ZnPcS4 suspension concentration: 0.0005 M (D4): 
o Molar Mass = 898.15g/mol 
o n = m/M = 0.0006g / 898.15g/mol = 0.0000006mol 
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o C = n/V = 0.0000006mol / 0.00125L (1.25ml 0.001M PBS) = 0.00048M = 
0.0005M (stock) 
o Thus, to make up 0.0005M ZnPcS4 solution, weigh off 0.0006g of ZnPcS4 
powder  and add 1.25ml of 0.001M PBS and mix well  
o Store at room temp. and wrap in tin foil due to light sensitivity 
• ZnPcS4 working stock concentration: 0.000125 M or 125 µM (D5): 
o Dilute 0.0005 M ZnPcS4 stock solution to utilize at different concentrations i.e. 
using C1V1 = C2V2 formula 
o The following calculation was done: 
o C1V1 = C2V2 
o (X) (4ml) = (0.0005 M of ZnPcS4) (1 ml) 
o X = 0.000125 M = 125 µM 
o Take 1ml of 0.0005 M ZnPcS4 stock and add 4ml 0.001M PBS and mix well to 
make 0.000125 M or 125 µM 
• Calculation of Required ZnPcS4 PS Concentrations for PDT Dose Response Assays: 
o ZnPcS4 PDT dose response concentrations to add to CRC cells: 0.0312, 0.0625, 
0.125 and 0.25 µM 
o Eg: ZnPcS4 working stock concentration: 0.000125M and you want a concentration 
of 0.125 µM in 3ml cell culture media. 
o C1V1 = C2V2 
o (125 µM of ZnPcS4) (X) = (0.125 µM of ZnPcS4) (3 ml of growth medium) 
o X = 0.003 ml x 1000 = 3 µl 
o Therefore 3 µl of the stock solution of 125 µM ZnPcS4 PS was added to the cell 
culture plate which contained 2997ul of relevant complete growth culture medium 
to make the final volume of 3ml. 
PS Conc (M) PS Conc (uM) *Vol PS to 3 ml culture media 
0.000 0000312M 0.0312 µM 0.75 µl of PS to 2999.25 µl culture media 
0.000 0000625M 0.0625 µM 1.5 µl of PS to 2998.5 µl culture media 
0.000 000125M 0.125 µM 3 µl of PS to 2997 µl culture media 
0.000 00025M 0.25 µM 6 µl of PS to 2994 µl culture media 
E.7 Final Targeted PS Nanoconjugate Calculation 
The molecular characterization results noted that the final actively targeted PS 
nanoconjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC Ab) consisted of 30.91 
µg/ml of Anti-GCC Ab, which was successfully bound to 0.95 X 1015 AuNP-PEG5000-SH-
NH2 particles/ml and on average 0.000035 M / 35 uM of ZnPcS4 in 0.001 M PBS (w/v) 
(Section 4.4.1.5). Therefore, the ZnPcS4 PS drug concentration of 0.000035 M / 35 uM, 
when bound to control ZnPcS4 -AuNP-PEG5000-SH-NH2 and the experimental 
synthesized final molecular drug conjugate (ZnPcS4 – AuNP-PEG5000-SH-NH2 - Anti-GCC 
Ab) needed to be adjusted to a 0.125 µM ZnPcS4 PS PDT (IC50) concentration, with cell 
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culture media volume adjustment, when being added to cell culture plates for consistency 
as shown in below. 
Description  Conc (M) Conc (µM) *Vol PS conjugate added to 3 ml culture 
media 
ZnPcS4 PS IC50 0.000 00125M 0.125 µM • C1V1 = C2V2 
• (125 µM of ZnPcS4) (X) = (0.125 µM of 
ZnPcS4) (3 ml of growth medium) 
• X = 0.003 ml x 1000 = 3 µl 
• Therefore 3 µl of the stock solution of 125 
µM ZnPcS4 PS was added to the culture 
plate which contained 2997ul of relevant 
complete growth culture medium in order 
to acquire a working concentration of 
0.125 µM of ZnPcS4 PS. 
ZnPcS4 - AuNP 0.000 00125M 0.125 µM ZnPcS4 bound to AuNPs synthesized stock 
concentration was 0.0000555 M / 56 uM and a 
concentration of 0.000 00125M / 0.125 uM in 3 
ml cell culture media was needed to meet IC50 
criteria; 
• C1V1 = C2V2 
• (0.125uM final) (3 ml) = (56uM stock) (X) 
• X = 0.0067 ml x 1000 = 6.7 µl 
• Thus add 6.7 µl of 0.0000555 M / 56 uM of 
ZnPcS4 bound to AuNPs synthesized stock 
concentration to 2993.3 ul of cell culture 




0.000 00125M 0.125 ZnPcS4 final molecular conjugate or just bound 
to AuNPs synthesized stock concentration was 
0.000035 M / 35 uM and a concentration of 
0.000 00125M / 0.125 uM in 3 ml cell culture 
media was needed to meet IC50 criteria: 
• C1V1 = C2V2 
• (0.000 00125 M final) (3 ml) = (0.000035 M 
stock) (X) 
• X  = 0.0107 ml x 1000 = 10.71 µl 
• Thus add 10.71 µl of 0.000035 M / 35 uM 
ZnPcS4 final molecular conjugate stock to 
2989.29 ul of cell culture media to get 
0.125 µM IC50 concentration. 
Note: ZnPcS4 final molecular conjugate synthesized stock concentration was 0.000035 M / 35 uM 
and a concentration of 0.000 00125M / 0.125 uM of ZnPcS4 in 3 ml cell culture media was needed 
to meet IC50 criteria; 
• 35uM / 0.125uM = 280-fold dilution 
• ZnPcS4 final molecular conjugate synthesized stock concentration was 0.000035 M of 
ZnPcS4  bound to 30.91 µg/ml of Anti-GCC Ab, which was successfully bound to 0.95 X 
1015 AuNP-PEG5000-SH-NH2 particles/ml and this 280 fold affects diluted Anti-GCC Ab 
to 0.11 µg/ml bound to 3.39 X 1012 AuNP-PEG5000-SH-NH2  
E.8 Calculation of Working Concentration of 20 µg/ml Hoechst Working 
Solution from Stock Concentration of 1.0 mg/ml Hoechst 33258 Dye 
• A stock solution of 1.0 mg/ml of Hoechst 33258 Fluorescent Dye was made (D18).  
• The culture plate contained 1 ml of relevant complete growth media depending on the 
type of cell culture contained within. 
• Therefore, if you wanted to add a working concentration of 20 µg/ml of Hoechst 
Working Solution Stain to this culture plate the Hoechst 33258 Fluorescent Dye Stock 
Solution of 1.0 mg/ml, which is equivalent to 1000 µg/ml, it would have to be diluted. 
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o The following calculation was done: 
o C1V1 = C2V2 
o (1000 µg/ml)(X) = (20 µg/ml) (1 ml of growth medium) 
o X = 0.02 ml x 1000 = 20 µl 
• Therefore 20 µl of 1.0 mg/ml Hoechst 33258 Fluorescent Dye Stock Solution was 
added to the culture plate which contained 1 ml of relevant complete growth culture 
medium in order to acquire a working concentration of 20 µg/ml of Hoechst Working 
Solution Stain 
E.9 Cell Viability Calculation 
The formula below was utilized to calculate the percentage % of viable cells for all 
experimental or control groups: 
• Following the addition of 10 µl of suspended cells to 10 µl of 0.4% trypan blue 
solution in 0.5ul eppendorf tube, cells are gently mixed (briefly) and placed in a 
disposable slide for counting on the Countess II FL Automated Cell Counter. The 
Countess II FL Automated Cell Counter has advanced autofocusing and counting 
algorithms which allow quick and accurate cells counts within a population.  
• The amount of dead and alive cells were then calculated automatically per ml using 
this formula: 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 = 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛 𝑇𝑇𝑜𝑜 𝑇𝑇𝑙𝑙𝑙𝑙𝑐𝑐 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇 + 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑐𝑐𝑛𝑛 𝑇𝑇𝑜𝑜 𝑑𝑑𝑐𝑐𝑇𝑇𝑑𝑑 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐 
 
𝑃𝑃𝑐𝑐𝑛𝑛𝑐𝑐𝑐𝑐𝑛𝑛𝑇𝑇𝑇𝑇𝑃𝑃𝑐𝑐 𝑉𝑉𝑙𝑙𝑇𝑇𝑛𝑛𝑙𝑙𝑇𝑇𝑙𝑙𝑇𝑇𝑉𝑉 =  
𝑇𝑇𝑙𝑙𝑙𝑙𝑐𝑐 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑐𝑐𝑐𝑐𝑇𝑇𝑇𝑇𝑐𝑐
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Appendix G: Simiarity Report Index from Turn It  
 
 
 
 
 
 
 
